Cat. No.: HY-17413

Copy Link Print Information

Zidovudine

(Synonyms: Azidothymidine; AZT; ZDV)

10 Cited Publications

Avis client

Based on 10 publication(s) in Google Scholar

Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.97%
CAS No.: 30516-87-1
Formule: C₁₀H₁₃N₅O₄
Masse moléculaire:267.24

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Zidovudine Chemical Structure

CAS No.: 30516-87-1

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (10)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection.

IC₅₀ & Target^[1]^[2]

HIV-1

Voir tous les produits spécifiques à Isoform HIV :

Cellular Effect

Cell Line	Type	Value	Description	References
143B	IC₅₀	12.25 μM Compound: AZT, Zidovudine	Cytotoxicity against human 143B cells after 72 hrs by MTT assay Cytotoxicity against human 143B cells after 72 hrs by MTT assay	[PMID: 25440502]
143B	IC₅₀	148.42 μM Compound: AZT, Zidovudine	Cytotoxicity against human thymidine kinase-deficient 143B cells after 72 hrs by MTT assay Cytotoxicity against human thymidine kinase-deficient 143B cells after 72 hrs by MTT assay	[PMID: 25440502]
5637	IC₅₀	7 μM Compound: 1	Cytotoxicity against human 5637 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human 5637 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25811955]
5637	IC₅₀	128.82 μM Compound: AZT	Antiproliferative activity in human 5637 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity in human 5637 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 30108758]
A549	IC₅₀	0.011 μM Compound: AZT	Inhibition of Influenza A virus (A/Viet Nam/1203/2004(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry Inhibition of Influenza A virus (A/Viet Nam/1203/2004(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry	[PMID: 19537689]
A549	IC₅₀	0.012 μM Compound: AZT	Inhibition of Influenza A virus (A/Bar-headed Goose/Qinghai/59/05(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry Inhibition of Influenza A virus (A/Bar-headed Goose/Qinghai/59/05(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry	[PMID: 19537689]
A549	IC₅₀	16.19 μM Compound: 13, AZT	Cytotoxicity against human A549 cells after 48 hrs by SRB method Cytotoxicity against human A549 cells after 48 hrs by SRB method	[PMID: 25933593]
A549	IC₅₀	11.86 μM Compound: 3; AZT	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
A549	IC₅₀	20.74 μM Compound: AZT	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis	[PMID: 38964258]
AA5	IC₅₀	<0.0003 μM Compound: AZT	Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
AA5	IC₅₀	>0.1 μM Compound: AZT	Cytotoxicity against human AA5 cells by MTS assay Cytotoxicity against human AA5 cells by MTS assay	[PMID: 20086149]
AA5	IC₅₀	0.0003 μM Compound: AZT	Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
AA5	IC₅₀	0.0004 μM Compound: AZT	Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
AA5	IC₅₀	0.006 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
AA5	IC₅₀	0.008 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
AA5	IC₅₀	0.009 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
B(EBV+)	EC₅₀	0.001 μM Compound: AZT	Effective concentration required for antiviral activity against B(EBV+) cell line of AA5 cells of Human by XTT assay Effective concentration required for antiviral activity against B(EBV+) cell line of AA5 cells of Human by XTT assay	[PMID: 7932526]
Bel-7402	EC₅₀	4.62 μM Compound: Zidovudine	Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay	[PMID: 18313175]
Bone marrow cell	CC₅₀	0.5 μM Compound: ZDV, AZT	Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay	[PMID: 20439609]
Bone marrow cell	CC₅₀	0.89 μM Compound: ZDV, AZT	Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay	[PMID: 20439609]
BxT	EC₅₀	0.055 μM Compound: AZT	Effective concentration required for antiviral activity against BxT cell line of 174xCEM cells of Human by XTT assay Effective concentration required for antiviral activity against BxT cell line of 174xCEM cells of Human by XTT assay	[PMID: 7932526]
C3H	CC₅₀	>20 μM Compound: 3[AZT]	Compound was evaluated cytotoxicity against moloney sarcoma virus (MSV) infected C3H cell cultures. Compound was evaluated cytotoxicity against moloney sarcoma virus (MSV) infected C3H cell cultures.	10.1016/0960-894X(96)00433-7
C3H/3T3	EC₅₀	>100 μM Compound: AZT	Effect of compound against Moloney murine sarcoma virus (MSV)-induced transformation of C3H/3T3 embryo murine fibroblasts Effect of compound against Moloney murine sarcoma virus (MSV)-induced transformation of C3H/3T3 embryo murine fibroblasts	[PMID: 10229629]
C3H/3T3	EC₅₀	0.02 μM Compound: AZT	Concentration of compound required to inhibit HIV-1 induced cytopathogenicity of MSV-induced transformation of C3H/3T3 cells by 50%. Concentration of compound required to inhibit HIV-1 induced cytopathogenicity of MSV-induced transformation of C3H/3T3 cells by 50%.	[PMID: 2016718]
C8166	EC₅₀	0.02 μM Compound: AZT	In vitro antiviral activity against HIV-1 IIIB in C8166 (human CD4) cells. In vitro antiviral activity against HIV-1 IIIB in C8166 (human CD4) cells.	[PMID: 11020296]
C8166	EC₅₀	0.016 μg/mL Compound: AZT	Antiviral activity against HIV1 MN infected in human C8166 cells assessed as reduction in antigen gp120 production by ELISA Antiviral activity against HIV1 MN infected in human C8166 cells assessed as reduction in antigen gp120 production by ELISA	[PMID: 11374977]
C8166	EC₅₀	0.4 μM Compound: AZT	Concentration which produces a 50% survival of HIV-1 infected cells relative to uninfected control C8166 cells Concentration which produces a 50% survival of HIV-1 infected cells relative to uninfected control C8166 cells	[PMID: 11462972]
C8166	IC₅₀	>100 μM Compound: AZT	Concentration which results in 50% survival of uninfected untreated control C8166 cells (cytotoxicity of the compound) Concentration which results in 50% survival of uninfected untreated control C8166 cells (cytotoxicity of the compound)	[PMID: 11462972]
C8166	CC₅₀	>1 μM Compound: AZT	Cytotoxicity against C8166 cells by MTT assay Cytotoxicity against C8166 cells by MTT assay	[PMID: 16279773]
C8166	EC₅₀	0.0019 μM Compound: AZT	Inhibition of HIV1-3B replication in C8166 cells Inhibition of HIV1-3B replication in C8166 cells	[PMID: 16279773]
C8166	CC₅₀	>200 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 16499331]
C8166	EC₅₀	0.0034 μg/mL Compound: AZT	Antiviral activity against HIV1 infected in human C8166 cells assessed as inhibition of viral-induced cytopathic effect Antiviral activity against HIV1 infected in human C8166 cells assessed as inhibition of viral-induced cytopathic effect	[PMID: 16499331]
C8166	CC₅₀	>200 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells by MTT method Cytotoxicity against human C8166 cells by MTT method	[PMID: 16643044]
C8166	EC₅₀	0.0033 μg/mL Compound: AZT	Antiviral activity against HIV1 3B in human C8166 cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HIV1 3B in human C8166 cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 16643044]
C8166	CC₅₀	4552.1 μM Compound: AZT	Cytotoxicity against C8166 cells by MTT method Cytotoxicity against C8166 cells by MTT method	[PMID: 17291043]
C8166	EC₅₀	0.017 μM Compound: AZT	Antiviral activity against on HIV1 3b infected C8166 cells assessed as syncytial cell formation after 3 days Antiviral activity against on HIV1 3b infected C8166 cells assessed as syncytial cell formation after 3 days	[PMID: 17291043]
C8166	CC₅₀	5746.1 μM Compound: AZT	Cytotoxicity against C8166 cells by MTT assay Cytotoxicity against C8166 cells by MTT assay	[PMID: 17315963]
C8166	CC₅₀	>200 μg/mL Compound: AZT	Cytotoxicity against C8166 cells after 72 hrs by MTT method Cytotoxicity against C8166 cells after 72 hrs by MTT method	[PMID: 17489633]
C8166	EC₅₀	0.0043 μg/mL Compound: AZT	Antiviral activity against HIV1 3B in C8166 cells Antiviral activity against HIV1 3B in C8166 cells	[PMID: 17489633]
C8166	CC₅₀	>5.092 mM Compound: AZT	Cytotoxicity in human C8166 cells Cytotoxicity in human C8166 cells	[PMID: 17574419]
C8166	CC₅₀	>200 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells by MTT method Cytotoxicity against human C8166 cells by MTT method	[PMID: 18088099]
C8166	EC₅₀	0.0034 μg/mL Compound: AZT	Antiviral activity against HIV1 in C8166 cells after 72 hrs Antiviral activity against HIV1 in C8166 cells after 72 hrs	[PMID: 18088099]
C8166	CC₅₀	>749 μM Compound: AZT, zidovudine	Cytotoxicity against human C8166 cells after 72 hrs by MTT method Cytotoxicity against human C8166 cells after 72 hrs by MTT method	[PMID: 18316190]
C8166	EC₅₀	0.011 μM Compound: AZT, zidovudine	Antiviral activity against HIV1 3B in C8166 cells by syncytium reduction assay Antiviral activity against HIV1 3B in C8166 cells by syncytium reduction assay	[PMID: 18316190]
C8166	CC₅₀	5091 μM Compound: AZT	Cytotoxicity against human C8166 cells after 72 hrs by MTT assay Cytotoxicity against human C8166 cells after 72 hrs by MTT assay	[PMID: 18396905]
C8166	EC₅₀	0.0108 μM Compound: AZT	Antiviral activity against HIV1 in human C8166 cells assessed as protection against viral-induced cytopathic effect by syncytium reduction assay Antiviral activity against HIV1 in human C8166 cells assessed as protection against viral-induced cytopathic effect by syncytium reduction assay	[PMID: 18396905]
C8166	EC₅₀	0.0019 μM Compound: AZT	Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay	[PMID: 19170521]
C8166	CC₅₀	>1000 μM Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 19413342]
C8166	EC₅₀	1.95 x 10^-3 μM Compound: AZT	Antiviral activity against HIV1 3B in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity Antiviral activity against HIV1 3B in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity	[PMID: 19413342]
C8166	CC₅₀	>100 μg/mL Compound: AZT	Cytotoxicity against HIV1 infected human C8166-CCR5 cells assessed as decrease in cell viability by cell associated dehydrogenase activity assay Cytotoxicity against HIV1 infected human C8166-CCR5 cells assessed as decrease in cell viability by cell associated dehydrogenase activity assay	[PMID: 19515569]
C8166	CC₅₀	200 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 19685905]
C8166	EC₅₀	0.0045 μg/mL Compound: AZT	Antiviral activity against HIV1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HIV1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 19685905]
C8166	CC₅₀	>200 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 20146529]
C8166	EC₅₀	0.0045 μg/mL Compound: AZT	Antiviral activity against HIV1-infected human C8166 cells Antiviral activity against HIV1-infected human C8166 cells	[PMID: 20146529]
C8166	CC₅₀	1139.47 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells after 3 days by MTT assay Cytotoxicity against human C8166 cells after 3 days by MTT assay	[PMID: 20488700]
C8166	EC₅₀	0.00324 μg/mL Compound: AZT	Antiviral activity against HIV1 3B infected in C8166 cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B infected in C8166 cells assessed as inhibition of syncytia formation	[PMID: 20488700]
C8166	CC₅₀	1145 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells after 3 days by MTT assay Cytotoxicity against human C8166 cells after 3 days by MTT assay	[PMID: 20598530]
C8166	EC₅₀	0.004 μg/mL Compound: AZT	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral replication Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral replication	[PMID: 20598530]
C8166	CC₅₀	5041 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days Antiviral activity against HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days	[PMID: 21194939]
C8166	CC₅₀	4.07 μM Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 21534540]
C8166	EC₅₀	uM μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Human immunodeficiency virus 1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21534540]
C8166	CC₅₀	4071.9 μM Compound: AZT	Cytotoxicity against human C8166 cells after 3 days by MTT assay Cytotoxicity against human C8166 cells after 3 days by MTT assay	[PMID: 21561060]
C8166	EC₅₀	4.5 nM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human C8166 cells assessed as numbers of syncytia after 3 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human C8166 cells assessed as numbers of syncytia after 3 days by MTT assay	[PMID: 21561060]
C8166	EC₅₀	4.5 x 10^-3 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human C8166 cells assessed as numbers of syncytia after 3 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human C8166 cells assessed as numbers of syncytia after 3 days by MTT assay	[PMID: 21561060]
C8166	CC₅₀	4.07 μM Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 21650224]
C8166	IC₅₀	0.0085 μM Compound: 1	Antiviral activity against HIV-1 (RF strain) in C8166 cells Antiviral activity against HIV-1 (RF strain) in C8166 cells	[PMID: 2165161]
C8166	CC₅₀	5601.71 μM Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 21689939]
C8166	EC₅₀	0.00812 μM Compound: AZT	Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB A17 harboring reverse transcriptase K103N and Y181C double mutant infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB A17 harboring reverse transcriptase K103N and Y181C double mutant infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction	[PMID: 21689939]
C8166	EC₅₀	0.1293 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 2 ROD infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay Antiviral activity against Human immunodeficiency virus 2 ROD infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay	[PMID: 21689939]
C8166	EC₅₀	10.59 nM Compound: AZT	Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay	[PMID: 21689939]
C8166	CC₅₀	5401.4 μM Compound: AZT	Cytotoxicity against human C8166 cells by MTT colorimetric assay Cytotoxicity against human C8166 cells by MTT colorimetric assay	[PMID: 21719299]
C8166	EC₅₀	0.023 μM Compound: AZT	Antiviral activity against HIV1 A17 expressing reverse transcriptase K103N/Y181C double mutant infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope Antiviral activity against HIV1 A17 expressing reverse transcriptase K103N/Y181C double mutant infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope	[PMID: 21719299]
C8166	EC₅₀	12.82 nM Compound: AZT	Antiviral activity against wild-type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope Antiviral activity against wild-type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope	[PMID: 21719299]
C8166	EC₅₀	39 μM Compound: AZT	Antiviral activity against HIV-2 ROD infected in human C8166 cells assessed as protection against viral cytopathogenicity after 3 days by measuring syncytia under inverted microscope Antiviral activity against HIV-2 ROD infected in human C8166 cells assessed as protection against viral cytopathogenicity after 3 days by measuring syncytia under inverted microscope	[PMID: 21719299]
C8166	CC₅₀	5401.4 μM Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 21788138]
C8166	EC₅₀	0.0128 μM Compound: AZT	Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay	[PMID: 21788138]
C8166	EC₅₀	0.023 μM Compound: AZT	Antiviral activity against wild type HIV1 A17 harboring reverse transcriptase K103N and Y181C mutant infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay Antiviral activity against wild type HIV1 A17 harboring reverse transcriptase K103N and Y181C mutant infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay	[PMID: 21788138]
C8166	CC₅₀	4107.39 μM Compound: AZT	Cytotoxicity against human C8166 cells after 3 days by MTT assay Cytotoxicity against human C8166 cells after 3 days by MTT assay	[PMID: 23046280]
C8166	EC₅₀	0.0087 μM Compound: AZT	Antiviral activity against HIV-1 3B infected in C8166 cells assessed as virus-induced cytopathic effect measuring scintia formation after 3 days by microscopy Antiviral activity against HIV-1 3B infected in C8166 cells assessed as virus-induced cytopathic effect measuring scintia formation after 3 days by microscopy	[PMID: 23046280]
C8166	CC₅₀	>200 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 23078294]
C8166	EC₅₀	0.034 μg/mL Compound: AZT	Antiviral activity against HIV1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HIV1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23078294]
C8166	CC₅₀	5110 μM Compound: AZT	Cytotoxicity against human C8166 cells after 3 days by MTT assay Cytotoxicity against human C8166 cells after 3 days by MTT assay	[PMID: 23099098]
C8166	EC₅₀	0.019 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of syncytia after 3 days Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of syncytia after 3 days	[PMID: 23099098]
C8166	CC₅₀	4913.8 μM Compound: AZT	Cytotoxicity against human C8166 cells assessed as decrease in cell viability by MTT assay Cytotoxicity against human C8166 cells assessed as decrease in cell viability by MTT assay	[PMID: 23164656]
C8166	EC₅₀	0.0228 μM Compound: AZT	Antiviral activity against HIV1 A17 harbouring RT K103N/Y181C mutant infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay Antiviral activity against HIV1 A17 harbouring RT K103N/Y181C mutant infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay	[PMID: 23164656]
C8166	EC₅₀	12.8 nM Compound: AZT	Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay	[PMID: 23164656]
C8166	EC₅₀	39 μM Compound: AZT	Antiviral activity against HIV2 ROD infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay Antiviral activity against HIV2 ROD infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay	[PMID: 23164656]
C8166	CC₅₀	>200 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 23327759]
C8166	CC₅₀	>200 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells assessed as inhibition of cell viability after 3 days by MTT assay Cytotoxicity against human C8166 cells assessed as inhibition of cell viability after 3 days by MTT assay	[PMID: 23368966]
C8166	EC₅₀	0.034 μg/mL Compound: AZT	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of syncytia formation after 3 days Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of syncytia formation after 3 days	[PMID: 23368966]
C8166	CC₅₀	>200 μM Compound: AZT	Cytotoxicity against human C8166 cells after 3 days by MTT assay Cytotoxicity against human C8166 cells after 3 days by MTT assay	[PMID: 23738539]
C8166	EC₅₀	0.034 μM Compound: AZT	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect after 3 days by Syncytia Assay Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect after 3 days by Syncytia Assay	[PMID: 23738539]
C8166	EC₅₀	0.02 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity by syncytium formation assay Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity by syncytium formation assay	[PMID: 24299567]
C8166	CC₅₀	4690 μM Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 26214125]
C8166	CC₅₀	4676.07 μM Compound: AZT; zidovudine	Cytotoxicity against human C8166 cells after 72 hrs by MTT assay Cytotoxicity against human C8166 cells after 72 hrs by MTT assay	[PMID: 27039251]
C8166	EC₅₀	0.00152 μM Compound: AZT; zidovudine	Antiviral activity against HIV1 74V infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method Antiviral activity against HIV1 74V infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method	[PMID: 27039251]
C8166	EC₅₀	0.00436 μM Compound: AZT; zidovudine	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 2 hrs followed by cell plating for 72 hrs by ELISA method Antiviral activity against HIV1 3B infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 2 hrs followed by cell plating for 72 hrs by ELISA method	[PMID: 27039251]
C8166	EC₅₀	0.00794 μM Compound: AZT; zidovudine	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as cytopathic effect by counting the number of syncytia by microscopy Antiviral activity against HIV1 3B infected in human C8166 cells assessed as cytopathic effect by counting the number of syncytia by microscopy	[PMID: 27039251]
C8166	CC₅₀	5858.85 μM Compound: Zidovudine	Cytotoxicity against human C8166 cells measured after 72 hrs by MTT assay Cytotoxicity against human C8166 cells measured after 72 hrs by MTT assay	[PMID: 27894873]
C8166	EC₅₀	0.013 μM Compound: Zidovudine	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathic effect by measuring syncytia formation after 72 hrs by inverted microscopic method Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathic effect by measuring syncytia formation after 72 hrs by inverted microscopic method	[PMID: 27894873]
C8166	CC₅₀	5231.6 μM Compound: AZT	Cytotoxicity against human C8166 cells after 72 hrs by MTT assay Cytotoxicity against human C8166 cells after 72 hrs by MTT assay	[PMID: 30596489]
C8166	IC₅₀	1565.72 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells assessed as reduction in cell viability Cytotoxicity against human C8166 cells assessed as reduction in cell viability	[PMID: 31401538]
C8166	CC₅₀	3987.58 μM Compound: AZT	Cytotoxicity against human C8166 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity against human C8166 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 34812640]
C8166	EC₅₀	0.02 μM Compound: AZT	Inhibition of p24 antigen formation in infected C8166-cells Inhibition of p24 antigen formation in infected C8166-cells	[PMID: 7504733]
C8166	EC₅₀	0.03 μM Compound: AZT	Inhibition of syncytia formation in infected C8166-cells Inhibition of syncytia formation in infected C8166-cells	[PMID: 7504733]
C8166	EC₅₀	0.03 μM Compound: AZT	Inhibitory effects on HIV-1 induced syncytium formation in C8166 cells Inhibitory effects on HIV-1 induced syncytium formation in C8166 cells	[PMID: 8230098]
C8166	CC₅₀	>500 μM Compound: AZT	Ability to reduce 50% viability of C8166 cells acutely infected with HIV-2 strain IIIB Ability to reduce 50% viability of C8166 cells acutely infected with HIV-2 strain IIIB	[PMID: 8642557]
C8166	EC₅₀	0.006 μM Compound: AZT	Effective dose to achieve 50% protection of C8166 cells acutely infected with HIV-2 strain IIIB Effective dose to achieve 50% protection of C8166 cells acutely infected with HIV-2 strain IIIB	[PMID: 8642557]
C8166	EC₅₀	0.015 μM Compound: AZT	Ability to inhibit HIV-2 multiplication in acutely infected C8166 cells Ability to inhibit HIV-2 multiplication in acutely infected C8166 cells	[PMID: 9154967]
C8166	EC₅₀	0.016 μM Compound: AZT	Inhibitory activity against HIV-111B in C8166 cells Inhibitory activity against HIV-111B in C8166 cells	10.1016/0960-894X(95)00203-6
C8166	EC₅₀	0.03 μM Compound: AZT	Concentration required to inhibit p24 viral antigen production by 50% in C-8166 cells Concentration required to inhibit p24 viral antigen production by 50% in C-8166 cells	10.1016/0960-894X(95)00208-B
C8166	CC₅₀	1400 μM Compound: AZT	Cytotoxic activity was evaluated in CD4+ lymphoblastoid cell line Cytotoxic activity was evaluated in CD4+ lymphoblastoid cell line	10.1016/0960-894X(95)00257-T
C8166	IC₅₀	0.004 μM Compound: AZT	Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain	10.1016/0960-894X(95)00257-T
C8166	EC₅₀	0.04 μM Compound: AZT	Compound was evaluated for the inhibition of p24 viral antigen production in C-8166 cells. Compound was evaluated for the inhibition of p24 viral antigen production in C-8166 cells.	10.1016/0960-894X(95)00585-H
C8166	CC₅₀	>1000 μM Compound: AZT	Cytotoxicity in C8166 cell lines Cytotoxicity in C8166 cell lines	10.1016/0960-894X(96)00443-X
C8166	EC₅₀	0.016 μM Compound: AZT	Anti-HIV activity against HIV-1 infected C8166 cell lines Anti-HIV activity against HIV-1 infected C8166 cell lines	10.1016/0960-894X(96)00443-X
C8166	CC₅₀	>1000 μM Compound: AZT	Concentration of compound required to reduce viability of C8166 cells by 50%. Concentration of compound required to reduce viability of C8166 cells by 50%.	10.1016/0960-894X(96)00444-1
C8166	EC₅₀	0.016 μM Compound: AZT	Compound was evaluated for anti-HIV activity against HIV-1 infected C8166 cell lines Compound was evaluated for anti-HIV activity against HIV-1 infected C8166 cell lines	10.1016/0960-894X(96)00444-1
C8166	CC₅₀	>1000 μM Compound: 1	Concentration which reduces the viability of uninfected C8166 cells by 50% Concentration which reduces the viability of uninfected C8166 cells by 50%	10.1016/0960-894X(96)00446-5
C8166	EC₅₀	0.016 μM Compound: 1	Compound was evaluated for inhibitory activity against HIV-1 infected C8166 cells. Compound was evaluated for inhibitory activity against HIV-1 infected C8166 cells.	10.1016/0960-894X(96)00446-5
C8166	ED₅₀	0.01 μM Compound: 1a	Compound was tested for its ability to inhibit the replication of HIV-1 in C8166 T-cells Compound was tested for its ability to inhibit the replication of HIV-1 in C8166 T-cells	10.1016/S0960-894X(00)80316-9
C8166	EC₅₀	0.016 μM Compound: AZT	Tested against HIV-1 111B for Inhibition of viral replication by determining reduction of syncytia formation and antigen gp120 in C8166 cells, estimated by ELISA Tested against HIV-1 111B for Inhibition of viral replication by determining reduction of syncytia formation and antigen gp120 in C8166 cells, estimated by ELISA	10.1016/S0960-894X(97)00022-X
Caco-2	IC₅₀	0.015 mg/mL Compound: AZT	Cytotoxicity against human Caco-2 cells after 72 hrs Cytotoxicity against human Caco-2 cells after 72 hrs	[PMID: 17079149]
Caco-2	IC₅₀	0.015 mg/mL Compound: AZT	Growth inhibition of human Caco-2 cells after 72 hrs Growth inhibition of human Caco-2 cells after 72 hrs	[PMID: 17079149]
Caco-2	IC₅₀	0.006 mg/mL Compound: AZT	Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs	[PMID: 17337193]
Caco-2	IC₅₀	0.02 mg/mL Compound: AZT	Antiviral activity against rotavirus RF in human Caco-2 cells after neutralization of virus in solution pre-incubated with compound for 12 hrs before infection Antiviral activity against rotavirus RF in human Caco-2 cells after neutralization of virus in solution pre-incubated with compound for 12 hrs before infection	[PMID: 17337193]
Caco-2	IC₅₀	22.45 μM Compound: AZT	Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs	[PMID: 17337193]
Caco-2	IC₅₀	74.84 μM Compound: AZT	Antiviral activity against rotavirus RF in human Caco-2 cells after neutralization of virus in solution pre-incubated with compound for 12 hrs before infection Antiviral activity against rotavirus RF in human Caco-2 cells after neutralization of virus in solution pre-incubated with compound for 12 hrs before infection	[PMID: 17337193]
Caco-2	CC₅₀	56.1 μM Compound: AZT	Cytotoxicity against human Caco-2 cells after 72 hrs Cytotoxicity against human Caco-2 cells after 72 hrs	[PMID: 17548129]
Caco-2	IC₅₀	22.45 μM Compound: AZT	Antiviral activity against gastrointestinal rotavirus in human Caco-2 cells assessed as inhibition of infectivity following virus attachment Antiviral activity against gastrointestinal rotavirus in human Caco-2 cells assessed as inhibition of infectivity following virus attachment	[PMID: 17548129]
Caco-2	IC₅₀	74.84 μM Compound: AZT	Antiviral activity against gastrointestinal rotavirus in human Caco-2 cells assessed as neutralization of virus in the solution before attachment Antiviral activity against gastrointestinal rotavirus in human Caco-2 cells assessed as neutralization of virus in the solution before attachment	[PMID: 17548129]
Caco-2	IC₅₀	22.39 μM Compound: AZT	Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs	[PMID: 17555969]
Caco-2	IC₅₀	74.62 μM Compound: AZT	Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as neutralization of virus in solution before its attachment after 72 hrs Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as neutralization of virus in solution before its attachment after 72 hrs	[PMID: 17555969]
Caco-2	CC₅₀	56.1 μM Compound: AZT	Cytotoxicity against human Caco-2 cells after 72 hrs Cytotoxicity against human Caco-2 cells after 72 hrs	[PMID: 18037195]
Caco-2	IC₅₀	22.45 μM Compound: AZT	Antiviral activity against rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs Antiviral activity against rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs	[PMID: 18037195]
Caco-2	IC₅₀	74.84 μM Compound: AZT	Antiviral activity against rotavirus RF in human Caco-2 cells assessed as neutralization of virus before its attachment after 72 hrs Antiviral activity against rotavirus RF in human Caco-2 cells assessed as neutralization of virus before its attachment after 72 hrs	[PMID: 18037195]
CCRF-CEM	IC₅₀	30.9 μM Compound: AZT	Tested in vitro for anticancer activity against CEM cells Tested in vitro for anticancer activity against CEM cells	[PMID: 10072683]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Inhibitory activity was evaluated on mitochondrial DNA content of CEM cells Inhibitory activity was evaluated on mitochondrial DNA content of CEM cells	[PMID: 10197975]
CCRF-CEM	CC₅₀	>100 μM Compound: AZT	In vitro cytotoxic concentration in CEM cells. In vitro cytotoxic concentration in CEM cells.	[PMID: 10229629]
CCRF-CEM	CC₅₀	>1 μM Compound: AZT	Tested for cytotoxic concentration in CEM-SS cell culture Tested for cytotoxic concentration in CEM-SS cell culture	[PMID: 11087582]
CCRF-CEM	CC₅₀	>100 μM Compound: AZT	Tested for cytotoxic concentration in CEM/TK- cell culture Tested for cytotoxic concentration in CEM/TK- cell culture	[PMID: 11087582]
CCRF-CEM	EC₅₀	>100 μM Compound: AZT	Tested for anti-HIV -1 Activity in CEM/TK- cell culture Tested for anti-HIV -1 Activity in CEM/TK- cell culture	[PMID: 11087582]
CCRF-CEM	EC₅₀	0.003 μM Compound: AZT	Tested for anti-HIV -1 Activity in CEM-SS cell culture Tested for anti-HIV -1 Activity in CEM-SS cell culture	[PMID: 11087582]
CCRF-CEM	EC₅₀	<0.001 μM Compound: AZT	Effective concentration of required to inhibit the replication of HIV-1 BY 50% in CEM cells Effective concentration of required to inhibit the replication of HIV-1 BY 50% in CEM cells	[PMID: 11170632]
CCRF-CEM	IC₅₀	14.2 μM Compound: AZT	Concentration required to kill 50% of CEM cells Concentration required to kill 50% of CEM cells	[PMID: 11170632]
CCRF-CEM	CC₅₀	>500 μM Compound: AZT	Concentration required to reduce CEM/0 cell viability by 50% Concentration required to reduce CEM/0 cell viability by 50%	[PMID: 11356105]
CCRF-CEM	EC₅₀	0.006 μM Compound: AZT	Concentration required to protect CEM/0 cells against the cytopathicity of HIV-2 by 50%. Concentration required to protect CEM/0 cells against the cytopathicity of HIV-2 by 50%.	[PMID: 11356105]
CCRF-CEM	EC₅₀	0.0064 μM Compound: AZT	Concentration required to protect CEM/0 cells against the cytopathicity of HIV-1 by 50%. Concentration required to protect CEM/0 cells against the cytopathicity of HIV-1 by 50%.	[PMID: 11356105]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	In vitro cytotoxicity in CEM cells. In vitro cytotoxicity in CEM cells.	[PMID: 11689085]
CCRF-CEM	IC₅₀	0.006 μM Compound: AZT	Antiviral activity against site directed resistant isolate HIV-1 L100I in CEM cells Antiviral activity against site directed resistant isolate HIV-1 L100I in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.007 μM Compound: AZT	Antiviral activity against site directed resistant isolate HIV-1 K103N in CEM cells Antiviral activity against site directed resistant isolate HIV-1 K103N in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.008 μM Compound: AZT	Antiviral activity against site directed resistant isolates in HIV-1 A98G CEM cells Antiviral activity against site directed resistant isolates in HIV-1 A98G CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.014 μM Compound: AZT	Antiviral activity against site directed resistant isolate HIV-1 V106A in CEM cells Antiviral activity against site directed resistant isolate HIV-1 V106A in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.017 μM Compound: AZT	Antiviral activity against site directed wild-type enzyme isolate HIV-1 NL4-3WT in CEM cells Antiviral activity against site directed wild-type enzyme isolate HIV-1 NL4-3WT in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.02 μM Compound: AZT	Antiviral activity against site directed resistant isolate HIV-1 V179D in CEM cells Antiviral activity against site directed resistant isolate HIV-1 V179D in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.04 μM Compound: AZT	Antiviral activity against site directed resistant isolate HIV-1 L74V in CEM cells Antiviral activity against site directed resistant isolate HIV-1 L74V in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.046 μM Compound: AZT	Antiviral activity against site directed resistant isolate HIV-1 K101E in CEM cells Antiviral activity against site directed resistant isolate HIV-1 K101E in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.08 μM Compound: AZT	Antiviral activity against site directed resistant isolate HIV-1 Y181C in CEM cells Antiviral activity against site directed resistant isolate HIV-1 Y181C in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.082 μM Compound: AZT	Antiviral activity against site directed 4X AZT resistant isolate HIV-1 in CEM cells Antiviral activity against site directed 4X AZT resistant isolate HIV-1 in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.087 μM Compound: AZT	Antiviral activity against site directed resistant isolate HIV-1 Y188C in CEM cells Antiviral activity against site directed resistant isolate HIV-1 Y188C in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.87 μM Compound: AZT	Antiviral activity against site directed 4X AZT resistant isolate HIV-1 L100I in CEM cells Antiviral activity against site directed 4X AZT resistant isolate HIV-1 L100I in CEM cells	[PMID: 11708913]
CCRF-CEM	CC₅₀	6 μM Compound: n AZT	Concentration required to reduce the viability of mock-infected CEM cells by 50% Concentration required to reduce the viability of mock-infected CEM cells by 50%	[PMID: 11714616]
CCRF-CEM	EC₅₀	0.003 μM Compound: n AZT	Effective concentration required to inhibit HIV-1 induced cytopathicity by 50% in CEM cells Effective concentration required to inhibit HIV-1 induced cytopathicity by 50% in CEM cells	[PMID: 11714616]
CCRF-CEM	EC₅₀	0.004 μM Compound: n AZT	Effective concentration required to inhibit HIV-2 induced cytopathicity by 50% in CEM cells Effective concentration required to inhibit HIV-2 induced cytopathicity by 50% in CEM cells	[PMID: 11714616]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against CEM cells Cytotoxicity against CEM cells	[PMID: 11882000]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against CEM cells Cytotoxicity against CEM cells	[PMID: 12383014]
CCRF-CEM	IC₅₀	29 μM Compound: AZT	Evaluated in vitro for their potential toxic effects human CEM cells Evaluated in vitro for their potential toxic effects human CEM cells	[PMID: 12540238]
CCRF-CEM	CC₅₀	>100 μM Compound: AZT	Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM/TK cells Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM/TK cells	[PMID: 12593658]
CCRF-CEM	EC₅₀	>100 μM Compound: AZT	Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM/TK cells Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM/TK cells	[PMID: 12593658]
CCRF-CEM	EC₅₀	0.004 μM Compound: AZT	Effective concentration against cytopathicity of HIV-1 strain (HTLV IIIB) in CEM cell line Effective concentration against cytopathicity of HIV-1 strain (HTLV IIIB) in CEM cell line	[PMID: 12801219]
CCRF-CEM	EC₅₀	0.004 μM Compound: AZT	Effective concentration against cytopathicity of HIV-2 strain (ROD) in CEM cell line Effective concentration against cytopathicity of HIV-2 strain (ROD) in CEM cell line	[PMID: 12801219]
CCRF-CEM	IC₅₀	>375 μM Compound: AZT	Antiproliferative activity was determined against human T-lymphocyte cells-CEM Antiproliferative activity was determined against human T-lymphocyte cells-CEM	[PMID: 12801219]
CCRF-CEM	IC₅₀	30.9 μM Compound: AZT	Cytotoxicity was determined in CEM cells, relative to RVT Cytotoxicity was determined in CEM cells, relative to RVT	[PMID: 15081000]
CCRF-CEM	IC₅₀	14.3 μM Compound: Zidovudine (AZT)	Inhibitory concentration against CEM cell line Inhibitory concentration against CEM cell line	[PMID: 15916425]
CCRF-CEM	CC₅₀	>100 μM Compound: AZT	Cytotoxicity in CEM cells Cytotoxicity in CEM cells	[PMID: 16392791]
CCRF-CEM	EC₅₀	0.0055 μM Compound: AZT	Antiviral activity against HIV1 IIIB in CEM cells Antiviral activity against HIV1 IIIB in CEM cells	[PMID: 16392791]
CCRF-CEM	EC₅₀	0.0055 μM Compound: AZT	Antiviral activity against HIV2 ROD in CEM cells Antiviral activity against HIV2 ROD in CEM cells	[PMID: 16392791]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 16509580]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against CEM cells Cytotoxicity against CEM cells	[PMID: 17085053]
CCRF-CEM	ED₅₀	0.12 μM Compound: AZT	Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 11. Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 11.	[PMID: 1712047]
CCRF-CEM	ED₅₀	0.12 μM Compound: AZT	Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 7. Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 7.	[PMID: 1712047]
CCRF-CEM	ED₅₀	0.18 μM Compound: AZT	Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 19. Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 19.	[PMID: 1712047]
CCRF-CEM	ED₅₀	0.45 μM Compound: AZT	Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 22. Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 22.	[PMID: 1712047]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against human CEM cells after 6 days Cytotoxicity against human CEM cells after 6 days	[PMID: 17158051]
CCRF-CEM	IC₅₀	<0.03 μg/mL Compound: AZT	Compound was tested for its inhibitory activity against HIV replication in CEM cells. Compound was tested for its inhibitory activity against HIV replication in CEM cells.	[PMID: 1738145]
CCRF-CEM	CC₅₀	>100 μM Compound: AZT, zidovudine	Cytotoxicity against human thymidine kinase-deficient CEM cells Cytotoxicity against human thymidine kinase-deficient CEM cells	[PMID: 18585917]
CCRF-CEM	EC₅₀	>100 μM Compound: AZT, zidovudine	Antiviral activity against HIV1 infected human thymidine kinase-deficient CEM cells Antiviral activity against HIV1 infected human thymidine kinase-deficient CEM cells	[PMID: 18585917]
CCRF-CEM	EC₅₀	0.007 μM Compound: AZT	Antiviral activity against HIV1 LAI infected in CEM cells Antiviral activity against HIV1 LAI infected in CEM cells	[PMID: 19153047]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against human CEM cells after 3 days by MTT assay Cytotoxicity against human CEM cells after 3 days by MTT assay	[PMID: 19153047]
CCRF-CEM	CC₅₀	86.2 μM Compound: AZT	Cytotoxicity against human CEM cells after 2 to 4 days by MTT assay Cytotoxicity against human CEM cells after 2 to 4 days by MTT assay	[PMID: 19596885]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against human CEM cells after 5 days Cytotoxicity against human CEM cells after 5 days	[PMID: 19948402]
CCRF-CEM	CC₅₀	24.06 μM Compound: AZT	Cytotoxicity against GFP expressing human CEM cells after 48 to 72 hrs by MTT assay Cytotoxicity against GFP expressing human CEM cells after 48 to 72 hrs by MTT assay	[PMID: 20137956]
CCRF-CEM	IC₅₀	1.05 μM Compound: AZT	Antiviral activity against HIV1 NL4-3 infected in GFP expressing human CEM cells assessed as inhibition of viral infection measured after 9 days postinfection by microfluorometry Antiviral activity against HIV1 NL4-3 infected in GFP expressing human CEM cells assessed as inhibition of viral infection measured after 9 days postinfection by microfluorometry	[PMID: 20137956]
CCRF-CEM	CC₅₀	24 μM Compound: AZT	Cytotoxicity against human CEM cells expressing GFP after 48 to 72 hrs by MTT assay Cytotoxicity against human CEM cells expressing GFP after 48 to 72 hrs by MTT assay	[PMID: 20350812]
CCRF-CEM	IC₅₀	1.04 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected human CEM cells expressing GFP measured up to 8 days postinfection by p24 antigen capture ELISA Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected human CEM cells expressing GFP measured up to 8 days postinfection by p24 antigen capture ELISA	[PMID: 20350812]
CCRF-CEM	CC₅₀	23.04 μM Compound: AZT	Cytotoxicity against human CEM cells expressing green fluorescent protein by MTT assay Cytotoxicity against human CEM cells expressing green fluorescent protein by MTT assay	[PMID: 20598537]
CCRF-CEM	EC₅₀	0.7 μM Compound: AZT	Cytotoxicity against african human CEM cells after 6 days by XTT assay Cytotoxicity against african human CEM cells after 6 days by XTT assay	[PMID: 20691339]
CCRF-CEM	IC₅₀	35.6 μM Compound: AZT	Antiviral activity against HIV1 infected in human CEM cells assessed as protection against virus-induced cytopathic effect after 6 days by XTT assay Antiviral activity against HIV1 infected in human CEM cells assessed as protection against virus-induced cytopathic effect after 6 days by XTT assay	[PMID: 20691339]
CCRF-CEM	CC₅₀	24.1 μM Compound: AZT	Cytotoxicity against human CEM-GFP cells after 48 hrs by MTT assay Cytotoxicity against human CEM-GFP cells after 48 hrs by MTT assay	[PMID: 21227704]
CCRF-CEM	EC₅₀	1.1 μM Compound: AZT	Antiviral activity against HIV1 NL4.3 infected in human CEM-GFP T cells assessed as inhibition of p24 antigen production after 7 days by ELISA Antiviral activity against HIV1 NL4.3 infected in human CEM-GFP T cells assessed as inhibition of p24 antigen production after 7 days by ELISA	[PMID: 21227704]
CCRF-CEM	CC₅₀	24.06 μM Compound: AZT	Cytotoxicity against human CEM cells expressing green fluorescent protein after 48 hrs by MTT assay Cytotoxicity against human CEM cells expressing green fluorescent protein after 48 hrs by MTT assay	[PMID: 21295891]
CCRF-CEM	EC₅₀	1.05 μM Compound: AZT	Antiviral activity against 0.05 MOI Human immunodeficiency virus 1 NL4.3 infected in human CEM cells expressing green fluorescent protein assessed as p24 antigen production measured 7 days post infection by ELISA Antiviral activity against 0.05 MOI Human immunodeficiency virus 1 NL4.3 infected in human CEM cells expressing green fluorescent protein assessed as p24 antigen production measured 7 days post infection by ELISA	[PMID: 21295891]
CCRF-CEM	IC₅₀	56.1 μM Compound: AZT	Cytotoxicity against human CEM cells after 5 days by trypan blue assay Cytotoxicity against human CEM cells after 5 days by trypan blue assay	[PMID: 21371895]
CCRF-CEM	EC₅₀	0.00032 μM Compound: N3ddThd	Concentration of the drug resulting in 50% reduction of the viral cytopathic effect against HIV-1 replication in CEM cells. Concentration of the drug resulting in 50% reduction of the viral cytopathic effect against HIV-1 replication in CEM cells.	[PMID: 2153206]
CCRF-CEM	IC₅₀	>100 μM Compound: N3ddThd	Concentration of the drug resulting in 50% growth inhibition of normal, uninfected cells against HIV-1 replication in CEM cells. Concentration of the drug resulting in 50% growth inhibition of normal, uninfected cells against HIV-1 replication in CEM cells.	[PMID: 2153206]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method	[PMID: 22014549]
CCRF-CEM	IC₅₀	7.7 μM Compound: AZT	Antiviral activity against HIV1 infected in CEM cells after 72 hrs by GFP reporter gene assay Antiviral activity against HIV1 infected in CEM cells after 72 hrs by GFP reporter gene assay	[PMID: 22549138]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT, zidovudine	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 23085031]
CCRF-CEM	CC₅₀	14.3 μM Compound: AZT	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 23623492]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 24091080]
CCRF-CEM	CC₅₀	>250 μM Compound: 4, AZT	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 24177359]
CCRF-CEM	EC₅₀	0.012 μM Compound: 4, AZT	Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis	[PMID: 24177359]
CCRF-CEM	EC₅₀	0.067 μM Compound: 4, AZT	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis	[PMID: 24177359]
CCRF-CEM	CC₅₀	>467.7 μM Compound: AZT	Cytotoxicity against human CEM/0 cells Cytotoxicity against human CEM/0 cells	[PMID: 24411122]
CCRF-CEM	IC₅₀	>14.9 μM Compound: AZT	Antiviral activity against HIV-2 ROD infected in thymidine kinase-deficient human CEM cells Antiviral activity against HIV-2 ROD infected in thymidine kinase-deficient human CEM cells	[PMID: 24411122]
CCRF-CEM	CC₅₀	14 μM Compound: AZT	Cytotoxicity against human CEM cell Cytotoxicity against human CEM cell	[PMID: 25458500]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against human CEM cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay Cytotoxicity against human CEM cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay	[PMID: 25701249]
CCRF-CEM	CC₅₀	>250 μM Compound: AZT	Cytotoxicity against human CEM/0 cells assessed as reduction in cell proliferation incubated for 4 to 5 days Cytotoxicity against human CEM/0 cells assessed as reduction in cell proliferation incubated for 4 to 5 days	[PMID: 26125628]
CCRF-CEM	CC₅₀	56.1 μM Compound: AZT	Cytotoxicity against human CEM cells assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay Cytotoxicity against human CEM cells assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay	[PMID: 26451771]
CCRF-CEM	IC₅₀	0.1 μM Compound: 1	Concentration of compound required to inhibit 50% of viral replication of human immunodeficiency virus in CEM-F cells Concentration of compound required to inhibit 50% of viral replication of human immunodeficiency virus in CEM-F cells	[PMID: 2754712]
CCRF-CEM	CC₅₀	>100 μM Compound: 1b; AZT	Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days	[PMID: 32515595]
CCRF-CEM	EC₅₀	0.003 μM Compound: AZT	Tested for the inhibitory activity of virus induced giant cell formation in HIV-1 infected CEM cells Tested for the inhibitory activity of virus induced giant cell formation in HIV-1 infected CEM cells	[PMID: 7527463]
CCRF-CEM	EC₅₀	0.004 μM Compound: AZT	Tested for the inhibitory activity of virus induced giant cell formation in HIV-2 infected CEM cells Tested for the inhibitory activity of virus induced giant cell formation in HIV-2 infected CEM cells	[PMID: 7527463]
CCRF-CEM	EC₅₀	>35 μM Compound: 2 (AZT)	Inhibitory effect against HIV-2 replication in CEM /TK-(thymidine kinase deficient) cells. Inhibitory effect against HIV-2 replication in CEM /TK-(thymidine kinase deficient) cells.	[PMID: 7538589]
CCRF-CEM	EC₅₀	0.011 μM Compound: 2 (AZT)	Inhibitory effect against HIV-1 replication in CEM cells. Inhibitory effect against HIV-1 replication in CEM cells.	[PMID: 7538589]
CCRF-CEM	EC₅₀	0.011 μM Compound: 2 (AZT)	Inhibitory effect against HIV-2 replication in CEM cells. Inhibitory effect against HIV-2 replication in CEM cells.	[PMID: 7538589]
CCRF-CEM	CC₅₀	500 μM Compound: AZT	Cytotoxic concentration against HIV-1 infected CEM cell lines Cytotoxic concentration against HIV-1 infected CEM cell lines	[PMID: 7837220]
CCRF-CEM	IC₅₀	0.01 μM Compound: AZT	Inhibitory concentration against HIV-1 infected CEM cell lines Inhibitory concentration against HIV-1 infected CEM cell lines	[PMID: 7837220]
CCRF-CEM	EC₅₀	3.0 x 10^-9 M Compound: AZT	Tested for in vitro drug concentration which produces 50% survival of HIV-1 infected CEM cells relative to uninfected untreated controls Tested for in vitro drug concentration which produces 50% survival of HIV-1 infected CEM cells relative to uninfected untreated controls	[PMID: 7932583]
CCRF-CEM	IC₅₀	0.0005 M Compound: AZT	Tested for in vitro drug concentration which results in 50% survival of uninfected untreated control CEM cells Tested for in vitro drug concentration which results in 50% survival of uninfected untreated control CEM cells	[PMID: 7932583]
CCRF-CEM	EC₅₀	3.0 x 10^-9 M Compound: AZT	Effective concentration in vitro against HIV-1-infected CEM cells relative to uninfected untreated controls Effective concentration in vitro against HIV-1-infected CEM cells relative to uninfected untreated controls	[PMID: 7996541]
CCRF-CEM	IC₅₀	0.0005 M Compound: AZT	Inhibitory concentration (cytotoxic activity) which results in a 50% survival of HIV-1-infected CEM cells relative to uninfected untreated control cells Inhibitory concentration (cytotoxic activity) which results in a 50% survival of HIV-1-infected CEM cells relative to uninfected untreated control cells	[PMID: 7996541]
CCRF-CEM	IC₅₀	13 μM Compound: AZT	Cytotoxic concentration against CEM cells was determined on day 6 Cytotoxic concentration against CEM cells was determined on day 6	[PMID: 8057301]
CCRF-CEM	IC₅₀	30.9 μM Compound: AZT	Cytotoxicity against uninfected PHA-stimulated CEM cells was determined. Cytotoxicity against uninfected PHA-stimulated CEM cells was determined.	[PMID: 8421287]
CCRF-CEM	CC₅₀	>500 μM Compound: 1	cytotoxic activity in CEM/0 cell line cytotoxic activity in CEM/0 cell line	[PMID: 8478904]
CCRF-CEM	EC₅₀	>100 μM Compound: 1	Antiviral activity in HIV-2 infected CEM cells which are deficient in Thymidine Kinase Antiviral activity in HIV-2 infected CEM cells which are deficient in Thymidine Kinase	[PMID: 8478904]
CCRF-CEM	EC₅₀	0.003 μM Compound: 1	Anti HIV-1 activity in human lymphocyte CEM/0 cell line Anti HIV-1 activity in human lymphocyte CEM/0 cell line	[PMID: 8478904]
CCRF-CEM	EC₅₀	0.004 μM Compound: 1	Anti HIV-2 activity in human lymphocyte CEM/0 cell line Anti HIV-2 activity in human lymphocyte CEM/0 cell line	[PMID: 8478904]
CCRF-CEM	EC₅₀	0.186 μM Compound: AZT	Effective concentration against HIV-1-infected CEM cells in mice administered intraperitoneally Effective concentration against HIV-1-infected CEM cells in mice administered intraperitoneally	[PMID: 8627600]
CCRF-CEM	IC₅₀	191 μM Compound: AZT	Ability to reduce viable cell number on HIV-1-infected CEM cells in mice after intraperitoneal administration Ability to reduce viable cell number on HIV-1-infected CEM cells in mice after intraperitoneal administration	[PMID: 8627600]
CCRF-CEM	EC₅₀	0.023 μM Compound: AZT	Anti-HIV activity against HIV-I RFII strain in CEM cell line Anti-HIV activity against HIV-I RFII strain in CEM cell line	[PMID: 8632437]
CCRF-CEM	IC₅₀	301.6 μM Compound: AZT	Anti-HIV activity against HIV-I RFII strain in CEM cell line Anti-HIV activity against HIV-I RFII strain in CEM cell line	[PMID: 8632437]
CCRF-CEM	CC₅₀	>500 μM Compound: 1	Cytotoxic concentration against CEM cells (in vitro) Cytotoxic concentration against CEM cells (in vitro)	[PMID: 8648614]
CCRF-CEM	EC₅₀	0.003 μM Compound: 1	Activity against HIV-1 in CEM cells (in vitro) Activity against HIV-1 in CEM cells (in vitro)	[PMID: 8648614]
CCRF-CEM	EC₅₀	0.004 μM Compound: 1	Activity against HIV-2 in CEM cells (in vitro) Activity against HIV-2 in CEM cells (in vitro)	[PMID: 8648614]
CCRF-CEM	CC₅₀	>125 μg/mL Compound: zidovudine	Cytotoxic concentration required to reduce CEM cell viability by 50% Cytotoxic concentration required to reduce CEM cell viability by 50%	[PMID: 8709116]
CCRF-CEM	CC₅₀	>100 μM Compound: AZT	Concentration required to reduce 50% of the number of CEM/O cells in the mock infected cell cultures. Concentration required to reduce 50% of the number of CEM/O cells in the mock infected cell cultures.	[PMID: 8765527]
CCRF-CEM	EC₅₀	0.004 μM Compound: AZT	Concentration required to reduce 50% of the number of CEM/O cells in the HIV-2 infected cell cultures. Concentration required to reduce 50% of the number of CEM/O cells in the HIV-2 infected cell cultures.	[PMID: 8765527]
CCRF-CEM	EC₅₀	0.006 μM Compound: AZT	Concentration required to reduce 50% of the number of CEM/O cells in the HIV-1 infected cell cultures. Concentration required to reduce 50% of the number of CEM/O cells in the HIV-1 infected cell cultures.	[PMID: 8765527]
CCRF-CEM	IC₅₀	0.005 μg/mL Compound: Azidothymidine	Inhibition of human immunodeficiency virus-1 (HIV-1) induced cytopathicity in CEM cells Inhibition of human immunodeficiency virus-1 (HIV-1) induced cytopathicity in CEM cells	[PMID: 8831773]
CCRF-CEM	IC₅₀	0.008 μg/mL Compound: Azidothymidine	Inhibition of human immunodeficiency virus-2 (HIV-2) induced cytopathicity in CEM cells Inhibition of human immunodeficiency virus-2 (HIV-2) induced cytopathicity in CEM cells	[PMID: 8831773]
CCRF-CEM	CC₅₀	>100 μg/mL Compound: AZT	Cytotoxic concentration which is required to reduce human CEM cell viability by 50%. Cytotoxic concentration which is required to reduce human CEM cell viability by 50%.	[PMID: 9046339]
CCRF-CEM	EC₅₀	0.0007 μg/mL Compound: AZT	50% effective concentration of compound which is required to protect human CEM cells against HIV-1 induced giant cell formation. 50% effective concentration of compound which is required to protect human CEM cells against HIV-1 induced giant cell formation.	[PMID: 9046339]
CCRF-CEM	EC₅₀	0.0009 μg/mL Compound: AZT	50% effective concentration of compound which is required to protect human CEM cells against HIV-2 induced giant cell formation. 50% effective concentration of compound which is required to protect human CEM cells against HIV-2 induced giant cell formation.	[PMID: 9046339]
CCRF-CEM	CC₅₀	14.3 mM Compound: AZT	Cytotoxic concentration required to inhibit 50% of HIV-1 in CEM cells Cytotoxic concentration required to inhibit 50% of HIV-1 in CEM cells	[PMID: 9341906]
CCRF-CEM	IC₅₀	13 μM Compound: AZT	Compound was evaluated for its toxicity by Calorimetric assay in CEM Compound was evaluated for its toxicity by Calorimetric assay in CEM	[PMID: 9357530]
CCRF-CEM	CC₅₀	35.6 μg/mL Compound: AZT	compound tested for anti-HIV-1 activity by plaque reduction assay against HIV-1 in CEM cells compound tested for anti-HIV-1 activity by plaque reduction assay against HIV-1 in CEM cells	[PMID: 9548818]
CCRF-CEM	IC₅₀	0.003 μg/mL Compound: AZT	compound tested for inhibitory activity by plaque reduction assay against HIV-1 in CEM cells compound tested for inhibitory activity by plaque reduction assay against HIV-1 in CEM cells	[PMID: 9548818]
CCRF-CEM	CC₅₀	>100 μM Compound: AZT	The cytotoxicity was measured on wild type CEM/O cells. The cytotoxicity was measured on wild type CEM/O cells.	[PMID: 9554875]
CCRF-CEM	EC₅₀	>100 μM Compound: AZT	Antiviral activity was measured on HIV-2 in mutant thymidine kinase-deficient CEM/TK- cells Antiviral activity was measured on HIV-2 in mutant thymidine kinase-deficient CEM/TK- cells	[PMID: 9554875]
CCRF-CEM	EC₅₀	0.006 μM Compound: AZT	Antiviral activity was measured on HIV-2 in wild-type CEM/O cells Antiviral activity was measured on HIV-2 in wild-type CEM/O cells	[PMID: 9554875]
CCRF-CEM	EC₅₀	0.007 μM Compound: AZT	Antiviral activity was measured on HIV-1 in wild-type CEM/O cells Antiviral activity was measured on HIV-1 in wild-type CEM/O cells	[PMID: 9554875]
CCRF-CEM	CC₅₀	>0.0001 M Compound: AZT	Compound was evaluated for cytotoxicity against thymidine kinase deficient CEM cell line infected with HIV-1 Compound was evaluated for cytotoxicity against thymidine kinase deficient CEM cell line infected with HIV-1	[PMID: 9871705]
CCRF-CEM	EC₅₀	>0.0001 M Compound: AZT	Compound was evaluated for anti-HIV activity against thymidine kinase deficient CEM cell line infected with HIV-1 Compound was evaluated for anti-HIV activity against thymidine kinase deficient CEM cell line infected with HIV-1	[PMID: 9871705]
CCRF-CEM	IC₅₀	14 μM Compound: AZT	Compound was evaluated for its cytotoxicity against CEM cells. Compound was evaluated for its cytotoxicity against CEM cells.	[PMID: 9873395]
CCRF-CEM	CC₅₀	>100 μM Compound: AZT	Compound was tested for cytotoxicity against HIV-1 in CEM/TK- cells Compound was tested for cytotoxicity against HIV-1 in CEM/TK- cells	[PMID: 9873664]
CCRF-CEM	IC₅₀	>100 μM Compound: AZT	Compound was tested for inhibitory activity against HIV-1 replication in CEM/TK- cells Compound was tested for inhibitory activity against HIV-1 replication in CEM/TK- cells	[PMID: 9873664]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against Homo sapiens (human) CEM cells after 5 days celltiter 96 aqueous assay Cytotoxicity against Homo sapiens (human) CEM cells after 5 days celltiter 96 aqueous assay	10.1007/s00044-011-9912-x
CCRF-CEM	EC₅₀	>100000 nM Compound: 1	In vitro inhibitory activity against replication of HIV-2 in human lymphocyte thymidine kinase deficient CEM cells In vitro inhibitory activity against replication of HIV-2 in human lymphocyte thymidine kinase deficient CEM cells	10.1016/0960-894X(94)80009-X
CCRF-CEM	EC₅₀	3 nM Compound: 1	In vitro inhibitory activity against replication of HIV-1 in human lymphocyte CEM cells In vitro inhibitory activity against replication of HIV-1 in human lymphocyte CEM cells	10.1016/0960-894X(94)80009-X
CCRF-CEM	EC₅₀	3.5 nM Compound: 1	In vitro inhibitory activity against replication of HIV-2 in human lymphocyte CEM cells In vitro inhibitory activity against replication of HIV-2 in human lymphocyte CEM cells	10.1016/0960-894X(94)80009-X
CCRF-CEM	IC₅₀	14 μM Compound: AZT	Cytotoxicity in CEM cells Cytotoxicity in CEM cells	10.1016/0960-894X(95)00133-E
CCRF-CEM	CC₅₀	14.3 μM Compound: AZT	Cytotoxic concentration towards CEM cells Cytotoxic concentration towards CEM cells	10.1016/0960-894X(95)00302-A
CCRF-CEM	IC₅₀	14 μM Compound: AZT	Compound was evaluated for cytotoxicity against CEM cells Compound was evaluated for cytotoxicity against CEM cells	10.1016/0960-894X(96)00171-0
CCRF-CEM	CC₅₀	>100 μM Compound: 3 (AZT)	Compound was evaluated for the cytotoxic concentration to inhibit HIV replication in CEM cells. Compound was evaluated for the cytotoxic concentration to inhibit HIV replication in CEM cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	EC₅₀	>100 μM Compound: 3 (AZT)	Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells. Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	EC₅₀	0.005 μM Compound: 3 (AZT)	Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells. Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	EC₅₀	0.008 μM Compound: 3 (AZT)	Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells. Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	CC₅₀	>100 μM Compound: 3[AZT]	Compound was evaluated for cytotoxic activity against CEM cells. Compound was evaluated for cytotoxic activity against CEM cells.	10.1016/0960-894X(96)00433-7
CCRF-CEM	EC₅₀	0.005 μM Compound: 3[AZT]	Compound was evaluated for antiviral activity against HIV-1 (IIIB) infected CEM cells. Compound was evaluated for antiviral activity against HIV-1 (IIIB) infected CEM cells.	10.1016/0960-894X(96)00433-7
CCRF-CEM	EC₅₀	0.008 μM Compound: 3[AZT]	Compound was evaluated for antiviral activity against HIV-2 (ROD) infected CEM cells. Compound was evaluated for antiviral activity against HIV-2 (ROD) infected CEM cells.	10.1016/0960-894X(96)00433-7
CCRF-CEM	CC₅₀	>250 μM Compound: AZT	Concentration required to reduce cell viability of CEM/0 cells by 50% Concentration required to reduce cell viability of CEM/0 cells by 50%	10.1016/0960-894X(96)00443-X
CCRF-CEM	EC₅₀	0.003 μM Compound: AZT	Anti-HIV activity against HIV-1 infected CEM/0 cell lines. Anti-HIV activity against HIV-1 infected CEM/0 cell lines.	10.1016/0960-894X(96)00443-X
CCRF-CEM	EC₅₀	0.006 μM Compound: AZT	Anti-HIV activity against HIV-2 infected CEM/0 cell lines. Anti-HIV activity against HIV-2 infected CEM/0 cell lines.	10.1016/0960-894X(96)00443-X
CCRF-CEM	CC₅₀	>250 μM Compound: AZT	Concentration of compound required to reduce viability of CEM/0 cells by 50%. Concentration of compound required to reduce viability of CEM/0 cells by 50%.	10.1016/0960-894X(96)00444-1
CCRF-CEM	EC₅₀	0.003 μM Compound: AZT	Compound was evaluated for anti-HIV activity against HIV-1 infected CEM/0 cell lines. Compound was evaluated for anti-HIV activity against HIV-1 infected CEM/0 cell lines.	10.1016/0960-894X(96)00444-1
CCRF-CEM	EC₅₀	0.006 μM Compound: AZT	Compound was evaluated for anti-HIV activity against HIV-2 infected CEM/0 cell lines. Compound was evaluated for anti-HIV activity against HIV-2 infected CEM/0 cell lines.	10.1016/0960-894X(96)00444-1
CEM-c113	EC₅₀	0.006 μM Compound: AZT	Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by MTT assay. Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by MTT assay.	[PMID: 8385224]
CEM-c113	IC₅₀	20 μM Compound: AZT	Antiviral activity measured in lymphocytic cell line (CEM-C113) infected with HIV-1 cell free supernatants Antiviral activity measured in lymphocytic cell line (CEM-C113) infected with HIV-1 cell free supernatants	[PMID: 8385224]
CEM-c113	CC₅₀	>5 μM Compound: AZT	Concentration required to reduce by 50% the viability of noninfected treated CEM-CL13 cells Concentration required to reduce by 50% the viability of noninfected treated CEM-CL13 cells	[PMID: 9154976]
CEM-SS	EC₅₀	11 nM Compound: AZT	Inhibitory activity against HIV-1 IIIB in CEM-SS infected cells (Experiment 2) Inhibitory activity against HIV-1 IIIB in CEM-SS infected cells (Experiment 2)	[PMID: 10206539]
CEM-SS	EC₅₀	126 nM Compound: AZT	Inhibitory activity against HIV-1 IIIB in CEM-SS infected cells (Experiment 1) Inhibitory activity against HIV-1 IIIB in CEM-SS infected cells (Experiment 1)	[PMID: 10206539]
CEM-SS	EC₅₀	0.0038 μM Compound: AZT	The compound was tested for anti HIV activity in CEM-SS cell lines The compound was tested for anti HIV activity in CEM-SS cell lines	[PMID: 10411486]
CEM-SS	IC₅₀	>1 μM Compound: AZT	The compound was tested for anti HIV activity in CEM-SS cell lines The compound was tested for anti HIV activity in CEM-SS cell lines	[PMID: 10411486]
CEM-SS	CC₅₀	>100 μM Compound: 1, AZT	Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50% Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%	[PMID: 10821705]
CEM-SS	EC₅₀	0.002 μM Compound: 1, AZT	Effective concentration required to achieve 50% inhibition of HIV-1 LAI replication in human T4 lymphoblastoid CEM-SS cells. Effective concentration required to achieve 50% inhibition of HIV-1 LAI replication in human T4 lymphoblastoid CEM-SS cells.	[PMID: 10821705]
CEM-SS	CC₅₀	>100000 nM Compound: AZT	Tested for cytotoxic concentration on HIV-I Lai wild type in CEM-SS cell line Tested for cytotoxic concentration on HIV-I Lai wild type in CEM-SS cell line	[PMID: 11052800]
CEM-SS	IC₅₀	3 nM Compound: AZT	Tested for inhibitory concentration on HIV-I Lai wild type in CEM-SS cell line Tested for inhibitory concentration on HIV-I Lai wild type in CEM-SS cell line	[PMID: 11052800]
CEM-SS	CC₅₀	>100 μM Compound: AZT	Cytotoxic concentration to inhibit HIV replication in TK CEM-SS cell line Cytotoxic concentration to inhibit HIV replication in TK CEM-SS cell line	[PMID: 11425558]
CEM-SS	EC₅₀	>100 μM Compound: AZT	Effective concentration to inhibit HIV replication in TK CEM-SS cell line Effective concentration to inhibit HIV replication in TK CEM-SS cell line	[PMID: 11425558]
CEM-SS	EC₅₀	0.0019 μM Compound: AZT	Concentration which produces a 50% survival of HIV-1 infected cells relative to uninfected control CEM-SS cells (in vitro anti-HIV activity) Concentration which produces a 50% survival of HIV-1 infected cells relative to uninfected control CEM-SS cells (in vitro anti-HIV activity)	[PMID: 11462972]
CEM-SS	IC₅₀	>1 μM Compound: AZT	Concentration which results in 50% survival of uninfected untreated control CEM-SS cells (cytotoxicity of the compound) Concentration which results in 50% survival of uninfected untreated control CEM-SS cells (cytotoxicity of the compound)	[PMID: 11462972]
CEM-SS	CC₅₀	>100 μM Compound: AZT	Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM-SS cells Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM-SS cells	[PMID: 12593658]
CEM-SS	EC₅₀	0.003 μM Compound: AZT	Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM-SS cells Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM-SS cells	[PMID: 12593658]
CEM-SS	CC₅₀	>100 μM Compound: AZT	Cytotoxic concentration required to reduce viability of uninfected cells in CEM-SS cell line Cytotoxic concentration required to reduce viability of uninfected cells in CEM-SS cell line	[PMID: 14521418]
CEM-SS	EC₅₀	0.006 μM Compound: AZT	Effective concentration required to inhibit HIV-1 replication in CEM-SS cell line Effective concentration required to inhibit HIV-1 replication in CEM-SS cell line	[PMID: 14521418]
CEM-SS	EC₅₀	0.0063 μM Compound: AZT	Effective concentration of compound against HIV-1 LAI strain in CEM-SS cells Effective concentration of compound against HIV-1 LAI strain in CEM-SS cells	[PMID: 14698189]
CEM-SS	CC₅₀	>100 μM Compound: AZT, zidovudine	Cytotoxicity against human CEM-SS cells Cytotoxicity against human CEM-SS cells	[PMID: 18585917]
CEM-SS	EC₅₀	0.003 μM Compound: AZT, zidovudine	Antiviral activity against HIV1 infected human CEM-SS cells Antiviral activity against HIV1 infected human CEM-SS cells	[PMID: 18585917]
CEM-SS	IC₅₀	5.1 mM Compound: AZT	Concentration of compound required to 50% growth inhibition of HIV-1 in CEM-SS cells Concentration of compound required to 50% growth inhibition of HIV-1 in CEM-SS cells	[PMID: 1901911]
CEM-SS	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against human CEM-SS cells by MTT assay Cytotoxicity against human CEM-SS cells by MTT assay	[PMID: 19944610]
CEM-SS	IC₅₀	0.0051 μM Compound: AZT	Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as inhibition of viral replication by MTT assay Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as inhibition of viral replication by MTT assay	[PMID: 19944610]
CEM-SS	IC₅₀	>0.1 μM Compound: AZT	Cytotoxicity against human CEM-SS cells by MTS assay Cytotoxicity against human CEM-SS cells by MTS assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.002 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
CEM-SS	IC₅₀	0.003 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.003 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
CEM-SS	IC₅₀	0.004 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B expressing nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B expressing nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.006 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
CEM-SS	IC₅₀	0.007 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.01 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.015 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 D1 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 D1 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.028 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 A7 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 A7 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.04 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 H10 harboring Tyr127His, Gly140Glu, Glu149Lys, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporat Antiviral activity against Human immunodeficiency virus 1 H10 harboring Tyr127His, Gly140Glu, Glu149Lys, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporat	[PMID: 20086149]
CEM-SS	IC₅₀	0.08 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 A12 harboring Tyr127His, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 A12 harboring Tyr127His, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	EC₅₀	0.009 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay	[PMID: 20086159]
CEM-SS	CC₅₀	>1 μM Compound: AZT	Cytotoxicity against human CEM-SS cells by MTT assay Cytotoxicity against human CEM-SS cells by MTT assay	[PMID: 20112915]
CEM-SS	IC₅₀	0.0024 μM Compound: AZT	Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as RT activity after 5 days by single passage assay Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as RT activity after 5 days by single passage assay	[PMID: 20112915]
CEM-SS	IC₅₀	5.6 μM Compound: AZT	In vitro inhibition of CEM-SS cell growth by 50 % In vitro inhibition of CEM-SS cell growth by 50 %	[PMID: 2016713]
CEM-SS	CC₅₀	>1 μM Compound: AZT	Cytotoxicity against human CEM-SS cells assessed as cell viability by XTT assay Cytotoxicity against human CEM-SS cells assessed as cell viability by XTT assay	[PMID: 21035347]
CEM-SS	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 infected in human CEM-SS cells assessed as virus induced cytopathic effects Antiviral activity against Human immunodeficiency virus 1 infected in human CEM-SS cells assessed as virus induced cytopathic effects	[PMID: 21035347]
CEM-SS	EC₅₀	2 nM Compound: 2, AZT	Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay	[PMID: 22858097]
CEM-SS	CC₅₀	>1 μM Compound: AZT, 3'-azidothymidine	Cytotoxicity against human CEM-SS cells assessed as cell viability after 6 days by MTS assay Cytotoxicity against human CEM-SS cells assessed as cell viability after 6 days by MTS assay	[PMID: 24102161]
CEM-SS	EC₅₀	0.0053 μM Compound: AZT, 3'-azidothymidine	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay	[PMID: 24102161]
CEM-SS	CC₅₀	>0.1 μM Compound: AZT ; azidothymidine	Cytotoxicity against mock-infected human CEM-SS cells Cytotoxicity against mock-infected human CEM-SS cells	[PMID: 27234889]
CEM-SS	EC₅₀	0.002 μM Compound: AZT ; azidothymidine	Antiviral activity against HIV-1 RF infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay Antiviral activity against HIV-1 RF infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay	[PMID: 27234889]
CEM-SS	CC₅₀	>1000 μM Compound: AZT	Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33711763]
CEM-SS	CC₅₀	>100000 nM Compound: AZT	Cytotoxicity against wild type HIV-1-IIIB strain infected CEMSS cells. Cytotoxicity against wild type HIV-1-IIIB strain infected CEMSS cells.	[PMID: 7473595]
CEM-SS	IC₅₀	3 nM Compound: AZT	Inhibition of wild type HIV-1-IIIB strain replication in CEM-SS cells Inhibition of wild type HIV-1-IIIB strain replication in CEM-SS cells	[PMID: 7473595]
CEM-SS	CC₅₀	>100 μM Compound: AZT	Antiviral activity in CEM-SS cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50% Antiviral activity in CEM-SS cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%	[PMID: 7562927]
CEM-SS	EC₅₀	0.006 μM Compound: AZT	Antiviral activity in CEM-SS cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined Antiviral activity in CEM-SS cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined	[PMID: 7562927]
CEM-SS	IC₅₀	>1 μM Compound: AZT	Inhibitory activity against the cytopathic effect of HIV-2 G910-6(AZT-res) strain in CEM-SS cells Inhibitory activity against the cytopathic effect of HIV-2 G910-6(AZT-res) strain in CEM-SS cells	[PMID: 7650678]
CEM-SS	IC₅₀	0.002 μM Compound: AZT	Inhibitory activity against the cytopathic effect of HIV-1 IIIB strain in CEM-SS cells Inhibitory activity against the cytopathic effect of HIV-1 IIIB strain in CEM-SS cells	[PMID: 7650678]
CEM-SS	IC₅₀	0.002 μM Compound: AZT	Inhibitory activity against the HIV-1-induced cytopathic effect in CEM-SS cell line Inhibitory activity against the HIV-1-induced cytopathic effect in CEM-SS cell line	[PMID: 7650678]
CEM-SS	IC₅₀	0.003 μM Compound: AZT	Inhibitory activity against the cytopathic effect of HIV-1 RFstrain in CEM-SS cells Inhibitory activity against the cytopathic effect of HIV-1 RFstrain in CEM-SS cells	[PMID: 7650678]
CEM-SS	IC₅₀	0.004 μM Compound: AZT	Inhibitory activity against the cytopathic effect of HIV-1 LAV strain in CEM-SS cells Inhibitory activity against the cytopathic effect of HIV-1 LAV strain in CEM-SS cells	[PMID: 7650678]
CEM-SS	IC₅₀	0.005 μM Compound: AZT	Inhibitory activity against the cytopathic effect of HIV-2 A17 (pyridinone-res) strain in CEM-SS cells Inhibitory activity against the cytopathic effect of HIV-2 A17 (pyridinone-res) strain in CEM-SS cells	[PMID: 7650678]
CEM-SS	IC₅₀	0.005 μM Compound: AZT	Inhibitory activity against the cytopathic effect of HIV-2 ROD strain in CEM-SS cells Inhibitory activity against the cytopathic effect of HIV-2 ROD strain in CEM-SS cells	[PMID: 7650678]
CEM-SS	IC₅₀	0.03 μM Compound: AZT	Inhibitory activity against the cytopathic effect of HIV-2 MS strain in CEM-SS cells Inhibitory activity against the cytopathic effect of HIV-2 MS strain in CEM-SS cells	[PMID: 7650678]
CEM-SS	EC₅₀	0.004 μM Compound: AZT	Effective concentration required for antiviral activity against HIV strain IIIB in CEM-SS cells by XTT assay Effective concentration required for antiviral activity against HIV strain IIIB in CEM-SS cells by XTT assay	[PMID: 7932526]
CEM-SS	EC₅₀	0.095 μM Compound: AZT	Effective concentration required for antiviral activity against T cell line of CEM-SS cells of Human by XTT assay Effective concentration required for antiviral activity against T cell line of CEM-SS cells of Human by XTT assay	[PMID: 7932526]
CEM-SS	EC₅₀	0.0019 μM Compound: AZT	Effective concentration against 50% survival of HIV -1 infected cells relative to uninfected untreated control (in vitro anti HIV-1 activity) Effective concentration against 50% survival of HIV -1 infected cells relative to uninfected untreated control (in vitro anti HIV-1 activity)	[PMID: 8709096]
CEM-SS	IC₅₀	>1 μM Compound: AZT	Cytotoxic concentration against 50% survival of uninfected untreated control CEM-SS cells Cytotoxic concentration against 50% survival of uninfected untreated control CEM-SS cells	[PMID: 8709096]
CEM-SS	CC₅₀	>1 μM Compound: AZT	Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%. Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.	[PMID: 9240351]
CEM-SS	EC₅₀	0.0045 μM Compound: AZT	Concentration required to achieve 50% protection of CEM-SS cells against the cytopathic effect of HIV-1. Concentration required to achieve 50% protection of CEM-SS cells against the cytopathic effect of HIV-1.	[PMID: 9240351]
CEM-SS	IC₅₀	0.0026 μM Compound: Zidovudine (AZT)	Compound was tested for activity against HIV-1 by syncytial plaque assay performed in duplicate using CEM-SS cells Compound was tested for activity against HIV-1 by syncytial plaque assay performed in duplicate using CEM-SS cells	[PMID: 9548815]
CEM-SS	IC₅₀	0.0031 μM Compound: Zidovudine (AZT)	Antiviral activity against Human Immunodeficiency Virus by Reverse transcriptase assay in CEM-SS cells Antiviral activity against Human Immunodeficiency Virus by Reverse transcriptase assay in CEM-SS cells	[PMID: 9548815]
CEM-SS	IC₅₀	1.9 μM Compound: Zidovudine (AZT)	Compounds were tested for cytotoxicity against CEM-SS cells in terms of incorporation of [3H]dThd Compounds were tested for cytotoxicity against CEM-SS cells in terms of incorporation of [3H]dThd	[PMID: 9548815]
CEM-SS	CC₅₀	>100 μM Compound: AZT	Compound was tested for cytotoxicity against HIV-1 in CEM-SS cells Compound was tested for cytotoxicity against HIV-1 in CEM-SS cells	[PMID: 9873664]
CEM-SS	IC₅₀	0.006 μM Compound: AZT	Compound was tested for inhibitory activity against HIV-1 replication in CEM-SS cells Compound was tested for inhibitory activity against HIV-1 replication in CEM-SS cells	[PMID: 9873664]
CEM-SS	EC₅₀	0.02 μM Compound: AZT	Effective concentration required for 50% inhibition of viral replication by syncytium-forming assay carried out in CEM-SS cells Effective concentration required for 50% inhibition of viral replication by syncytium-forming assay carried out in CEM-SS cells	10.1016/0960-894X(95)00260-Z
CEM-SS	EC₅₀	0.3 μM Compound: AZT	Effective concentration required for 50% inhibition of viral replication by XTT cytoprotection assay carried out in CEM-SS cells Effective concentration required for 50% inhibition of viral replication by XTT cytoprotection assay carried out in CEM-SS cells	10.1016/0960-894X(95)00260-Z
CEM-SS	IC₅₀	>1887 μM Compound: AZT	Compound was evaluated for inhibitory activity against cell growth Compound was evaluated for inhibitory activity against cell growth	10.1016/0960-894X(95)00260-Z
CEM-SS	CC₅₀	>10 μM Compound: AZT	Compound was evaluated for cytotoxicity against CEM SS cells infected with HIV-1(LAI strain). Compound was evaluated for cytotoxicity against CEM SS cells infected with HIV-1(LAI strain).	10.1016/0960-894X(95)00584-G
CEM-SS	IC₅₀	3 μM Compound: AZT	Compound was evaluated for antiviral activity against CEM SS cells infected with HIV-1(LAI strain). Compound was evaluated for antiviral activity against CEM SS cells infected with HIV-1(LAI strain).	10.1016/0960-894X(95)00584-G
CEM-TK(-)	EC₅₀	>100 μM Compound: AZT	Concentration required to protect CEM/TK cells against the cytopathicity of HIV-2 by 50% Concentration required to protect CEM/TK cells against the cytopathicity of HIV-2 by 50%	[PMID: 11356105]
CEM-TK(-)	CC₅₀	>1000 μM Compound: AZT	Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33711763]
CEM-TK(-)	CC₅₀	>200 μg/mL Compound: AZT	Cytotoxic concentration which is required to reduce CEM/TK- cell viability by 50%. Cytotoxic concentration which is required to reduce CEM/TK- cell viability by 50%.	[PMID: 9046339]
CEM-TK(-)	EC₅₀	>25 μg/mL Compound: AZT	50% effective concentration of compound which is required to protect Thymidine kinase deficient human CEM (CEM/TK-) cells against HIV-2. 50% effective concentration of compound which is required to protect Thymidine kinase deficient human CEM (CEM/TK-) cells against HIV-2.	[PMID: 9046339]
CEM-TK(+)	CC₅₀	>100 μM Compound: AZT	Cytotoxic concentration required to reduce viability of uninfected cells in CEM/TK cell line Cytotoxic concentration required to reduce viability of uninfected cells in CEM/TK cell line	[PMID: 14521418]
CEM-TK(+)	CC₅₀	>100 μM Compound: AZT	Antiviral activity in CEM/TK cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50% Antiviral activity in CEM/TK cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%	[PMID: 7562927]
CEM-TK(+)	EC₅₀	>100 μM Compound: AZT	Antiviral activity in CEM/TK cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined Antiviral activity in CEM/TK cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined	[PMID: 7562927]
CEM-TK(+)	EC₅₀	>100 μM Compound: 1	Activity against HIV-1 in CEM/TK cells (in vitro) Activity against HIV-1 in CEM/TK cells (in vitro)	[PMID: 8648614]
CEM-TK(+)	EC₅₀	>100 μM Compound: AZT	Concentration required to reduce 50% of the number of CEM/TK cells in the HIV-2 infected cell cultures. Concentration required to reduce 50% of the number of CEM/TK cells in the HIV-2 infected cell cultures.	[PMID: 8765527]
CEM-TK(+)	EC₅₀	>250 μM Compound: AZT	Anti-HIV activity against HIV-2 infected CEM/TK- cell lines. Anti-HIV activity against HIV-2 infected CEM/TK- cell lines.	10.1016/0960-894X(96)00443-X
CEM-TK(+)	EC₅₀	>250 μM Compound: AZT	Compound was evaluated for anti-HIV activity against HIV-2 infected CEM/TK- cell lines. Compound was evaluated for anti-HIV activity against HIV-2 infected CEM/TK- cell lines.	10.1016/0960-894X(96)00444-1
CFU-GM	IC₅₀	1.5 μM Compound: AZT	Compound was tested for inhibitory activity against human myeloid cells (CFU-GM) Compound was tested for inhibitory activity against human myeloid cells (CFU-GM)	[PMID: 8057301]
DU-145	IC₅₀	34.45 μM Compound: 13, AZT	Cytotoxicity against human DU145 cells after 48 hrs by SRB method Cytotoxicity against human DU145 cells after 48 hrs by SRB method	[PMID: 25933593]
Fibroblast	IC₅₀	0.02 μg/mL Compound: Azidothymidine	Compound was tested for anti-retroviral activity against moloney murine sarcoma virus (MSV) in murine C3H/3T3 embryo fibroblast cell culture Compound was tested for anti-retroviral activity against moloney murine sarcoma virus (MSV) in murine C3H/3T3 embryo fibroblast cell culture	[PMID: 8831773]
FM3A	IC₅₀	203 μM Compound: AZT	Inhibitory effect of compound on the proliferation of murine mammary carcinoma cells FM3A/0 Inhibitory effect of compound on the proliferation of murine mammary carcinoma cells FM3A/0	[PMID: 11356105]
H9	EC₅₀	0.012 μg/mL Compound: AZT	Inhibitory concentration required to inhibit HIV replication in H9 lymphocytes growth by 50% Inhibitory concentration required to inhibit HIV replication in H9 lymphocytes growth by 50%	[PMID: 10021911]
H9	IC₅₀	500 μg/mL Compound: AZT	Inhibitory concentration required to inhibit uninfected H9 lymphocytic cell growth by 50% Inhibitory concentration required to inhibit uninfected H9 lymphocytic cell growth by 50%	[PMID: 10021911]
H9	EC₅₀	0.012 μg/mL Compound: AZT	Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication	[PMID: 10757718]
H9	IC₅₀	500 μg/mL Compound: AZT	Cytotoxicity against human H9 cells Cytotoxicity against human H9 cells	[PMID: 10757718]
H9	EC₅₀	0.045 μM Compound: AZT	Concentration required to inhibit HIV-1 replication in H9 lymphocyte cells Concentration required to inhibit HIV-1 replication in H9 lymphocyte cells	[PMID: 10843202]
H9	IC₅₀	1875 μM Compound: AZT	Concentration required to inhibit uninfected H9 cell growth Concentration required to inhibit uninfected H9 cell growth	[PMID: 10843202]
H9	EC₅₀	0.045 μM Compound: AZT	Cytotoxicity against mock-infected human H9 cells Cytotoxicity against mock-infected human H9 cells	[PMID: 11141100]
H9	IC₅₀	1871 μM Compound: AZT	Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days	[PMID: 11141100]
H9	EC₅₀	0.045 μM Compound: AZT	Evaluated for the anti-HIV activity against HIV-1 replication in H9 lymphocyte cells Evaluated for the anti-HIV activity against HIV-1 replication in H9 lymphocyte cells	[PMID: 11206454]
H9	IC₅₀	1873 μM Compound: AZT	Evaluated for the anti-HIV activity against HIV-1 replication in mock-infected H9 cells Evaluated for the anti-HIV activity against HIV-1 replication in mock-infected H9 cells	[PMID: 11206454]
H9	EC₅₀	4.5 μM Compound: AZT	Inhibitory activity against HIV-1 replication in H9 lymphocytes Inhibitory activity against HIV-1 replication in H9 lymphocytes	[PMID: 11262077]
H9	IC₅₀	1875 μM Compound: AZT	Inhibition of HIV replication was determined in H9 lymphocytes Inhibition of HIV replication was determined in H9 lymphocytes	[PMID: 11262077]
H9	EC₅₀	0.001 μM Compound: AZT	Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique	[PMID: 11430019]
H9	EC₅₀	0.001 μM Compound: AZT	Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique	[PMID: 11430019]
H9	EC₅₀	0.045 μM Compound: AZT	Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication	[PMID: 11473435]
H9	IC₅₀	1875 μM Compound: AZT	Cytotoxicity against human H9 cells Cytotoxicity against human H9 cells	[PMID: 11473435]
H9	EC₅₀	0.045 μM Compound: AZT	Inhibitory concentration against HIV-1 replication in acutely infected H9 lymphocytes Inhibitory concentration against HIV-1 replication in acutely infected H9 lymphocytes	[PMID: 11527717]
H9	IC₅₀	1875 μM Compound: AZT	Inhibitory concentration required to inhibit uninfected H9 cell growth by 50% Inhibitory concentration required to inhibit uninfected H9 cell growth by 50%	[PMID: 11527717]
H9	EC₅₀	0.00289 μg/mL Compound: AZT	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA	[PMID: 11678650]
H9	IC₅₀	500 μg/mL Compound: AZT	Cytotoxicity against human H9 cells Cytotoxicity against human H9 cells	[PMID: 11678650]
H9	EC₅₀	0.01 μg/mL Compound: AZT	Antiviral activity against HIV-1(IIIB) infected H9 cell lines. Antiviral activity against HIV-1(IIIB) infected H9 cell lines.	[PMID: 11720855]
H9	IC₅₀	500 μg/mL Compound: AZT	Concentration which was toxic to 50% of the mock-infected H9 lymphocyte. Concentration which was toxic to 50% of the mock-infected H9 lymphocyte.	[PMID: 11720855]
H9	EC₅₀	0.045 μM Compound: AZT	Concentration that inhibits HIV-1 replication in cell growth in H9 lymphocytes Concentration that inhibits HIV-1 replication in cell growth in H9 lymphocytes	[PMID: 12699758]
H9	IC₅₀	500 μM Compound: AZT	Concentration that inhibits HIV-1 replication in cell growth in H9 lymphocytes Concentration that inhibits HIV-1 replication in cell growth in H9 lymphocytes	[PMID: 12699758]
H9	EC₅₀	0.0221 μg/mL Compound: AZT	Effective concentration against HIV-1 replication in H9 lymphocytic cells Effective concentration against HIV-1 replication in H9 lymphocytic cells	[PMID: 12729671]
H9	IC₅₀	500 μg/mL Compound: AZT	Concentration that inhibits uninfected H9 cell growth by 50%. Concentration that inhibits uninfected H9 cell growth by 50%.	[PMID: 12729671]
H9	IC₅₀	1872 μM Compound: AZT	Concentration required to inhibit uninfected H9 cell growth by 50% Concentration required to inhibit uninfected H9 cell growth by 50%	[PMID: 14736256]
H9	EC₅₀	0.045 M Compound: AZT	Concentration required to inhibit HIV-1 replication by 50% in acutely infected H9 lymphocytes Concentration required to inhibit HIV-1 replication by 50% in acutely infected H9 lymphocytes	[PMID: 15149703]
H9	IC₅₀	1875 μM Compound: AZT	Concentration required to inhibit uninfected H9 cell growth by 50% Concentration required to inhibit uninfected H9 cell growth by 50%	[PMID: 15149703]
H9	IC₅₀	1873 μM Compound: AZT	Concentration required to produce 50% toxicity against mock-infected H9 cells Concentration required to produce 50% toxicity against mock-infected H9 cells	[PMID: 15501054]
H9	IC₅₀	>1872 μM Compound: AZT	Concentration required to inhibit 50% growth of uninfected H9 cells Concentration required to inhibit 50% growth of uninfected H9 cells	[PMID: 15501055]
H9	IC₅₀	0.03 μM Compound: AZT	In vitro Cytotoxic concentration which reduced HIV-1 LAV infected H9 cells by 50 percent In vitro Cytotoxic concentration which reduced HIV-1 LAV infected H9 cells by 50 percent	[PMID: 1573638]
H9	IC₅₀	500 μg/mL Compound: azt	Cytotoxicity against mock-infected human H9 lymphocytes Cytotoxicity against mock-infected human H9 lymphocytes	[PMID: 16989518]
H9	EC₅₀	0.023 μM Compound: AZT	Antiviral activity against HIV1 3B in H9 cells after 4 days by p24-antigen ELISA Antiviral activity against HIV1 3B in H9 cells after 4 days by p24-antigen ELISA	[PMID: 17190445]
H9	IC₅₀	1870 μM Compound: AZT	Cytotoxicity against human H9 cells after 4 days Cytotoxicity against human H9 cells after 4 days	[PMID: 17190445]
H9	EC₅₀	0.0137 μM Compound: AZT	Antiviral activity against HIV replication in H9 cells Antiviral activity against HIV replication in H9 cells	[PMID: 17533128]
H9	IC₅₀	500 μM Compound: AZT	Cytotoxicity against H9 cells assessed as growth inhibition Cytotoxicity against H9 cells assessed as growth inhibition	[PMID: 17533128]
H9	EC₅₀	0.05 μM Compound: AZT	Antiviral activity against HIV1 3B replication in H9 cells Antiviral activity against HIV1 3B replication in H9 cells	[PMID: 17719228]
H9	IC₅₀	1900 μM Compound: AZT	Reduction in cell viability of human H9 cells Reduction in cell viability of human H9 cells	[PMID: 17719228]
H9	IC₅₀	<0.0003 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	IC₅₀	<0.0003 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
H9	IC₅₀	<0.0003 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	IC₅₀	>0.1 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
H9	IC₅₀	>0.1 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
H9	IC₅₀	>0.1 μM Compound: AZT	Cytotoxicity against human H9 cells by MTS assay Cytotoxicity against human H9 cells by MTS assay	[PMID: 20086149]
H9	IC₅₀	0.001 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
H9	IC₅₀	0.002 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	IC₅₀	0.027 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	EC₅₀	0.044 μM Compound: AZT	Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA	[PMID: 20187635]
H9	CC₅₀	1873 μM Compound: AZT	Cytotoxicity against human H9 cells after 6 days by XTT assay Cytotoxicity against human H9 cells after 6 days by XTT assay	[PMID: 20527972]
H9	EC₅₀	0.052 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 days by p24 antigen based assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 days by p24 antigen based assay	[PMID: 20527972]
H9	EC₅₀	0.01 μM Compound: AZT	Cytotoxicity against human H9 cells after 6 days by MTT assay Cytotoxicity against human H9 cells after 6 days by MTT assay	[PMID: 20846868]
H9	IC₅₀	500 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 hrs by p24 antigen based assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 hrs by p24 antigen based assay	[PMID: 20846868]
H9	IC₅₀	150 μM Compound: 1	Evaluated in vitro for the concentration required to produce 50% inhibition of proliferation of H9 lymphocytes Evaluated in vitro for the concentration required to produce 50% inhibition of proliferation of H9 lymphocytes	[PMID: 2329572]
H9	CC₅₀	200 μM Compound: AZT	Cytotoxic concentration against HIV-1 infected H9 cell lines Cytotoxic concentration against HIV-1 infected H9 cell lines	[PMID: 7837220]
H9	IC₅₀	0.07 μM Compound: AZT	Inhibitory concentration against HIV-1 infected H9 cell lines Inhibitory concentration against HIV-1 infected H9 cell lines	[PMID: 7837220]
H9	EC₅₀	0.04 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8158164]
H9	IC₅₀	2000 μM Compound: AZT	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8158164]
H9	EC₅₀	0.04 μM Compound: AZT	Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8176401]
H9	IC₅₀	2000 μM Compound: AZT	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8176401]
H9	ED₅₀	0.04 μg/mL Compound: AZT	Effective dose required to inhibit virus replication growth by 50% Effective dose required to inhibit virus replication growth by 50%	[PMID: 8642556]
H9	IC₅₀	2000 μg/mL Compound: AZT	Inhibitory concentration required to inhibit uninfected growth of H9 lymphocytes by 50% Inhibitory concentration required to inhibit uninfected growth of H9 lymphocytes by 50%	[PMID: 8642556]
H9	EC₅₀	0.15 μM Compound: a AZT	Toxic concentration on HIV-1 mock infected H9 lymphocyte cells Toxic concentration on HIV-1 mock infected H9 lymphocyte cells	[PMID: 8676334]
H9	IC₅₀	1875 μM Compound: a AZT	Inhibitory activity against HIV-1 replication in mock infected H9 cells Inhibitory activity against HIV-1 replication in mock infected H9 cells	[PMID: 8676334]
H9	EC₅₀	0.002 μg/mL Compound: AZT	Cytotoxicity against mock-infected human H9 cells after 4 days Cytotoxicity against mock-infected human H9 cells after 4 days	[PMID: 8946749]
H9	IC₅₀	500 μg/mL Compound: AZT	Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 8946749]
H9	EC₅₀	>20 μM Compound: AZT	Ability to inhibit HIV-1 multiplication in chronically infected H9/IIIB cells Ability to inhibit HIV-1 multiplication in chronically infected H9/IIIB cells	[PMID: 9154967]
H9	EC₅₀	0.01 μg/mL Compound: AZT	Antiviral activity against HIV infected in human H9 cells assessed as viral replication Antiviral activity against HIV infected in human H9 cells assessed as viral replication	[PMID: 9584397]
H9	EC₅₀	50000 μg/mL Compound: AZT	Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV	[PMID: 9584397]
H9	IC₅₀	500 μg/mL Compound: AZT	Cytotoxicity against human H9 cells Cytotoxicity against human H9 cells	[PMID: 9584397]
H9	EC₅₀	0.012 μg/mL Compound: AZT	Cytotoxicity against mock-infected human H9 cells after 4 days Cytotoxicity against mock-infected human H9 cells after 4 days	[PMID: 9748372]
H9	IC₅₀	500 μg/mL Compound: AZT	Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA	[PMID: 9748372]
H9	EC₅₀	0.015 μM Compound: AZT	Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%. Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.	[PMID: 9804704]
H9	EC₅₀	0.015 μM Compound: AZT	Anti-HIV activity was measured in H9-cells. Anti-HIV activity was measured in H9-cells.	[PMID: 9804704]
H9	EC₅₀	0.037 μM Compound: AZT	Anti-HIV activity was measured in H9-cells by MAGI assay Anti-HIV activity was measured in H9-cells by MAGI assay	[PMID: 9804704]
H9	IC₅₀	500 μM Compound: AZT	Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound toxic to 50% of mock-infected H9 cells. Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound toxic to 50% of mock-infected H9 cells.	[PMID: 9804704]
H9	EC₅₀	0.015 μM Compound: AZT	Compound was evaluated for anti-HIV activity in H9 lymphocytes Compound was evaluated for anti-HIV activity in H9 lymphocytes	[PMID: 9871747]
H9	IC₅₀	500 μM Compound: AZT	Compound was evaluated for cytotoxicity in H9 lymphocytes Compound was evaluated for cytotoxicity in H9 lymphocytes	[PMID: 9871747]
H9	EC₅₀	0.045 μM Compound: AZT	Anti-HIV activity was evaluated as the concentration required to inhibit HIV-1 replication in H9 lymphocyte cells by 50% Anti-HIV activity was evaluated as the concentration required to inhibit HIV-1 replication in H9 lymphocyte cells by 50%	[PMID: 9873374]
H9	IC₅₀	1875 μM Compound: AZT	Anti-HIV activity was evaluated as the concentration required to inhibit the growth of uninfected H9 lymphocyte cells by 50% Anti-HIV activity was evaluated as the concentration required to inhibit the growth of uninfected H9 lymphocyte cells by 50%	[PMID: 9873374]
H9	EC₅₀	0.045 μM Compound: AZT	Compound was evaluated for anti-HIV activity in acutely infected H9 Lymphocytes Compound was evaluated for anti-HIV activity in acutely infected H9 Lymphocytes	[PMID: 9873504]
H9	IC₅₀	1875 μM Compound: AZT	Compound was evaluated for anti-HIV activity and the concentration that inhibits uninfected H9 cell growth by 50% Compound was evaluated for anti-HIV activity and the concentration that inhibits uninfected H9 cell growth by 50%	[PMID: 9873504]
H9	EC₅₀	0.045 μg/mL Compound: AZT	Antiviral activity against HIV1 3B infected in human H9 T cells after 4 days by ELISA Antiviral activity against HIV1 3B infected in human H9 T cells after 4 days by ELISA	[PMID: 9917290]
H9	IC₅₀	1875 μg/mL Compound: AZT	Cytotoxicity against human H9 cells Cytotoxicity against human H9 cells	[PMID: 9917290]
H9	IC₅₀	50 nM Compound: AZT	Tested for the inhibitory activity against HIV-1 in H-9 cell lines assessed by syncytium formation and reverse transcriptase assay Tested for the inhibitory activity against HIV-1 in H-9 cell lines assessed by syncytium formation and reverse transcriptase assay	10.1016/0960-894X(95)00306-E
H9	EC₅₀	0.15 μM Compound: AZT	Effective concentration against HIV-1 replication in H9 lymphocyte cells was determined Effective concentration against HIV-1 replication in H9 lymphocyte cells was determined	10.1016/S0960-894X(01)80161-X
H9	IC₅₀	1875 μM Compound: AZT	Compound was tested for inhibitory activity against HIV-1 replication in H9 lymphocyte cells Compound was tested for inhibitory activity against HIV-1 replication in H9 lymphocyte cells	10.1016/S0960-894X(01)80161-X
H9	EC₅₀	0.04 μM Compound: AZT	Concentration of compound which inhibits virus replication of HIV by 50% (EC50 of 10 uM) in acutely infected H9 lymphocyte cells was determined Concentration of compound which inhibits virus replication of HIV by 50% (EC50 of 10 uM) in acutely infected H9 lymphocyte cells was determined	10.1016/S0960-894X(01)81071-4
H9	IC₅₀	2000 μM Compound: AZT	Concentration which inhibits uninfected cell growth of HIV by 50% (IC50>140 uM) in acutely infected H9 lymphocyte cells was determined Concentration which inhibits uninfected cell growth of HIV by 50% (IC50>140 uM) in acutely infected H9 lymphocyte cells was determined	10.1016/S0960-894X(01)81071-4
H9	EC₅₀	0.045 μM Compound: AZT	Anti-HIV activity was evaluated for the concentration that inhibits viral replication by 50% Anti-HIV activity was evaluated for the concentration that inhibits viral replication by 50%	10.1016/S0960-894X(97)10050-6
H9	IC₅₀	1875 μM Compound: AZT	Inhibitory activity against gorwth of uninfected H9 cell growth by 50% Inhibitory activity against gorwth of uninfected H9 cell growth by 50%	10.1016/S0960-894X(97)10050-6
H9	EC₅₀	0.009 μM Compound: AZT	Evaluation for anti-HIV activity using T cell line (H9). Evaluation for anti-HIV activity using T cell line (H9).	10.1016/S0960-894X(97)10108-1
H9	IC₅₀	500 μM Compound: AZT	Cytotoxicity against H9 cell line Cytotoxicity against H9 cell line	10.1016/S0960-894X(97)10108-1
HEK-293T	CC₅₀	>10 μM Compound: AZT	Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method	[PMID: 17470654]
HEK-293T	EC₅₀	200 nM Compound: AZT	Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay	[PMID: 22148316]
HEK-293T	EC₅₀	6 nM Compound: AZT	Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay	[PMID: 22148316]
HeLa	EC₅₀	0.002 μM Compound: AZT	Tested in vitro against HIV-1 104pre from HeLa-CD4-LT4-beta gal-cells using MAGI assay Tested in vitro against HIV-1 104pre from HeLa-CD4-LT4-beta gal-cells using MAGI assay	[PMID: 11087576]
HeLa	IC₅₀	>100 μM Compound: AZT, Zidovudine	Cytotoxicity against human HeLa cells at 100 uM after 48 hrs by MTT assay Cytotoxicity against human HeLa cells at 100 uM after 48 hrs by MTT assay	[PMID: 17416522]
HeLa	IC₅₀	>100 μM Compound: AZT, Zidovudine	Cytotoxicity against human HeLa cells at 125 uM after 48 hrs by MTT assay Cytotoxicity against human HeLa cells at 125 uM after 48 hrs by MTT assay	[PMID: 17416522]
HeLa	CC₅₀	>270 μM Compound: AZT	Cytotoxicity against human HeLa P4/R5 cells after 2 to 4 hrs by MTT assay Cytotoxicity against human HeLa P4/R5 cells after 2 to 4 hrs by MTT assay	[PMID: 19596885]
HeLa	IC₅₀	0.18 μM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase M184V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 harboring reverse transcriptase M184V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	IC₅₀	0.19 μM Compound: AZT	Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	IC₅₀	0.21 μM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase K65R mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 harboring reverse transcriptase K65R mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	IC₅₀	0.21 μM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase L74V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 harboring reverse transcriptase L74V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	IC₅₀	10.4 μM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase M41L/L210W/T215Y mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 harboring reverse transcriptase M41L/L210W/T215Y mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	IC₅₀	11.9 μM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase D67N/K70R/T215F/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 harboring reverse transcriptase D67N/K70R/T215F/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	IC₅₀	204.6 μM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase diserine insert between residues 69 and 70 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 harboring reverse transcriptase diserine insert between residues 69 and 70 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	IC₅₀	213.7 μM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase Q151M mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 harboring reverse transcriptase Q151M mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	IC₅₀	58.6 μM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	IC₅₀	96.7 μM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase M41L/D67N/K70R/T215F/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 harboring reverse transcriptase M41L/D67N/K70R/T215F/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	EC₅₀	>374 μM Compound: 2, AZT, Zidovudine	Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay	[PMID: 22352809]
HeLa	EC₅₀	10.8 μM Compound: 2, AZT, Zidovudine	Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay	[PMID: 22352809]
HeLa	EC₅₀	14.2 μM Compound: 2, AZT, Zidovudine	Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay	[PMID: 22352809]
HeLa	IC₅₀	>100 μM Compound: AZT	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 22858300]
HeLa	IC₅₀	0.04 μM Compound: AZT	Antiviral activity against VSV-G pseudotyped HIV1 lentiviral particles infected in human HeLa cells incubated for 48 hrs by spectrofluorometry Antiviral activity against VSV-G pseudotyped HIV1 lentiviral particles infected in human HeLa cells incubated for 48 hrs by spectrofluorometry	[PMID: 22858300]
HeLa	CC₅₀	>25 μM Compound: Zidovudine	Cytotoxicity against mock-infected human HeLa cells by MTT assay Cytotoxicity against mock-infected human HeLa cells by MTT assay	[PMID: 25682562]
HeLa	IC₅₀	65.46 μM Compound: 13, AZT	Cytotoxicity against human HeLa cells after 48 hrs by SRB method Cytotoxicity against human HeLa cells after 48 hrs by SRB method	[PMID: 25933593]
HeLa	IC₅₀	10.77 μM Compound: AZT	Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
HeLa	IC₅₀	10.77 μM Compound: 3; AZT	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
HeLa	IC₅₀	>100 μM Compound: AZT	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis	[PMID: 38964258]
HeLa	EC₅₀	0.009 μM Compound: AZT	Compound was tested for Anti-HIV activity by plaque reduction assay with E89K virus in HT4-6C human CD4+ lymphocytes Compound was tested for Anti-HIV activity by plaque reduction assay with E89K virus in HT4-6C human CD4+ lymphocytes	[PMID: 9258355]
HeLa	EC₅₀	0.013 μM Compound: AZT	Compound was tested for Anti-HIV activity by plaque reduction assay with wild type HIV-1LAI virus in HT4-6C human CD4+ lymphocytes Compound was tested for Anti-HIV activity by plaque reduction assay with wild type HIV-1LAI virus in HT4-6C human CD4+ lymphocytes	[PMID: 9258355]
HeLa	EC₅₀	2.9 μM Compound: AZT	Compound was tested for Anti-HIV activity by plaque reduction assay with A018-post virus in HT4-6C human CD4+ lymphocytes Compound was tested for Anti-HIV activity by plaque reduction assay with A018-post virus in HT4-6C human CD4+ lymphocytes	[PMID: 9258355]
HepG2	IC₅₀	>479 μM Compound: AZT, zidovudine	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 25442310]
HepG2	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 25458500]
HepG2	IC₅₀	>479 μM Compound: AZT; Zidovudine	Cytotoxicity against human HepG2 cells assessed as growth inhibition measured after 3 days by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition measured after 3 days by MTT assay	[PMID: 27342752]
HepG2	IC₅₀	13.03 μM Compound: 3; AZT	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
HepG2	IC₅₀	>400 μM Compound: Azidothymidine	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 31546197]
HepG2	IC₅₀	>100 μM Compound: AZT	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis	[PMID: 38964258]
HepG2 2.2.15	EC₅₀	>10 μM Compound: AZT	Antiviral activity against Hepatitis-B virus 2.2.15(HBV) Antiviral activity against Hepatitis-B virus 2.2.15(HBV)	[PMID: 9357530]
HFF	IC₅₀	>100 μM Compound: Zidovudine (AZT)	Visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration Visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration	[PMID: 7562946]
HL-60	IC₅₀	96 μM Compound: AZT	Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay. Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.	[PMID: 1695683]
HOS	IC₅₀	1.4 μM Compound: AZT	Inhibition of HIV1 wild type reverse transcriptase-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay Inhibition of HIV1 wild type reverse transcriptase-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay	[PMID: 19678643]
HOS	IC₅₀	20.1 μM Compound: AZT	Inhibition of HIV1 reverse transcriptase M41L/D67N/K70R/T215Y/K219Q mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay Inhibition of HIV1 reverse transcriptase M41L/D67N/K70R/T215Y/K219Q mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay	[PMID: 19678643]
HOS	IC₅₀	3.6 μM Compound: AZT	Inhibition of HIV1 reverse transcriptase M184V mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay Inhibition of HIV1 reverse transcriptase M184V mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay	[PMID: 19678643]
HOS	IC₅₀	39.6 μM Compound: AZT	Inhibition of HIV1 reverse transcriptase SSGR/T215Y mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay Inhibition of HIV1 reverse transcriptase SSGR/T215Y mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay	[PMID: 19678643]
Huh-7	CC₅₀	>10 μM Compound: AZT	Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs	[PMID: 22014549]
Huh-7	EC₅₀	>10 μM Compound: AZT	Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR	[PMID: 22014549]
Huh-7	CC₅₀	>10 μM Compound: AZT	Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels at 120 hrs by RT-PCR analysis Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels at 120 hrs by RT-PCR analysis	[PMID: 23623492]
Huh-7	EC₅₀	>10 μM Compound: AZT	Antiviral activity against Hepatitis C virus infected in human HuH7 cells Antiviral activity against Hepatitis C virus infected in human HuH7 cells	[PMID: 23623492]
JM1	CC₅₀	>1000 μM Compound: AZT	Concentration required to reduce cell viability of JM cells by 50% Concentration required to reduce cell viability of JM cells by 50%	10.1016/0960-894X(96)00443-X
JM1	EC₅₀	200 μM Compound: AZT	Anti-HIV activity against HIV-1 infected JM cell lines Anti-HIV activity against HIV-1 infected JM cell lines	10.1016/0960-894X(96)00443-X
JM1	ED₅₀	100 μM Compound: 1	Effective dose of compound that decreases antigen production in HIV-1 infected JM cells to 50% of control Effective dose of compound that decreases antigen production in HIV-1 infected JM cells to 50% of control	10.1016/S0960-894X(00)80395-9
Jurkat	IC₅₀	120 nM Compound: AZT	Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay	[PMID: 21414776]
Jurkat	EC₅₀	0.09 μM Compound: AZT	Antiviral activity against HIV1 pseudovirus infected in Jurkat cells coexpressing GFP assessed as viral growth inhibition incubated for 2 to 8 hrs prior to infection measured after 48 hrs by flow cytofluorimetric analysis Antiviral activity against HIV1 pseudovirus infected in Jurkat cells coexpressing GFP assessed as viral growth inhibition incubated for 2 to 8 hrs prior to infection measured after 48 hrs by flow cytofluorimetric analysis	[PMID: 22954898]
Jurkat	CC₅₀	>500 μM Compound: AZT	Cytotoxic concentration against HIV-1 infected Jurkat cell lines Cytotoxic concentration against HIV-1 infected Jurkat cell lines	[PMID: 7837220]
Jurkat	IC₅₀	0.01 μM Compound: AZT	Inhibitory concentration against HIV-1 infected Jurkat cell lines Inhibitory concentration against HIV-1 infected Jurkat cell lines	[PMID: 7837220]
KB	IC₅₀	3.12 μg/mL Compound: AZT, Zidovudine	Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay	[PMID: 21945463]
KB	IC₅₀	>479 μM Compound: AZT, zidovudine	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 25442310]
KB	IC₅₀	9.77 μM Compound: AZT	Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
KB	IC₅₀	9.77 μM Compound: 3; AZT	Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
KB	IC₅₀	>400 μM Compound: Azidothymidine	Antiproliferative activity against human KB cells by MTT assay Antiproliferative activity against human KB cells by MTT assay	[PMID: 31546197]
KB 3-1	IC₅₀	9.17 μM Compound: AZT, Zidovudine	Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay	[PMID: 25440502]
L1210	IC₅₀	6.18 μM Compound: AZT	Inhibitory effect of compound on the proliferation of murine leukemia cells L1210/0. Inhibitory effect of compound on the proliferation of murine leukemia cells L1210/0.	[PMID: 11356105]
L1210/TK-	IC₅₀	>500 μM Compound: AZT	Inhibitory effect of compound on the proliferation of murine leukemia cells L1210/TK- Inhibitory effect of compound on the proliferation of murine leukemia cells L1210/TK-	[PMID: 11356105]
M	EC₅₀	0.015 μM Compound: AZT	Effective concentration required for antiviral activity against M cell line of macrophage cells of Human by XTT assay Effective concentration required for antiviral activity against M cell line of macrophage cells of Human by XTT assay	[PMID: 7932526]
Macrophage	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against macrophages Cytotoxicity against macrophages	[PMID: 16279773]
MCF7	IC₅₀	>10 μM Compound: AZT	Tested in vitro for anticancer activity against MCF-7 cells Tested in vitro for anticancer activity against MCF-7 cells	[PMID: 10072683]
MCF7	IC₅₀	2.6 μg/mL Compound: AZT, Zidovudine	Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay	[PMID: 21945463]
MCF7	IC₅₀	13.74 μM Compound: AZT, Zidovudine	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 25440502]
MCF7	IC₅₀	34.97 μM Compound: 13, AZT	Cytotoxicity against human MCF7 cells after 48 hrs by SRB method Cytotoxicity against human MCF7 cells after 48 hrs by SRB method	[PMID: 25933593]
MCF7	IC₅₀	7.67 μM Compound: AZT	Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
MCF7	IC₅₀	>100 μM Compound: AZT	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis	[PMID: 38964258]
MOLT-3	CC₅₀	3.24 μg/mL Compound: AZT	Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay	[PMID: 21334901]
MOLT-3	CC₅₀	12.1 μM Compound: AZT	Cytotoxicity against human MOLT3 cells by MTS assay Cytotoxicity against human MOLT3 cells by MTS assay	[PMID: 22549138]
MOLT-4	EC₅₀	6.2 nM Compound: AZT	Compound was evaluated for anti-HIV activity against HIV-1Lal inoculated with Molt-4 cells Compound was evaluated for anti-HIV activity against HIV-1Lal inoculated with Molt-4 cells	[PMID: 10866387]
MOLT-4	IC₅₀	62.8 μM Compound: AZT	Inhibitory effect of compound on the proliferation of human T-lymphocyte cells Molt4/C8 Inhibitory effect of compound on the proliferation of human T-lymphocyte cells Molt4/C8	[PMID: 11356105]
MOLT-4	IC₅₀	>375 μM Compound: AZT	Antiproliferative activity was determined against human T-lymphocyte cells -Molt4/C8 Antiproliferative activity was determined against human T-lymphocyte cells -Molt4/C8	[PMID: 12801219]
MOLT-4	EC₅₀	>10 μM Compound: AZT	Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay	[PMID: 18316521]
MT2	CC₅₀	>100 μM Compound: AZT	Anti-HIV activity based on reduction of the viability of mock-infected MT-2 cells. Anti-HIV activity based on reduction of the viability of mock-infected MT-2 cells.	[PMID: 12699395]
MT2	IC₅₀	27 nM Compound: AZT	Anti-HIV activity based on inhibition of HIV-1 induced cytopathogenicity in MT-2 cells. Anti-HIV activity based on inhibition of HIV-1 induced cytopathogenicity in MT-2 cells.	[PMID: 12699395]
MT2	EC₅₀	0.03 μM Compound: AZT	Effective concentration required to protect MT-2 cells against cytopathogenicity of HIV-1 LAI Effective concentration required to protect MT-2 cells against cytopathogenicity of HIV-1 LAI	[PMID: 12852759]
MT2	CC₅₀	>10 μM Compound: AZT	Cytotoxicity against MT2 cells Cytotoxicity against MT2 cells	[PMID: 15615545]
MT2	IC₅₀	0.16 μM Compound: AZT	In vitro Cytotoxic concentration which reduced HIV-1 LAV infected MT-2 cells by 50 percent In vitro Cytotoxic concentration which reduced HIV-1 LAV infected MT-2 cells by 50 percent	[PMID: 1573638]
MT2	IC₅₀	0.2 μM Compound: AZT	In vitro Cytotoxic concentration which reduced H 112-2(pre-AZT) infected MT-2 cells by 50 percent In vitro Cytotoxic concentration which reduced H 112-2(pre-AZT) infected MT-2 cells by 50 percent	[PMID: 1573638]
MT2	IC₅₀	0.22 μM Compound: AZT	In vitro Cytotoxic concentration which reduced G 762-3(pre-AZT) infected MT-2 cells by 50 percent In vitro Cytotoxic concentration which reduced G 762-3(pre-AZT) infected MT-2 cells by 50 percent	[PMID: 1573638]
MT2	IC₅₀	10 μM Compound: AZT	In vitro Cytotoxic concentration which reduced G 691-2(post-AZT) infected MT-2 cells by 50 percent In vitro Cytotoxic concentration which reduced G 691-2(post-AZT) infected MT-2 cells by 50 percent	[PMID: 1573638]
MT2	IC₅₀	31 μM Compound: AZT	In vitro Cytotoxic concentration which reduced G 910-6p2 (post-AZT) infected MT-2 cells by 50 percent In vitro Cytotoxic concentration which reduced G 910-6p2 (post-AZT) infected MT-2 cells by 50 percent	[PMID: 1573638]
MT2	CC₅₀	>10 μM Compound: AZT	Cytotoxicity against MT2 cells Cytotoxicity against MT2 cells	[PMID: 17004726]
MT2	EC₅₀	0.02 μM Compound: AZT	Inhibition of HIV1 LAI replication in MT2 cells by cytopathic effect assay Inhibition of HIV1 LAI replication in MT2 cells by cytopathic effect assay	[PMID: 17004726]
MT2	IC₅₀	0.14 μg/mL Compound: AZT	Compound was tested for its inhibitory activity against HIV replication in MT-2 cells. Compound was tested for its inhibitory activity against HIV replication in MT-2 cells.	[PMID: 1738145]
MT2	CC₅₀	>200 μM Compound: 3	Cytotoxicity against MT2 cells Cytotoxicity against MT2 cells	[PMID: 17562366]
MT2	EC₅₀	0.16 μM Compound: 3	Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days	[PMID: 17562366]
MT2	IC₅₀	1870 μM Compound: AZT	Cytotoxicity against MT2 cells by XTT assay Cytotoxicity against MT2 cells by XTT assay	[PMID: 17935987]
MT2	CC₅₀	>200 μM Compound: AZT	Cytotoxicity against human MT2 cells Cytotoxicity against human MT2 cells	[PMID: 18164198]
MT2	EC₅₀	0.16 μM Compound: AZT	Antiviral activity against wild type HIV1 3B in MT2 cells Antiviral activity against wild type HIV1 3B in MT2 cells	[PMID: 18164198]
MT2	IC₅₀	0.05 μM Compound: AZT	Inhibition of wild type HIV 3B reverse transcriptase in MT2 cells Inhibition of wild type HIV 3B reverse transcriptase in MT2 cells	[PMID: 18164198]
MT2	EC₅₀	0.0012 μM Compound: AZT	Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0029 μM Compound: AZT	Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0038 μM Compound: AZT	Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0049 μM Compound: AZT	Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.005 μM Compound: AZT	Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT infected in human MT2 cells Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT infected in human MT2 cells	[PMID: 18316521]
MT2	EC₅₀	0.0063 μM Compound: AZT	Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells	[PMID: 18316521]
MT2	EC₅₀	0.014 μM Compound: AZT	Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.016 μM Compound: AZT	Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay	[PMID: 18316521]
MT2	EC₅₀	0.018 μM Compound: AZT	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.027 μM Compound: AZT	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.038 μM Compound: AZT	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.043 μM Compound: AZT	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.051 μM Compound: AZT	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.054 μM Compound: AZT	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.075 μM Compound: AZT	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.087 μM Compound: AZT	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.117 μM Compound: AZT	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.144 μM Compound: AZT	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.209 μM Compound: AZT	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.223 μM Compound: AZT	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.249 μM Compound: AZT	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.302 μM Compound: AZT	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	CC₅₀	>200 μM Compound: AZT, zidovudine	Cytotoxicity against human MT2 cells after 5 days Cytotoxicity against human MT2 cells after 5 days	[PMID: 19179082]
MT2	EC₅₀	0.16 μM Compound: AZT, zidovudine	Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay	[PMID: 19179082]
MT2	CC₅₀	1870 μM Compound: AZT	Cytotoxicity against human MT2 cells by XTT assay Cytotoxicity against human MT2 cells by XTT assay	[PMID: 19388685]
MT2	EC₅₀	0.056 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as p24 antigen level after 4 days by ELISA Antiviral activity against HIV1 3B infected in human MT2 cells assessed as p24 antigen level after 4 days by ELISA	[PMID: 19388685]
MT2	CC₅₀	150 μM Compound: AZT	Cytotoxicity against human MT2 cells after 2 to 4 days by MTT assay Cytotoxicity against human MT2 cells after 2 to 4 days by MTT assay	[PMID: 19596885]
MT2	IC₅₀	0.031 μM Compound: AZT	Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication	[PMID: 19596885]
MT2	EC₅₀	0.034 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral replication treated 1 day after infection measured on after 4 days postinfection by p24 antigen ELISA Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral replication treated 1 day after infection measured on after 4 days postinfection by p24 antigen ELISA	[PMID: 20329730]
MT2	IC₅₀	1870 μM Compound: AZT	Cytotoxicity against human MT2 cells by XTT assay Cytotoxicity against human MT2 cells by XTT assay	[PMID: 20329730]
MT2	EC₅₀	0.044 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 6 days by ELISA Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 6 days by ELISA	[PMID: 20537902]
MT2	IC₅₀	1872 μM Compound: AZT	Cytotoxicity against human MT2 cells after 6 days by XTT assay Cytotoxicity against human MT2 cells after 6 days by XTT assay	[PMID: 20537902]
MT2	CC₅₀	>200 μM Compound: AZT	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 20542430]
MT2	IC₅₀	0.047 μM Compound: AZT	Antiviral activity against HIV1 bearing VSV glycoprotein infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 bearing VSV glycoprotein infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 20542430]
MT2	IC₅₀	0.0493 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay	[PMID: 20728351]
MT2	EC₅₀	0.18 μM Compound: N3ddThd	Concentration of the drug resulting in 50% reduction of the viral cytopathic effect against HIV-1 replication in MT-2 cells. Concentration of the drug resulting in 50% reduction of the viral cytopathic effect against HIV-1 replication in MT-2 cells.	[PMID: 2153206]
MT2	IC₅₀	>970 μM Compound: N3ddThd	Concentration of the drug resulting in 50% growth inhibition of normal, uninfected cells against HIV-1 replication in MT-2 cells. Concentration of the drug resulting in 50% growth inhibition of normal, uninfected cells against HIV-1 replication in MT-2 cells.	[PMID: 2153206]
MT2	EC₅₀	47 nM Compound: AZT	Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay	[PMID: 21745701]
MT2	CC₅₀	≥25 μM Compound: AZT	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 23570720]
MT2	CC₅₀	123 μM Compound: AZT	Tested for the drug concentration required to decrease HIV-1IIIb infected MT-2 cell viability compared to uninfected controls Tested for the drug concentration required to decrease HIV-1IIIb infected MT-2 cell viability compared to uninfected controls	[PMID: 7512142]
MT2	ED₅₀	0.07 μM Compound: AZT	Effective antiviral dose required to block the spread of HIV-1 IIIb infection in MT-2 cells by monitoring the formation of syncytia Effective antiviral dose required to block the spread of HIV-1 IIIb infection in MT-2 cells by monitoring the formation of syncytia	[PMID: 7512142]
MT2	IC₅₀	0.006 μM Compound: AZT	Inhibitory activity against the HIV-1-induced cytopathic effect in MT-2 cell line Inhibitory activity against the HIV-1-induced cytopathic effect in MT-2 cell line	[PMID: 7650678]
MT2	CC₅₀	>10 μM Compound: AZT	Cytotoxic concentration against MT-2 cells Cytotoxic concentration against MT-2 cells	[PMID: 7684450]
MT2	ED₅₀	0.07 μM Compound: AZT	Inhibition of HIV-1 IIIB replication in MT2 (human lymphocyte) cells. Inhibition of HIV-1 IIIB replication in MT2 (human lymphocyte) cells.	[PMID: 7684450]
MT2	EC₅₀	0.003 μM Compound: AZT	Effective concentration required for antiviral activity against HIV strain IIIB in MT-2 cells by XTT assay Effective concentration required for antiviral activity against HIV strain IIIB in MT-2 cells by XTT assay	[PMID: 7932526]
MT2	EC₅₀	0.014 μM Compound: AZT	Anti-HIV activity against HIV-I A17 strain in MT2 cell line Anti-HIV activity against HIV-I A17 strain in MT2 cell line	[PMID: 8632437]
MT2	EC₅₀	0.029 μM Compound: AZT	Anti-HIV activity against HIV-I IIIB strain in MT2 cell line Anti-HIV activity against HIV-I IIIB strain in MT2 cell line	[PMID: 8632437]
MT2	EC₅₀	0.037 μM Compound: AZT	Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line	[PMID: 8632437]
MT2	IC₅₀	119.84 μM Compound: AZT	Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line	[PMID: 8632437]
MT2	IC₅₀	131.71 μM Compound: AZT	Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line	[PMID: 8632437]
MT2	IC₅₀	51.64 μM Compound: AZT	Anti-HIV activity against HIV-I IIIB strain in MT2 cell line Anti-HIV activity against HIV-I IIIB strain in MT2 cell line	[PMID: 8632437]
MT2	IC₅₀	83.44 μM Compound: AZT	Anti-HIV activity against HIV-I A17 strain in MT2 cell line Anti-HIV activity against HIV-I A17 strain in MT2 cell line	[PMID: 8632437]
MT4	EC₅₀	0.005 μM Compound: AZT	Concentration of compound required to protect 50% of MT-4 cells against retroviral cytopathic effects by HIV-1 (IIIa) Concentration of compound required to protect 50% of MT-4 cells against retroviral cytopathic effects by HIV-1 (IIIa)	[PMID: 10212126]
MT4	EC₅₀	0.005 μM Compound: AZT	Concentration of compound required to protect 50% of MT-4 cells against retroviral cytopathic effects by HIV-2 (ROD) Concentration of compound required to protect 50% of MT-4 cells against retroviral cytopathic effects by HIV-2 (ROD)	[PMID: 10212126]
MT4	IC₅₀	100 μM Compound: AZT	Concentration of compound required to reduce MT-4 cell viability by 50% Concentration of compound required to reduce MT-4 cell viability by 50%	[PMID: 10212126]
MT4	CC₅₀	2.5813 μg/mL Compound: zidovudine	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 10425115]
MT4	IC₅₀	0.0002 μg/mL Compound: zidovudine	Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 10425115]
MT4	CC₅₀	>100 μM Compound: 1, AZT	Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50% Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%	[PMID: 10821705]
MT4	EC₅₀	0.02 μM Compound: 1, AZT	Effective concentration required to achieve 50% inhibition of HIV-1 IIIB multiplication in hT4 lymphoblastoid MT-4 cells using MTT assay Effective concentration required to achieve 50% inhibition of HIV-1 IIIB multiplication in hT4 lymphoblastoid MT-4 cells using MTT assay	[PMID: 10821705]
MT4	IC₅₀	35.6 μM Compound: AZT	In vitro inhibitory activity against uninfected T4 cells In vitro inhibitory activity against uninfected T4 cells	[PMID: 10956199]
MT4	CC₅₀	>100 μM Compound: AZT	Tested in vitro against MT-4 cells using MTT assay Tested in vitro against MT-4 cells using MTT assay	[PMID: 11087576]
MT4	EC₅₀	0.038 μM Compound: AZT	Tested in vitro against HIV-1 LAI from MT-4 cells using MTT assay Tested in vitro against HIV-1 LAI from MT-4 cells using MTT assay	[PMID: 11087576]
MT4	CC₅₀	>1 μM Compound: AZT	Tested for cytotoxic concentration in MT-4 cell culture Tested for cytotoxic concentration in MT-4 cell culture	[PMID: 11087582]
MT4	EC₅₀	0.015 μM Compound: AZT	Tested for anti-HIV -1 Activity in MT-4 cell culture Tested for anti-HIV -1 Activity in MT-4 cell culture	[PMID: 11087582]
MT4	CC₅₀	<20 μM Compound: AZT	Compound was tested for reduction of the viability of mock infected MT-4 cell in test-II Compound was tested for reduction of the viability of mock infected MT-4 cell in test-II	[PMID: 11128640]
MT4	CC₅₀	190 μM Compound: AZT	Compound was tested for reduction of the viability of mock infected MT-4 cell in test-I Compound was tested for reduction of the viability of mock infected MT-4 cell in test-I	[PMID: 11128640]
MT4	EC₅₀	48 nM Compound: AZT	Inhibition of HIV-induced cytopathogenicity in MT-4 cell (ZIDOVUDINE control) Inhibition of HIV-induced cytopathogenicity in MT-4 cell (ZIDOVUDINE control)	[PMID: 11128640]
MT4	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against MT-4 (human leukemia) cells. Cytotoxicity against MT-4 (human leukemia) cells.	[PMID: 11262088]
MT4	CC₅₀	12 μM Compound: AZT	Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells on the MTT assay in test I Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells on the MTT assay in test I	[PMID: 11459656]
MT4	EC₅₀	7.9 nM Compound: AZT	Effective concentration for 50% protection of HIV-induced cytopathogenicity in MT-4 cells on the MTT assay (ZIDOVUDINE control) Effective concentration for 50% protection of HIV-induced cytopathogenicity in MT-4 cells on the MTT assay (ZIDOVUDINE control)	[PMID: 11459656]
MT4	CC₅₀	42 μM Compound: AZT	Conc. required to cause 50% death of uninfected MT-4 cells Conc. required to cause 50% death of uninfected MT-4 cells	[PMID: 11520210]
MT4	EC₅₀	12 nM Compound: AZT	Conc. required to inhibit the cytopathicity on HIV-1 by 50% on MT-4 cells Conc. required to inhibit the cytopathicity on HIV-1 by 50% on MT-4 cells	[PMID: 11520210]
MT4	CC₅₀	>500 μM Compound: AZT	The compound was tested for cytotoxic concentration required to reduce the viability of MT-4 cells The compound was tested for cytotoxic concentration required to reduce the viability of MT-4 cells	[PMID: 11858989]
MT4	EC₅₀	0.006 μM Compound: AZT	The compound was tested for effective concentration required to protect MT-4 cells against the cytopathicity of HIV-2(ROD) The compound was tested for effective concentration required to protect MT-4 cells against the cytopathicity of HIV-2(ROD)	[PMID: 11858989]
MT4	EC₅₀	0.0064 μM Compound: AZT	The compound was tested for effective concentration required to protect MT-4 cells against the cytopathicity of HIV-1(IIIB) The compound was tested for effective concentration required to protect MT-4 cells against the cytopathicity of HIV-1(IIIB)	[PMID: 11858989]
MT4	EC₅₀	12 nM Compound: AZT	Concentration required to inhibit the cytopathicity of HIV-1 strain IIIB by 50% in MT-4 cells (expressed in AZT equivalent) Concentration required to inhibit the cytopathicity of HIV-1 strain IIIB by 50% in MT-4 cells (expressed in AZT equivalent)	[PMID: 11881996]
MT4	EC₅₀	25 nM Compound: AZT	Concentration required to inhibit the cytopathicity of HIV-1 strain BRU by 50% in MT-4 cells (expressed in AZT equivalent) Concentration required to inhibit the cytopathicity of HIV-1 strain BRU by 50% in MT-4 cells (expressed in AZT equivalent)	[PMID: 11881996]
MT4	CC₅₀	12 μM Compound: AZT	Cytotoxicity based on the reduction of the viability of mock-infected MT-4 cells using the MTT method Cytotoxicity based on the reduction of the viability of mock-infected MT-4 cells using the MTT method	[PMID: 11958995]
MT4	EC₅₀	0.3 μM Compound: AZT	Anti-HIV activity based on the protection against HIV-induced cytopathogenicity in MT-4 cells using MTT method Anti-HIV activity based on the protection against HIV-induced cytopathogenicity in MT-4 cells using MTT method	[PMID: 11958995]
MT4	CC₅₀	0.52 μg/mL Compound: AZT	Cytotoxicity indicative of 50% survival concentration in virus-uninfected MT-4 cells. Cytotoxicity indicative of 50% survival concentration in virus-uninfected MT-4 cells.	[PMID: 12161143]
MT4	EC₅₀	0.0005 μg/mL Compound: AZT	Compound was tested for antiviral activity indicative of 50% cytopathic concentration in virus (HIV-1) infected MT-4 cells. Compound was tested for antiviral activity indicative of 50% cytopathic concentration in virus (HIV-1) infected MT-4 cells.	[PMID: 12161143]
MT4	CC₅₀	1.9 μg/mL Compound: AZT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 12444692]
MT4	EC₅₀	0.001 μg/mL Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 12444692]
MT4	EC₅₀	0.007 μg/mL Compound: AZT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 12444692]
MT4	CC₅₀	>100 μM Compound: AZT	Cytotoxic concentration required to reduce the viability of HIV-1 by 50% MT-4 cells Cytotoxic concentration required to reduce the viability of HIV-1 by 50% MT-4 cells	[PMID: 12593658]
MT4	EC₅₀	0.015 μM Compound: AZT	Effective concentration required to inhibit the replication of HIV-1 by 50% in MT-4 cells Effective concentration required to inhibit the replication of HIV-1 by 50% in MT-4 cells	[PMID: 12593658]
MT4	EC₅₀	0.02 μM Compound: AZT	Effective concentration required to protect MT-4 cells against cytopathogenicity of HIV-1 LAI Effective concentration required to protect MT-4 cells against cytopathogenicity of HIV-1 LAI	[PMID: 12852759]
MT4	EC₅₀	2 ng/mL Compound: AZT	Inhibitory activity toward HIV replication in MT-4 cells Inhibitory activity toward HIV replication in MT-4 cells	[PMID: 1323681]
MT4	IC₅₀	60 nM Compound: 1	Average antiviral activity against HIV-1 in MT-4 cells using cell-protection assay Average antiviral activity against HIV-1 in MT-4 cells using cell-protection assay	[PMID: 1380561]
MT4	CC₅₀	1.64 μg/mL Compound: AZT	Cytotoxicity against MT-4 cells Cytotoxicity against MT-4 cells	[PMID: 14505657]
MT4	EC₅₀	0.0012 μg/mL Compound: AZT	Compound was evaluated for its inhibitory effect on the replication of HIV-1(IIIB) in MT-4 cells Compound was evaluated for its inhibitory effect on the replication of HIV-1(IIIB) in MT-4 cells	[PMID: 14505657]
MT4	EC₅₀	0.01 μg/mL Compound: AZT	Compound was evaluated for its inhibitory effect on the replication of HIV-2 (ROD) in MT-4 cells Compound was evaluated for its inhibitory effect on the replication of HIV-2 (ROD) in MT-4 cells	[PMID: 14505657]
MT4	CC₅₀	75 μM Compound: AZT	Cytotoxic concentration required to reduce viability of uninfected cells in MT-4 cell line Cytotoxic concentration required to reduce viability of uninfected cells in MT-4 cell line	[PMID: 14521418]
MT4	EC₅₀	0.017 μM Compound: AZT	Effective concentration required to inhibit HIV-1 replication in MT-4 cell line Effective concentration required to inhibit HIV-1 replication in MT-4 cell line	[PMID: 14521418]
MT4	CC₅₀	7.8 μM Compound: AZT	Concentration required to reduce viability of mock-infected MT-4 cells Concentration required to reduce viability of mock-infected MT-4 cells	[PMID: 1469700]
MT4	CC₅₀	7.8 μM Compound: AZT	Concentration to required to reduce viability of Mock infected MT-4 cells Concentration to required to reduce viability of Mock infected MT-4 cells	[PMID: 1469700]
MT4	EC₅₀	0.0028 μM Compound: AZT	Concentration required to inhibit replication of HIV-2 LAV-2rod strain in MT-4 cells Concentration required to inhibit replication of HIV-2 LAV-2rod strain in MT-4 cells	[PMID: 1469700]
MT4	EC₅₀	0.003 μM Compound: AZT	Effective concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1 Effective concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1	[PMID: 1469700]
MT4	EC₅₀	0.0099 μM Compound: AZT	Effective concentration of compound against HIV-1 IIIB strain in MT-4 cells Effective concentration of compound against HIV-1 IIIB strain in MT-4 cells	[PMID: 14698189]
MT4	IC₅₀	0.04 μM Compound: AZT	Potency against non nucleoside reverse transcriptor was determined in MT-4 cells Potency against non nucleoside reverse transcriptor was determined in MT-4 cells	[PMID: 15109677]
MT4	EC₅₀	0.1 μM Compound: AZT	Effective concentration against HIV-I RTMDR1 in MT-4 cells Effective concentration against HIV-I RTMDR1 in MT-4 cells	[PMID: 15267246]
MT4	IC₅₀	>37.5 μM Compound: AZT	Inhibitory concentration against HIV-I RTMDR1 in MT-4 cells Inhibitory concentration against HIV-I RTMDR1 in MT-4 cells	[PMID: 15267246]
MT4	ED₅₀	0.004 μM Compound: 2	Concentration required to affect a 50% reduction in the cytopathic effect of HIV for MT-4 cells Concentration required to affect a 50% reduction in the cytopathic effect of HIV for MT-4 cells	[PMID: 1527788]
MT4	CC₅₀	57 μM Compound: AZT	Cytotoxic concentration against the mock infected MT-4 cells Cytotoxic concentration against the mock infected MT-4 cells	[PMID: 15658852]
MT4	EC₅₀	0.018 μM Compound: AZT	Effective concentration against HIV-induced cytopathogenicity in MT-4 cells Effective concentration against HIV-induced cytopathogenicity in MT-4 cells	[PMID: 15658852]
MT4	CC₅₀	3.7 μM Compound: AZT	Cytotoxicity against MT4 cells by MTT method Cytotoxicity against MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	0.003 μM Compound: AZT	Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	0.003 μM Compound: AZT	Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	0.003 μM Compound: AZT	Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method	[PMID: 16335924]
MT4	CC₅₀	3.7 μM Compound: AZT	Cytotoxicity against MT4 cells by MTT assay Cytotoxicity against MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.003 μM Compound: AZT	Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.003 μM Compound: AZT	Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.003 μM Compound: AZT	Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.013 μM Compound: AZT	Antiviral activity against HIV1 NL4-3 replication in human MT4 cells Antiviral activity against HIV1 NL4-3 replication in human MT4 cells	[PMID: 16942019]
MT4	EC₅₀	0.019 μM Compound: AZT	Antiviral activity against HIV1 FHR2 replication in MT4 cells Antiviral activity against HIV1 FHR2 replication in MT4 cells	[PMID: 16942019]
MT4	EC₅₀	0.019 μM Compound: AZT	Antiviral activity against HIV1 PI-R replication in human MT4 cells Antiviral activity against HIV1 PI-R replication in human MT4 cells	[PMID: 16942019]
MT4	IC₅₀	>37.5 μM Compound: AZT	Cytotoxicity against human MT4 cells Cytotoxicity against human MT4 cells	[PMID: 16942019]
MT4	EC₅₀	0.0045 μM Compound: AZT	AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the reverse transcriptase (RT) assay AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the reverse transcriptase (RT) assay	[PMID: 1695683]
MT4	EC₅₀	0.006 μM Compound: AZT	AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the P24 antigen enzyme-linked immunosorbent assay (ELISA). AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the P24 antigen enzyme-linked immunosorbent assay (ELISA).	[PMID: 1695683]
MT4	IC₅₀	53 μM Compound: AZT	Cytotoxicity was tested in MT-4 cells by the XTT-microculture tetrazolium assay. Cytotoxicity was tested in MT-4 cells by the XTT-microculture tetrazolium assay.	[PMID: 1695683]
MT4	CC₅₀	4.8 μM Compound: AzddThd	Cytotoxic concentration required to reduce the viability of normal uninfected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of normal uninfected MT-4 cells by 50%	[PMID: 1697345]
MT4	EC₅₀	0.003 μM Compound: AzddThd	Effective concentration achieving 50% protection of MT-4 cells against the cytopathic effect of HIV-1 Effective concentration achieving 50% protection of MT-4 cells against the cytopathic effect of HIV-1	[PMID: 1697345]
MT4	EC₅₀	0.0008 μM Compound: AZT	Antiviral activity against HIV1 in MT4 cells Antiviral activity against HIV1 in MT4 cells	[PMID: 17188402]
MT4	CC₅₀	7.8 μM Compound: AZT	Concentration required to reduce the viability of mock-infected MT-4 cells by 50%. Concentration required to reduce the viability of mock-infected MT-4 cells by 50%.	[PMID: 1732552]
MT4	EC₅₀	0.006 μM Compound: AZT	Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1. Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1.	[PMID: 1732552]
MT4	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 17548498]
MT4	EC₅₀	0.033 μM Compound: AZT	Antiviral activity against X4-HIV1 NL4-3 assessed as inhibition of p24 Gag protein production in human MT4 cells by MTT assay Antiviral activity against X4-HIV1 NL4-3 assessed as inhibition of p24 Gag protein production in human MT4 cells by MTT assay	[PMID: 17548498]
MT4	CC₅₀	35.6 μM Compound: AZT, zidovudine	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 17964796]
MT4	EC₅₀	0.0007 μM Compound: AZT, zidovudine	Antiviral activity against HIV1 3B assessed as inhibition of virus-induced cytopathogenicity in MT4 cells after 4 days by MTT assay Antiviral activity against HIV1 3B assessed as inhibition of virus-induced cytopathogenicity in MT4 cells after 4 days by MTT assay	[PMID: 17964796]
MT4	IC₅₀	0.05 μM Compound: AZT	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect by MTT assay	[PMID: 18212100]
MT4	CC₅₀	>93.55 μM Compound: AZT	Cytotoxicity against human MT4 cells Cytotoxicity against human MT4 cells	[PMID: 18267363]
MT4	EC₅₀	0.005 μM Compound: AZT	Antiviral activity against HIV1 3B infected in MT4 cells by MTT Antiviral activity against HIV1 3B infected in MT4 cells by MTT	[PMID: 18267363]
MT4	EC₅₀	0.006 μM Compound: AZT	Antiviral activity against HIV1 RES056 infected in MT4 cells by MTT Antiviral activity against HIV1 RES056 infected in MT4 cells by MTT	[PMID: 18267363]
MT4	EC₅₀	0.004 μM Compound: Zidovudine	Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.005 μM Compound: Zidovudine	Antiviral activity against HIV 1 NL4.3 harboring integrase L74M mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 NL4.3 harboring integrase L74M mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.006 μM Compound: Zidovudine	Antiviral activity against HIV 1 NL4.3 integrase S230N mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 NL4.3 integrase S230N mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.007 μM Compound: Zidovudine	Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.007 μM Compound: Zidovudine	Antiviral activity against HIV 1 NL4.3 integrase E92Q mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 NL4.3 integrase E92Q mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.018 μM Compound: Zidovudine	Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.018 μM Compound: Zidovudine	Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.018 μM Compound: Zidovudine	Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.022 μM Compound: Zidovudine	Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.022 μM Compound: Zidovudine	Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.022 μM Compound: Zidovudine	Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.011 μM Compound: AZT	Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.02 μM Compound: AZT	Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.021 μM Compound: AZT	Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.026 μM Compound: AZT	Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.027 μM Compound: AZT	Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.056 μM Compound: AZT	Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.067 μM Compound: AZT	Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.2 μM Compound: AZT	Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	CC₅₀	>100 μM Compound: AZT, zidovudine	Cytotoxicity against human MT4 cells Cytotoxicity against human MT4 cells	[PMID: 18585917]
MT4	EC₅₀	0.015 μM Compound: AZT, zidovudine	Antiviral activity against HIV1 infected human MT4 cells Antiviral activity against HIV1 infected human MT4 cells	[PMID: 18585917]
MT4	CC₅₀	>93.55 μM Compound: AZT, zidovudine	Cytotoxicity against human MT4 cells Cytotoxicity against human MT4 cells	[PMID: 18824350]
MT4	EC₅₀	0.0151 μM Compound: AZT, zidovudine	Antiviral activity against HIV1 3B in human MT4 cells assessed as protection of cell against virus-induced cytopathogenicity Antiviral activity against HIV1 3B in human MT4 cells assessed as protection of cell against virus-induced cytopathogenicity	[PMID: 18824350]
MT4	CC₅₀	2.01 μg/mL Compound: AZT	Cytotoxicity against mock-infected human MT4 cells by MTT assay Cytotoxicity against mock-infected human MT4 cells by MTT assay	[PMID: 19091580]
MT4	EC₅₀	0.0008 μg/mL Compound: AZT	Antiviral activity against HIV ROD in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV ROD in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 19091580]
MT4	EC₅₀	0.0015 μg/mL Compound: AZT	Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 19091580]
MT4	CC₅₀	61 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTS method Cytotoxicity against human MT4 cells by MTS method	[PMID: 19254848]
MT4	EC₅₀	0.009 μM Compound: AZT	Antiviral activity against HIV1 BH10 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS method Antiviral activity against HIV1 BH10 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS method	[PMID: 19254848]
MT4	CC₅₀	60 μM Compound: AZT	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 19282192]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against efavirenz-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against efavirenz-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19282192]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19282192]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against non-nucleoside reverse transcriptase inhibitor-resistant HIV1 bearing reverse transcriptase A17 (K103N, Y181C) mutation infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT Antiviral activity against non-nucleoside reverse transcriptase inhibitor-resistant HIV1 bearing reverse transcriptase A17 (K103N, Y181C) mutation infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT	[PMID: 19282192]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against non-nucleoside reverse transcriptase inhibitor-resistant HIV1 bearing reverse transcriptase N119 (Y181C) mutation infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against non-nucleoside reverse transcriptase inhibitor-resistant HIV1 bearing reverse transcriptase N119 (Y181C) mutation infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19282192]
MT4	EC₅₀	0.1 μM Compound: AZT	Antiviral activity against MDR1-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against MDR1-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19282192]
MT4	EC₅₀	0.6 μM Compound: AZT	Antiviral activity against azidothymidine-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against azidothymidine-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19282192]
MT4	IC₅₀	0.004 μM Compound: AZT	Ability to block replication of HIV-1 virus in mock infected MT-4 cells Ability to block replication of HIV-1 virus in mock infected MT-4 cells	[PMID: 1956037]
MT4	CC₅₀	>93.55 μM Compound: AZT	Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay	[PMID: 19628308]
MT4	EC₅₀	0.0151 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay	[PMID: 19628308]
MT4	CC₅₀	>93.55 μM Compound: azidothymidine,AZT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 19643613]
MT4	EC₅₀	0.0151 μM Compound: azidothymidine,AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay	[PMID: 19643613]
MT4	CC₅₀	20 μM Compound: AZT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 1992136]
MT4	EC₅₀	0.016 μM Compound: AZT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB). Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB).	[PMID: 1992136]
MT4	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 19944610]
MT4	IC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity by MTT assay	[PMID: 19944610]
MT4	CC₅₀	9.3 μM Compound: AZT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%. Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%.	[PMID: 1995896]
MT4	IC₅₀	0.0015 μM Compound: AZT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1.	[PMID: 1995896]
MT4	CC₅₀	>1 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 20112915]
MT4	IC₅₀	0.018 μM Compound: AZT	Antiviral activity against HIV1 3B in human MT4 cells assessed as RT activity after 5 days by single passage assay Antiviral activity against HIV1 3B in human MT4 cells assessed as RT activity after 5 days by single passage assay	[PMID: 20112915]
MT4	CC₅₀	7.8 μM Compound: AZT	Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells against the HIV-1 (HTLV-IIIB)induced cytopathic effect Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells against the HIV-1 (HTLV-IIIB)induced cytopathic effect	[PMID: 2016715]
MT4	EC₅₀	0.0028 μM Compound: AZT	Inhibitory activity against HIV-2(LAV-2ROD strain) replication in MT-4 cells Inhibitory activity against HIV-2(LAV-2ROD strain) replication in MT-4 cells	[PMID: 2016715]
MT4	EC₅₀	0.003 μM Compound: AZT	Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in MT-4 cells Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in MT-4 cells	[PMID: 2016715]
MT4	CC₅₀	20 μM Compound: AZT	Concentration of compound required to reduce MT-4 cells viability by 50%. Concentration of compound required to reduce MT-4 cells viability by 50%.	[PMID: 2016718]
MT4	EC₅₀	0.004 μM Compound: AZT	Concentration of compound required to inhibit HIV-1 replication in MT-4 cells by 50% Concentration of compound required to inhibit HIV-1 replication in MT-4 cells by 50%	[PMID: 2016718]
MT4	CC₅₀	7.8 μM Compound: AZT	Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50% Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50%	[PMID: 2016729]
MT4	EC₅₀	0.003 μM Compound: AZT	Concentration of compound required to achieve 50% protection of MT-4 cells against HIV-1 virus induced cytopathic effect Concentration of compound required to achieve 50% protection of MT-4 cells against HIV-1 virus induced cytopathic effect	[PMID: 2016729]
MT4	CC₅₀	93.55 μM Compound: AZT	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 20638854]
MT4	IC₅₀	0.005 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 20638854]
MT4	EC₅₀	0.027 μM Compound: AZT	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of viral replication after 4 days by p24 antigen based ELISA assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of viral replication after 4 days by p24 antigen based ELISA assay	[PMID: 20673723]
MT4	IC₅₀	>37.4 μM Compound: AZT	Cytotoxicity against human MT4 cells after 4 days Cytotoxicity against human MT4 cells after 4 days	[PMID: 20673723]
MT4	CC₅₀	65.4 μg/mL Compound: AZT	Cytotoxicity against human mock-infected MT4 cells after 4 days by MTT assay Cytotoxicity against human mock-infected MT4 cells after 4 days by MTT assay	[PMID: 21515046]
MT4	EC₅₀	0.0012 μg/mL Compound: AZT	Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21515046]
MT4	CC₅₀	>93.55 μM Compound: AZT, azidothymidine	Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay	[PMID: 21683601]
MT4	EC₅₀	0.015 μM Compound: AZT, azidothymidine	Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 21683601]
MT4	CC₅₀	>93.55 μM Compound: Zidovudine	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	0.006 μM Compound: Zidovudine	Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	0.006 μM Compound: Zidovudine	Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	0.007 μM Compound: Zidovudine	Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21824782]
MT4	CC₅₀	>88.26 μM Compound: AZT, azidothymidine	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.0033 μM Compound: AZT, azidothymidine	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.0049 μM Compound: AZT, azidothymidine	Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.0076 μM Compound: AZT, azidothymidine	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.011 μM Compound: AZT, azidothymidine	Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.02 μM Compound: AZT, azidothymidine	Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.0075 μM Compound: Zidovudine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	EC₅₀	0.0075 μM Compound: Zidovudine	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	EC₅₀	0.013 μM Compound: Zidovudine	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	CC₅₀	≥46.44 μM Compound: Zidovudine	Cytotoxicity against human MT4 cells measured by MTT assay Cytotoxicity against human MT4 cells measured by MTT assay	[PMID: 22037050]
MT4	IC₅₀	1.5 nM Compound: AZT	Antiviral activity against HIV1 3B infected in MT4 cells Antiviral activity against HIV1 3B infected in MT4 cells	[PMID: 22268494]
MT4	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22277590]
MT4	EC₅₀	0.02 μM Compound: AZT	Antiviral activity against X4 tropic HIV1 NL4-3 in MT4 cells assessed as protection from virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against X4 tropic HIV1 NL4-3 in MT4 cells assessed as protection from virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22277590]
MT4	CC₅₀	249.5 μM Compound: AZT, Azidothymidine	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22405288]
MT4	EC₅₀	0.0086 μM Compound: AZT, Azidothymidine	Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 22405288]
MT4	EC₅₀	20.6 nM Compound: AZT, Azidothymidine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 22405288]
MT4	EC₅₀	0.007 μM Compound: AZT	Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	EC₅₀	0.007 μM Compound: AZT	Antiviral activity against HIV2 ROD mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	EC₅₀	0.013 μM Compound: AZT	Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	CC₅₀	≥46 μM Compound: AZT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22575532]
MT4	CC₅₀	100 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction of cell viability Cytotoxicity against human MT4 cells assessed as reduction of cell viability	[PMID: 22579418]
MT4	EC₅₀	0.058 μM Compound: AZT	Antiviral activity against X4-tropic HIV1 NL4.3 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity Antiviral activity against X4-tropic HIV1 NL4.3 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity	[PMID: 22579418]
MT4	EC₅₀	0.007 μM Compound: AZT, Azidothymidine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22591854]
MT4	EC₅₀	0.01 μM Compound: AZT, Azidothymidine	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22591854]
MT4	EC₅₀	6 nM Compound: AZT, Azidothymidine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22591854]
MT4	CC₅₀	≥49.77 μM Compound: AZT, Azidothymidine	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22591854]
MT4	CC₅₀	>1 μg/mL Compound: AZT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22652226]
MT4	EC₅₀	0.004 μM Compound: AZT	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	[PMID: 22652226]
MT4	CC₅₀	>18710 nM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay	[PMID: 22712652]
MT4	EC₅₀	1.6 nM Compound: AZT	Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	11.7 nM Compound: AZT	Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	15.6 nM Compound: AZT	Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	3.8 nM Compound: AZT	Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	7.8 nM Compound: AZT	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	0.007 μM Compound: AZT, azidothymidine	Antiviral activity against HIV-2 ROD infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay Antiviral activity against HIV-2 ROD infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	[PMID: 22883027]
MT4	EC₅₀	0.01 μM Compound: AZT, azidothymidine	Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	[PMID: 22883027]
MT4	EC₅₀	6 μM Compound: AZT, azidothymidine	Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	[PMID: 22883027]
MT4	CC₅₀	≥50 μM Compound: AZT, azidothymidine	Cytotoxicity against mock-infected human MT4 cells by MTT assay Cytotoxicity against mock-infected human MT4 cells by MTT assay	[PMID: 22883027]
MT4	CC₅₀	>37 μM Compound: AZT	Cytotoxicity against human MT4 cells after 2 days Cytotoxicity against human MT4 cells after 2 days	[PMID: 22978745]
MT4	IC₅₀	0.03 μM Compound: AZT	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as p24 antigen level after 4 days by ELISA Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as p24 antigen level after 4 days by ELISA	[PMID: 22978745]
MT4	ED₅₀	0.004 μM Compound: AZT	Cytopathogenicity against HIV-1 induced, replication in MT-4 cells was determined Cytopathogenicity against HIV-1 induced, replication in MT-4 cells was determined	[PMID: 2299647]
MT4	ED₅₀	0.004 μM Compound: AZT	Cytopathogenicity against HIV-2 induced replication in MT-4 cells was determined Cytopathogenicity against HIV-2 induced replication in MT-4 cells was determined	[PMID: 2299647]
MT4	CC₅₀	249 μM Compound: AZT, azidothymidine	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 23084898]
MT4	EC₅₀	0.004 μM Compound: AZT, azidothymidine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	[PMID: 23084898]
MT4	EC₅₀	0.006 μM Compound: AZT, azidothymidine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	[PMID: 23084898]
MT4	EC₅₀	0.009 μM Compound: AZT, azidothymidine	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	[PMID: 23084898]
MT4	CC₅₀	249 μM Compound: AZT, azidothymidine	Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay	[PMID: 23098609]
MT4	CC₅₀	249 μM Compound: AZT, azidothymidine	Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay	[PMID: 23098609]
MT4	EC₅₀	0.004 μM Compound: AZT, azidothymidine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 23098609]
MT4	EC₅₀	0.021 μM Compound: AZT, azidothymidine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 23098609]
MT4	CC₅₀	>93.55 μM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability by MTT assay	[PMID: 23099090]
MT4	IC₅₀	>0.009 μM Compound: AZT	Antiviral activity against HIV-2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HIV-2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathicity	[PMID: 23099090]
MT4	IC₅₀	0.007 μM Compound: AZT	Antiviral activity against HIV-1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HIV-1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathicity	[PMID: 23099090]
MT4	CC₅₀	>93.63 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 23159806]
MT4	EC₅₀	0.006 μM Compound: AZT	Antiviral activity against HIV1 RES056 harbouring RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harbouring RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23159806]
MT4	EC₅₀	0.006 μM Compound: AZT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23159806]
MT4	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23159806]
MT4	EC₅₀	20 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathicity treated post-viral infection measured after 5 days by Cell-Titer Glo assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathicity treated post-viral infection measured after 5 days by Cell-Titer Glo assay	[PMID: 23375089]
MT4	ED₅₀	0.003 μM Compound: AzddThd (AZT)	Effective dose achieving 50% protection of MT-4 cells against the cytopathic effect of HIV Effective dose achieving 50% protection of MT-4 cells against the cytopathic effect of HIV	[PMID: 2342078]
MT4	CC₅₀	>93.55 μM Compound: AZT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 23707918]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23707918]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23707918]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23707918]
MT4	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 23916148]
MT4	EC₅₀	0.04 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytopathogenicity after 4 days by MTT assay	[PMID: 23916148]
MT4	CC₅₀	93.56 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	0.0059 μM Compound: AZT	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	0.0064 μM Compound: AZT	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	0.0066 μM Compound: AZT	Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	CC₅₀	>94 μM Compound: AZT, Zidovudine	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 24275349]
MT4	EC₅₀	0.0057 μM Compound: AZT, Zidovudine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay	[PMID: 24275349]
MT4	EC₅₀	0.0072 μM Compound: AZT, Zidovudine	Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay	[PMID: 24275349]
MT4	EC₅₀	0.0074 μM Compound: AZT, Zidovudine	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay	[PMID: 24275349]
MT4	CC₅₀	>93.5 μM Compound: AZT	Cytotoxicity against human MT4 cells Cytotoxicity against human MT4 cells	[PMID: 24411122]
MT4	IC₅₀	0.007 μM Compound: AZT	Antiviral activity against HIV-1 3B infected in human MT4 cells Antiviral activity against HIV-1 3B infected in human MT4 cells	[PMID: 24411122]
MT4	IC₅₀	0.007 μM Compound: AZT	Antiviral activity against HIV-2 ROD infected in human MT4 cells Antiviral activity against HIV-2 ROD infected in human MT4 cells	[PMID: 24411122]
MT4	CC₅₀	>93.55 μM Compound: AZT, Azidothymidine	Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay	[PMID: 24602795]
MT4	EC₅₀	0.0075 μM Compound: AZT, Azidothymidine	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24602795]
MT4	EC₅₀	0.012 μM Compound: AZT, Azidothymidine	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24602795]
MT4	EC₅₀	0.016 μM Compound: AZT, Azidothymidine	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24602795]
MT4	CC₅₀	>93.6 μM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 24680058]
MT4	EC₅₀	0.006 μM Compound: AZT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	[PMID: 24680058]
MT4	EC₅₀	0.007 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	[PMID: 24680058]
MT4	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	[PMID: 24680058]
MT4	CC₅₀	>30595 nM Compound: AZT	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 24769348]
MT4	EC₅₀	16 nM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	16 nM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	3.7 nM Compound: AZT	Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	33 nM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	6 nM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	CC₅₀	>93.5 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 24794751]
MT4	EC₅₀	0.005 μM Compound: AZT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	EC₅₀	0.006 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	EC₅₀	0.007 μM Compound: AZT	Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	CC₅₀	20 μM Compound: AZT	Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 2479745]
MT4	EC₅₀	0.016 μM Compound: AZT	Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1	[PMID: 2479745]
MT4	CC₅₀	50 μM Compound: AZT	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.009 μM Compound: AZT	Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in	[PMID: 24805780]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.02 μM Compound: AZT	Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.2 μM Compound: AZT	Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.2 μM Compound: AZT	Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	CC₅₀	>25 μM Compound: azidothymidine	Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay	[PMID: 24926807]
MT4	IC₅₀	0.006 μM Compound: azidothymidine	Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay	[PMID: 24926807]
MT4	IC₅₀	0.0071 μM Compound: azidothymidine	Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay	[PMID: 24926807]
MT4	CC₅₀	>93.5489 μM Compound: AZT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 24952305]
MT4	IC₅₀	0.0017 μM Compound: AZT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24952305]
MT4	IC₅₀	0.0066 μM Compound: AZT	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24952305]
MT4	IC₅₀	0.0077 μM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24952305]
MT4	CC₅₀	>93.55 μM Compound: AZT, azidothymidine	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	0.0067 μM Compound: AZT, azidothymidine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	0.0071 μM Compound: AZT, azidothymidine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	0.01 μM Compound: AZT, azidothymidine	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	CC₅₀	>93.55 μM Compound: AZT	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 25537532]
MT4	EC₅₀	0.0066 μM Compound: AZT	Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	EC₅₀	0.0071 μM Compound: AZT	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	CC₅₀	>94 μM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	7.1 nM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	0.0016 μM Compound: Zidovudine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 25682562]
MT4	EC₅₀	0.0019 μM Compound: Zidovudine	Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 25682562]
MT4	CC₅₀	>94 μM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25707013]
MT4	EC₅₀	0.007 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25707013]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25707013]
MT4	CC₅₀	>94 μM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25907370]
MT4	EC₅₀	0.0052 μM Compound: AZT	Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay	[PMID: 25907370]
MT4	EC₅₀	0.0056 μM Compound: AZT	Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay	[PMID: 25907370]
MT4	CC₅₀	>25 μM Compound: azidothymidine	Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay	[PMID: 25946116]
MT4	EC₅₀	0.006 μM Compound: azidothymidine	Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay	[PMID: 25946116]
MT4	EC₅₀	0.0071 μM Compound: azidothymidine	Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay	[PMID: 25946116]
MT4	EC₅₀	6 μM Compound: azidothymidine	Antiviral activity against HIV2 ROD infected in MT4 cells assessed as cell viability after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 25970561]
MT4	EC₅₀	7.1 μM Compound: azidothymidine	Antiviral activity against HIV1 3B infected in MT4 cells assessed as cell viability after 5 days by MTT assay Antiviral activity against HIV1 3B infected in MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 25970561]
MT4	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 26094944]
MT4	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine	[PMID: 26094944]
MT4	CC₅₀	27 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTT assay in presence of 2.5 uM of chloroquine Cytotoxicity against human MT4 cells by MTT assay in presence of 2.5 uM of chloroquine	[PMID: 26094944]
MT4	CC₅₀	31 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTT assay in presence of 10 uM of chloroquine Cytotoxicity against human MT4 cells by MTT assay in presence of 10 uM of chloroquine	[PMID: 26094944]
MT4	EC₅₀	0.013 μM Compound: AZT	Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 5 uM of chloroquine Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 5 uM of chloroquine	[PMID: 26094944]
MT4	EC₅₀	0.015 μM Compound: AZT	Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 2.5 uM of chloroquine Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 2.5 uM of chloroquine	[PMID: 26094944]
MT4	EC₅₀	0.12 μM Compound: AZT	Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 26094944]
MT4	EC₅₀	0.032 μM Compound: AZT	Antiviral activity against HIV-1 NL4-3 infected in MT4 cells assessed as viral replication measured on day 4 post infection by ELISA Antiviral activity against HIV-1 NL4-3 infected in MT4 cells assessed as viral replication measured on day 4 post infection by ELISA	[PMID: 26562066]
MT4	CC₅₀	≥3.74 μM Compound: AZT	Cytotoxicity against human MT4 cells by cellTiterGlo assay Cytotoxicity against human MT4 cells by cellTiterGlo assay	[PMID: 26562066]
MT4	CC₅₀	>7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 26613134]
MT4	EC₅₀	>7.48 μM Compound: AZT	Antiviral activity against NRTI/NNRTI-resistant HIV1 L6 harboring reverse transcriptase V75I/F77L/K103N/F116Y/Q151M/M184V mutant infected in human MT4 cells Antiviral activity against NRTI/NNRTI-resistant HIV1 L6 harboring reverse transcriptase V75I/F77L/K103N/F116Y/Q151M/M184V mutant infected in human MT4 cells	[PMID: 26613134]
MT4	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26613134]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26613134]
MT4	EC₅₀	0.03 μM Compound: AZT	Antiviral activity against AZT-resistant HIV1 ADP/141 harboring reverse transcriptase D67N/K70R/T215F/K219Q mutant infected in human MT4 cells Antiviral activity against AZT-resistant HIV1 ADP/141 harboring reverse transcriptase D67N/K70R/T215F/K219Q mutant infected in human MT4 cells	[PMID: 26613134]
MT4	CC₅₀	>25 μg/mL Compound: Azidothymidine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 3 to 6 days by MTS assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 3 to 6 days by MTS assay	[PMID: 26707844]
MT4	CC₅₀	>0.1 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay	[PMID: 26756779]
MT4	EC₅₀	0.004 μM Compound: AZT	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by luciferase reporter gene assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by luciferase reporter gene assay	[PMID: 26756779]
MT4	EC₅₀	0.0048 μM Compound: AZT	Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.0052 μM Compound: AZT	Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.0067 μM Compound: AZT	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.0071 μM Compound: AZT	Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.0083 μM Compound: AZT	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.011 μM Compound: AZT	Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.013 μM Compound: AZT	Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	CC₅₀	>7.48 μM Compound: AZT; zidovudine	Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay	[PMID: 26994843]
MT4	EC₅₀	0.007 μM Compound: AZT; zidovudine	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	EC₅₀	0.0082 μM Compound: AZT; zidovudine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	EC₅₀	0.017 μM Compound: AZT; zidovudine	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	CC₅₀	2 μg/mL Compound: Zidovudine	Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay	[PMID: 27105027]
MT4	IC₅₀	0.002 μg/mL Compound: Zidovudine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay	[PMID: 27105027]
MT4	CC₅₀	>99 μM Compound: Azidothymidine	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 27112451]
MT4	EC₅₀	0.008 μM Compound: Azidothymidine	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27112451]
MT4	CC₅₀	>25 μg/mL Compound: AZT	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 27214512]
MT4	EC₅₀	0.00094 μg/mL Compound: AZT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay	[PMID: 27214512]
MT4	EC₅₀	0.0022 μg/mL Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay	[PMID: 27214512]
MT4	CC₅₀	>7.5 μM Compound: AZT ; azidothymidine	Cytotoxicity against mock-infected human MT4 cells Cytotoxicity against mock-infected human MT4 cells	[PMID: 27234889]
MT4	EC₅₀	0.006 μM Compound: AZT ; azidothymidine	Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	EC₅₀	0.008 μM Compound: AZT ; azidothymidine	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	EC₅₀	0.016 μM Compound: AZT ; azidothymidine	Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	CC₅₀	>93.5 μM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27267005]
MT4	EC₅₀	0.006 μM Compound: AZT	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27267005]
MT4	EC₅₀	0.007 μM Compound: AZT	Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27267005]
MT4	CC₅₀	>93550 nM Compound: AZT	Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	10 nM Compound: AZT	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	3.8 nM Compound: AZT	Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	4.8 nM Compound: AZT	Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	5.2 nM Compound: AZT	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	5.8 nM Compound: AZT	Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	6.3 nM Compound: AZT	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	6.6 nM Compound: AZT	Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	6.7 nM Compound: AZT	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	7.3 nM Compound: AZT	Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	ED₅₀	0.003 μM Compound: AZT	Inhibitory activity against HIV-1 replication in MT-4 cells Inhibitory activity against HIV-1 replication in MT-4 cells	[PMID: 2754700]
MT4	CC₅₀	>25 μg/mL Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27647368]
MT4	IC₅₀	0.00094 μg/mL Compound: AZT	Antiviral activity against HIV-2 ROD infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay	[PMID: 27647368]
MT4	IC₅₀	0.0022 μg/mL Compound: AZT	Antiviral activity against HIV-1 3B infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay	[PMID: 27647368]
MT4	CC₅₀	>7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 28254696]
MT4	CC₅₀	7.5 μM Compound: Azidothymidine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 28314514]
MT4	CC₅₀	>7 μM Compound: Azidothymidine	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 28314598]
MT4	CC₅₀	>0.00748 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 28481112]
MT4	CC₅₀	>30595 nM Compound: AZT	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 28628334]
MT4	CC₅₀	>0.5 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 6 days by XTT tetrazolium dye-based assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 6 days by XTT tetrazolium dye-based assay	[PMID: 28682067]
MT4	CC₅₀	>7.48 μM Compound: AZT	Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 28987601]
MT4	CC₅₀	>7.484 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 29152052]
MT4	CC₅₀	>2000 nM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 29353724]
MT4	CC₅₀	>7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 29559197]
MT4	CC₅₀	>7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 29635166]
MT4	CC₅₀	>7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 29670703]
MT4	CC₅₀	>3.74 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by cytoTox-Glo reagent based assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by cytoTox-Glo reagent based assay	[PMID: 30010341]
MT4	CC₅₀	>0.4 μM Compound: AZT	Cytotoxicity against human MT4 cells after 3 days by CytoTox-Glo assay Cytotoxicity against human MT4 cells after 3 days by CytoTox-Glo assay	[PMID: 30031972]
MT4	CC₅₀	77.5 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo luminescent assay	[PMID: 30703659]
MT4	CC₅₀	>7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 30721060]
MT4	CC₅₀	>0.37 μM Compound: AZT	Cytotoxicity against human MT4 cells measured after 3 days by CytoTox-Glo assay Cytotoxicity against human MT4 cells measured after 3 days by CytoTox-Glo assay	[PMID: 31184480]
MT4	CC₅₀	>7.49 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31434039]
MT4	ED₅₀	0.004 μM Compound: 1a	Dose required to inhibit cytopathic effect of human immunodeficiency virus replication in MT-4 cells. Dose required to inhibit cytopathic effect of human immunodeficiency virus replication in MT-4 cells.	[PMID: 3172142]
MT4	CC₅₀	>15 μM Compound: Zidovudine	Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay	[PMID: 31767136]
MT4	CC₅₀	>15 μM Compound: AZT	Cytotoxicity against human MT4 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human MT4 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31860304]
MT4	CC₅₀	>50 μM Compound: AZT	Cytotoxicity against Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 32305183]
MT4	CC₅₀	>7.48 μM Compound: AZT	Cytotoxicity in mock-infected human MT4 assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity in mock-infected human MT4 assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32631509]
MT4	CC₅₀	>30595 nM Compound: AZT	Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay	[PMID: 32883642]
MT4	CC₅₀	>7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32977301]
MT4	CC₅₀	>0.37 μM Compound: AZT	Cytotoxicity against human MT4 cells treated for 3 days measured by Celltiter-glo luminescent assay Cytotoxicity against human MT4 cells treated for 3 days measured by Celltiter-glo luminescent assay	[PMID: 33214842]
MT4	CC₅₀	>7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 33279288]
MT4	CC₅₀	74 μM Compound: AZT	Cytotoxicity against in human MT-4 after 5 days by MTT assay Cytotoxicity against in human MT-4 after 5 days by MTT assay	[PMID: 33316719]
MT4	CC₅₀	>7.5 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 33340914]
MT4	CC₅₀	140 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33711763]
MT4	CC₅₀	>7.48 μM Compound: Zidovudine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 33979774]
MT4	CC₅₀	>7.48 μM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay	[PMID: 34090079]
MT4	CC₅₀	>2 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 34583311]
MT4	CC₅₀	>7480 nM Compound: AZT	Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 34890994]
MT4	ED₅₀	0.006 μM Compound: AZT	Anti-HIV activity was determined as dose required to protect 50% of the HIV-infected MT-4 cells against destruction Anti-HIV activity was determined as dose required to protect 50% of the HIV-infected MT-4 cells against destruction	[PMID: 3499515]
MT4	CC₅₀	>7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay	[PMID: 35640327]
MT4	CC₅₀	7.06 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay	[PMID: 35679690]
MT4	CC₅₀	>7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability Cytotoxicity against human MT4 cells assessed as reduction in cell viability	[PMID: 36442370]
MT4	CC₅₀	>7.06 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 36577220]
MT4	CC₅₀	>7.1 μM Compound: Zidovudine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT spectrophotometric assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT spectrophotometric assay	[PMID: 36640458]
MT4	CC₅₀	>7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 37393790]
MT4	CC₅₀	>749 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 37976805]
MT4	CC₅₀	51 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 38954919]
MT4	CC₅₀	>7.49 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 38996652]
MT4	IC₅₀	0.02 μg/mL Compound: 4	Inhibitory Effect against HIV-1 (IIIB) in CEM cells Inhibitory Effect against HIV-1 (IIIB) in CEM cells	[PMID: 7473592]
MT4	IC₅₀	57.28 μg/mL Compound: 4	Concentration required to reduce the number of viable uninfected cells by 50% Concentration required to reduce the number of viable uninfected cells by 50%	[PMID: 7473592]
MT4	EC₅₀	0.003 μM Compound: AZT	Inhibition of reverse transcriptase of HIV-1 (strain RF)-infected MT-4 cells in RPMI 1640 growth medium in MTM assay Inhibition of reverse transcriptase of HIV-1 (strain RF)-infected MT-4 cells in RPMI 1640 growth medium in MTM assay	[PMID: 7504733]
MT4	EC₅₀	0.01 μM Compound: AZT	Inhibition of HIV-1 (strain A17)-infected MT-4 cells Inhibition of HIV-1 (strain A17)-infected MT-4 cells	[PMID: 7504733]
MT4	CC₅₀	>80 μM Compound: AZT	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% (4 days) Concentration required to reduce the viability of mock-infected MT-4 cells by 50% (4 days)	[PMID: 7523675]
MT4	EC₅₀	0.01 μM Compound: AZT	Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 (4 days) Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 (4 days)	[PMID: 7523675]
MT4	EC₅₀	0.04 μM Compound: AZT	Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-2 (8 days) Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-2 (8 days)	[PMID: 7523675]
MT4	CC₅₀	6 μM Compound: AZT	Tested for the cytotoxic concentration required to reduce the number of viable mock infected MT-4 cells Tested for the cytotoxic concentration required to reduce the number of viable mock infected MT-4 cells	[PMID: 7527463]
MT4	EC₅₀	0.002 μM Compound: AZT	Tested for the inhibitory activity of HIV-1 infected MT-4 cells Tested for the inhibitory activity of HIV-1 infected MT-4 cells	[PMID: 7527463]
MT4	EC₅₀	0.003 μM Compound: AZT	Tested for the inhibitory activity of HIV-2 infected MT-4 cells Tested for the inhibitory activity of HIV-2 infected MT-4 cells	[PMID: 7527463]
MT4	CC₅₀	3.2 μM Compound: AZT	Cytotoxic concentration based on the reduction of viability of mock-infected cells Cytotoxic concentration based on the reduction of viability of mock-infected cells	[PMID: 7540208]
MT4	EC₅₀	0.004 μM Compound: AZT	Compound was evaluated for the inhibition of HIV-1 induced CPE (HTLV-III B strain ) replication in MT-4 cells Compound was evaluated for the inhibition of HIV-1 induced CPE (HTLV-III B strain ) replication in MT-4 cells	[PMID: 7540208]
MT4	CC₅₀	75 μM Compound: AZT	Antiviral activity in MT-4 cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50% Antiviral activity in MT-4 cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%	[PMID: 7562927]
MT4	EC₅₀	0.017 μM Compound: AZT	Antiviral activity in MT-4 cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined Antiviral activity in MT-4 cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined	[PMID: 7562927]
MT4	CC₅₀	>20 μM Compound: AZT	Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells (4 days) Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells (4 days)	[PMID: 7562935]
MT4	EC₅₀	0.01 μM Compound: AZT	Protection of MT-4 cells against the cytopathic effect of HIV-1 (4 days) Protection of MT-4 cells against the cytopathic effect of HIV-1 (4 days)	[PMID: 7562935]
MT4	EC₅₀	0.04 μM Compound: AZT	Protection of MT-4 cells against the cytopathic effect of HIV-2 (8 days) Protection of MT-4 cells against the cytopathic effect of HIV-2 (8 days)	[PMID: 7562935]
MT4	CC₅₀	7.8 μM Compound: AZT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 7636846]
MT4	CC₅₀	7.8 μM Compound: AZT	The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus A012D strain The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus A012D strain	[PMID: 7636846]
MT4	CC₅₀	7.8 μM Compound: AZT	The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus LAV-2ROD strain The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus LAV-2ROD strain	[PMID: 7636846]
MT4	EC₅₀	0.0028 μM Compound: AZT	The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 virus LAV-2ROD The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 virus LAV-2ROD	[PMID: 7636846]
MT4	EC₅₀	0.003 μM Compound: AZT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus.	[PMID: 7636846]
MT4	EC₅₀	0.3 μM Compound: AZT	The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus A012D strain The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus A012D strain	[PMID: 7636846]
MT4	CC₅₀	>20 μM Compound: AZT	Compound dose required to reduce the viability of mock-infected cells by 50% Compound dose required to reduce the viability of mock-infected cells by 50%	[PMID: 7650679]
MT4	EC₅₀	0.01 μM Compound: AZT	Dose required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity Dose required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity	[PMID: 7650679]
MT4	CC₅₀	110 μM Compound: AZT	Cytotoxic concentration against HIV-1 infected MT-4 cell lines Cytotoxic concentration against HIV-1 infected MT-4 cell lines	[PMID: 7837220]
MT4	IC₅₀	0.005 μM Compound: AZT	Inhibitory concentration against HIV-1 infected MT-4 cell lines Inhibitory concentration against HIV-1 infected MT-4 cell lines	[PMID: 7837220]
MT4	IC₅₀	0.0041 μM Compound: AZT	Concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1 Concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1	[PMID: 7877144]
MT4	EC₅₀	0.085 μM Compound: AZT	Effective concentration required for antiviral activity against T (HTLV-1+)cell line of MT-4 cells of Human by XTT assay Effective concentration required for antiviral activity against T (HTLV-1+)cell line of MT-4 cells of Human by XTT assay	[PMID: 7932526]
MT4	EC₅₀	4.0 x 10^-9 M Compound: AZT	Tested for in vitro cytopathic effect of HIV for MT-4 cells Tested for in vitro cytopathic effect of HIV for MT-4 cells	[PMID: 7932583]
MT4	EC₅₀	0.02 μM Compound: AZT	Inhibition of cytopathic effect of HIV-1 strain RF in MT-4 cell culture Inhibition of cytopathic effect of HIV-1 strain RF in MT-4 cell culture	[PMID: 8230098]
MT4	CC₅₀	6 μM Compound: 1	cytotoxic activity in MT-4 cell line cytotoxic activity in MT-4 cell line	[PMID: 8478904]
MT4	EC₅₀	0.002 μM Compound: 1	Anti HIV-1 activity in human lymphocyte MT-4 cell line Anti HIV-1 activity in human lymphocyte MT-4 cell line	[PMID: 8478904]
MT4	EC₅₀	0.003 μM Compound: 1	Anti HIV-2 activity in human lymphocyte MT-4 cell line Anti HIV-2 activity in human lymphocyte MT-4 cell line	[PMID: 8478904]
MT4	CC₅₀	>20 μM Compound: AZT	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% Concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 8558522]
MT4	EC₅₀	0.01 μM Compound: AZT	Effective concentration against HIV-1 induced cytopathogenicity in MT-4 cells Effective concentration against HIV-1 induced cytopathogenicity in MT-4 cells	[PMID: 8558522]
MT4	CC₅₀	150 μM Compound: AZT	Ability to reduce 50% viability of MT-4 cells acutely infected with HIV-1 strain IIIB Ability to reduce 50% viability of MT-4 cells acutely infected with HIV-1 strain IIIB	[PMID: 8642557]
MT4	EC₅₀	0.005 μM Compound: AZT	Effective dose to achieve 50% protection of MT-4 cells from acutely infected HIV-1 strain IIIB Effective dose to achieve 50% protection of MT-4 cells from acutely infected HIV-1 strain IIIB	[PMID: 8642557]
MT4	CC₅₀	6 μM Compound: 1	Cytotoxic concentration against MT-4 cells (in vitro) Cytotoxic concentration against MT-4 cells (in vitro)	[PMID: 8648614]
MT4	EC₅₀	0.002 μM Compound: 1	Activity against HIV-1 in MT-4 cells (in vitro) Activity against HIV-1 in MT-4 cells (in vitro)	[PMID: 8648614]
MT4	EC₅₀	0.003 μM Compound: 1	Activity against HIV-2 in MT-4 cells (in vitro) Activity against HIV-2 in MT-4 cells (in vitro)	[PMID: 8648614]
MT4	CC₅₀	1.5 μg/mL Compound: AZT	Cytotoxic concentration which is required to reduce human MT-4 cell viability by 50%. Cytotoxic concentration which is required to reduce human MT-4 cell viability by 50%.	[PMID: 9046339]
MT4	EC₅₀	0.0005 μg/mL Compound: AZT	50% effective concentration of compound which is required to protect human MT-4 cells against cytopathogenicity of HIV-1. 50% effective concentration of compound which is required to protect human MT-4 cells against cytopathogenicity of HIV-1.	[PMID: 9046339]
MT4	EC₅₀	0.0007 μg/mL Compound: AZT	50% effective concentration of compound which is required to protect human MT-4 cells against cytopathogenicity of HIV-2. 50% effective concentration of compound which is required to protect human MT-4 cells against cytopathogenicity of HIV-2.	[PMID: 9046339]
MT4	CC₅₀	>80 μM Compound: AZT	Dose required to reduce the viability of mock-infected cells by 50% Dose required to reduce the viability of mock-infected cells by 50%	[PMID: 9154967]
MT4	EC₅₀	0.01 μM Compound: AZT	Dose required to achieve 50% protection of MT-4 cells from the HIV-1 induced cytopathogenicity in mock-infected MT-4 cells Dose required to achieve 50% protection of MT-4 cells from the HIV-1 induced cytopathogenicity in mock-infected MT-4 cells	[PMID: 9154967]
MT4	CC₅₀	35.6 μM Compound: AZT	Dose required to reduce the viability of mock-infected cells by 50%, determined by MTT method. Dose required to reduce the viability of mock-infected cells by 50%, determined by MTT method.	[PMID: 9767646]
MT4	EC₅₀	0.0007 μM Compound: AZT	Dose required to achieve 50% protection of MT-4 cells from HIV-1(IIIB) induced cytopathogenicity, determined by MIT method. Dose required to achieve 50% protection of MT-4 cells from HIV-1(IIIB) induced cytopathogenicity, determined by MIT method.	[PMID: 9767646]
MT4	CC₅₀	50 μM Compound: AZT	Concentration required to cause 50% death of uninfected MT-4 cells Concentration required to cause 50% death of uninfected MT-4 cells	[PMID: 9925728]
MT4	EC₅₀	0.05 μM Compound: AZT	Concentration required to inhibit syncytia formation by 50% on HIV-1 infected MT-4 cells Concentration required to inhibit syncytia formation by 50% on HIV-1 infected MT-4 cells	[PMID: 9925728]
MT4	CC₅₀	>93.55 μM Compound: AZT, azidothymidine	Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay	10.1007/s00044-009-9220-x
MT4	EC₅₀	0.0151 μM Compound: AZT, azidothymidine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay	10.1007/s00044-009-9220-x
MT4	CC₅₀	50 μM Compound: AZT	Cytotoxicity against Homo sapiens (human) MT4 cells containing integrated HTLV-1 genome after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells containing integrated HTLV-1 genome after 96 hr by MTT assay	10.1007/s00044-010-9513-0
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	10.1007/s00044-010-9513-0
MT4	CC₅₀	>25 μg/mL Compound: Zidovudine	Cytotoxicity against Homo sapiens (human) MT4 cells Cytotoxicity against Homo sapiens (human) MT4 cells	10.1007/s00044-011-9662-9
MT4	EC₅₀	0.002 μg/mL Compound: Zidovudine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
MT4	EC₅₀	0.002 μg/mL Compound: Zidovudine	Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
MT4	CC₅₀	>2.5 μg/mL Compound: Zidovudine	Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay	10.1007/s00044-011-9664-7
MT4	EC₅₀	0.0009 μg/mL Compound: Zidovudine	Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9664-7
MT4	EC₅₀	0.002 μg/mL Compound: Zidovudine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9664-7
MT4	CC₅₀	>25 μg/mL Compound: Zidovudine	Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay	10.1007/s00044-011-9705-2
MT4	EC₅₀	0.002 μg/mL Compound: Zidovudine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9705-2
MT4	EC₅₀	0.002 μg/mL Compound: Zidovudine	Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9705-2
MT4	CC₅₀	>25 μg/mL Compound: Zidovudine	Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay	10.1007/s00044-011-9776-0
MT4	EC₅₀	0.0009 μg/mL Compound: Zidovudine	Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9776-0
MT4	EC₅₀	0.002 μg/mL Compound: Zidovudine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9776-0
MT4	CC₅₀	50 μM Compound: AZT	Cytotoxicity against Homo sapiens (human) MT4 cells assessed as inhibition of cell vaibility after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells assessed as inhibition of cell vaibility after 96 hr by MTT assay	10.1007/s00044-012-0342-1
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as protection against virus-induced cytopathogenicity treated before viral infection measured after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as protection against virus-induced cytopathogenicity treated before viral infection measured after 4 days by MTT assay	10.1007/s00044-012-0342-1
MT4	CC₅₀	>25 μg/mL Compound: DDN, AZT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	10.1007/s00044-013-0567-7
MT4	IC₅₀	0.00094 μg/mL Compound: DDN, AZT	Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	10.1007/s00044-013-0567-7
MT4	IC₅₀	0.0022 μg/mL Compound: DDN, AZT	Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	10.1007/s00044-013-0567-7
MT4	CC₅₀	6000 nM Compound: 1	Cytotoxicity against human lymphocyte MT-4 cells Cytotoxicity against human lymphocyte MT-4 cells	10.1016/0960-894X(94)80009-X
MT4	EC₅₀	2.5 nM Compound: 1	In vitro inhibitory activity against replication of HIV-1 in human lymphocyte MT-4 cells In vitro inhibitory activity against replication of HIV-1 in human lymphocyte MT-4 cells	10.1016/0960-894X(94)80009-X
MT4	EC₅₀	2.6 nM Compound: 1	In vitro inhibitory activity against replication of HIV-2 in human lymphocyte MT-4 cells In vitro inhibitory activity against replication of HIV-2 in human lymphocyte MT-4 cells	10.1016/0960-894X(94)80009-X
MT4	CC₅₀	113 μM Compound: AZT	Cytotoxic concentration required to reduce the viability of MT-4 cells Cytotoxic concentration required to reduce the viability of MT-4 cells	10.1016/0960-894X(95)00208-B
MT4	EC₅₀	0.035 μM Compound: AZT	Concentration required to inhibit HIV-1-induced cytopathic effect by 50% in MT-4 cells Concentration required to inhibit HIV-1-induced cytopathic effect by 50% in MT-4 cells	10.1016/0960-894X(95)00208-B
MT4	EC₅₀	0.0032 μg/mL Compound: AZT	In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in MT-4 cells by indirect immunofluorescence assay In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in MT-4 cells by indirect immunofluorescence assay	10.1016/0960-894X(95)00395-A
MT4	CC₅₀	113 μM Compound: AZT	Compound was evaluated for the concentration required to reduce the viability of MT-4 cells. Compound was evaluated for the concentration required to reduce the viability of MT-4 cells.	10.1016/0960-894X(95)00585-H
MT4	EC₅₀	0.04 μM Compound: AZT	Compound was evaluated for the inhibition of HIV-1 induced cytopathic effect in MT-4 cells. Compound was evaluated for the inhibition of HIV-1 induced cytopathic effect in MT-4 cells.	10.1016/0960-894X(95)00585-H
MT4	EC₅₀	0.002 μM Compound: AZT (table 3)	Dose required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 Dose required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1	10.1016/0960-894X(96)00216-8
MT4	CC₅₀	3.2 μM Compound: AZT	Tested for 50% cytotoxic concentration based on the reduction of viability in mock-infected MT-4 cells Tested for 50% cytotoxic concentration based on the reduction of viability in mock-infected MT-4 cells	10.1016/0960-894X(96)00355-1
MT4	EC₅₀	0.004 μM Compound: AZT	Tested for 50% effective concentration based on the inhibition of HIV-I induced cytopathic effect in MT-4 cells Tested for 50% effective concentration based on the inhibition of HIV-I induced cytopathic effect in MT-4 cells	10.1016/0960-894X(96)00355-1
MT4	ED₅₀	0.06 μM Compound: AZT	Concentration that inhibits cellular growth of MT-4 cells acutely infected with HIV-1 RFstrain by 50% Concentration that inhibits cellular growth of MT-4 cells acutely infected with HIV-1 RFstrain by 50%	10.1016/S0960-894X(01)80332-2
MT4	CC₅₀	>20 μM Compound: AZT	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% Concentration required to reduce the viability of mock-infected MT-4 cells by 50%	10.1016/S0960-894X(97)00340-5
MT4	EC₅₀	0.01 μM Compound: AZT	Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1	10.1016/S0960-894X(97)00340-5
MT4	CC₅₀	249.5 μM Compound: AZT, Azidothymidine	Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	10.1039/C3MD00028A
MT4	CC₅₀	249.5 μM Compound: AZT, Azidothymidine	Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	10.1039/C3MD00028A
MT4	EC₅₀	0.0045 μM Compound: AZT, Azidothymidine	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	10.1039/C3MD00028A
MT4	EC₅₀	0.021 μM Compound: AZT, Azidothymidine	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	10.1039/C3MD00028A
MT4	CC₅₀	>93.56 μM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	EC₅₀	0.006 μM Compound: AZT	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	EC₅₀	0.0063 μM Compound: AZT	Antiviral activity against HIV-1 RES056 harboring RT K103N+Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay Antiviral activity against HIV-1 RES056 harboring RT K103N+Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	EC₅₀	0.0064 μM Compound: AZT	Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
NCI-H460	IC₅₀	6.81 μM Compound: AZT, Zidovudine	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 25440502]
NHDF	IC₅₀	14.41 μM Compound: AZT	Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
NHDF	IC₅₀	14.41 μM Compound: 3; AZT	Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
NIH3T3	IC₅₀	>200 μM Compound: 13, AZT	Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB method Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB method	[PMID: 25933593]
PBL	CC₅₀	26 μM Compound: AZT	Concentration required to reduce viability of Mock infected PBL (peripheral blood lymphocytes) cells. Concentration required to reduce viability of Mock infected PBL (peripheral blood lymphocytes) cells.	[PMID: 1469700]
PBL	EC₅₀	0.0014 μM Compound: AZT	Concentration required to inhibit replication of HIV-1 HTLV-IIIB strain in PBL (peripheral blood lymphocytes) cells Concentration required to inhibit replication of HIV-1 HTLV-IIIB strain in PBL (peripheral blood lymphocytes) cells	[PMID: 1469700]
PBL	CC₅₀	12 μM Compound: AZT	The cytotoxic concentration of compound required to reduce the viability of mock-infected PBL cells by 50% on HIV-1 virus HTLV-IIIB strain The cytotoxic concentration of compound required to reduce the viability of mock-infected PBL cells by 50% on HIV-1 virus HTLV-IIIB strain	[PMID: 7636846]
PBL	EC₅₀	0.029 μM Compound: AZT	Effective concentration required for antiviral activity against lymphocyte cell line of PBL cells of Human by XTT assay Effective concentration required for antiviral activity against lymphocyte cell line of PBL cells of Human by XTT assay	[PMID: 7932526]
PBMC	IC₅₀	>100 μM Compound: AZT	Inhibitory activity was evaluated in human peripheral blood mononuclear (PBM) cells infected with Human immunodeficiency virus-1 Inhibitory activity was evaluated in human peripheral blood mononuclear (PBM) cells infected with Human immunodeficiency virus-1	[PMID: 10197975]
PBMC	IC₅₀	0.004 μM Compound: 4	The compound was tested for anti HIV-activity (active) against PBM cell line The compound was tested for anti HIV-activity (active) against PBM cell line	[PMID: 10450963]
PBMC	EC₅₀	0.024 μM Compound: AZT	Effective concentration of compound against HIV-1 89.6 strain in PBMC cells Effective concentration of compound against HIV-1 89.6 strain in PBMC cells	[PMID: 14698189]
PBMC	EC₅₀	0.004 μM Compound: AZT	Anti-HIV activity in Human peripheral blood mononuclear (PBM) cells Anti-HIV activity in Human peripheral blood mononuclear (PBM) cells	[PMID: 15027854]
PBMC	EC₅₀	0.0018 μM Compound: Zidovudine (AZT)	Effective concentration to inhibit HIV-1 activity in human peripheral blood mononuclear cells Effective concentration to inhibit HIV-1 activity in human peripheral blood mononuclear cells	[PMID: 15916425]
PBMC	IC₅₀	>100 μM Compound: Zidovudine (AZT)	Inhibitory concentration was determined against PHA stimulated human peripheral blood mononuclear cells Inhibitory concentration was determined against PHA stimulated human peripheral blood mononuclear cells	[PMID: 15916425]
PBMC	CC₅₀	>1 μM Compound: AZT	Antiviral activity against HIV1 NL4-3 replication in PBMC at 1 uM Antiviral activity against HIV1 NL4-3 replication in PBMC at 1 uM	[PMID: 16420027]
PBMC	CC₅₀	>1 μM Compound: AZT	Antiviral activity against HIV1 TEKI replication in PBMC at 1 uM Antiviral activity against HIV1 TEKI replication in PBMC at 1 uM	[PMID: 16420027]
PBMC	IC₅₀	0.14 nM Compound: AZT	Antiviral activity against HIV1 TEKI replication in PBMC at 1 uM Antiviral activity against HIV1 TEKI replication in PBMC at 1 uM	[PMID: 16420027]
PBMC	IC₅₀	0.18 nM Compound: AZT	Antiviral activity against HIV1 NL4-3 replication in PBMC at 1 uM Antiviral activity against HIV1 NL4-3 replication in PBMC at 1 uM	[PMID: 16420027]
PBMC	IC₅₀	>100 μM Compound: AZT	Cytotoxicity against human PBMC Cytotoxicity against human PBMC	[PMID: 16509580]
PBMC	CC₅₀	>1000 nM Compound: AZT	Cytotoxicity against human PBMC Cytotoxicity against human PBMC	[PMID: 16698265]
PBMC	IC₅₀	>100 μM Compound: AZT	Cytotoxicity against human PBMC after 6 days Cytotoxicity against human PBMC after 6 days	[PMID: 17158051]
PBMC	CC₅₀	>10 μM Compound: AZT	Cytotoxicity against human PHA-PBMC cells by MTT assay Cytotoxicity against human PHA-PBMC cells by MTT assay	[PMID: 17548498]
PBMC	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	[PMID: 18316521]
PBMC	EC₅₀	0.016 μM Compound: AZT	Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	[PMID: 18316521]
PBMC	EC₅₀	0.018 μM Compound: AZT	Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	[PMID: 18316521]
PBMC	EC₅₀	0.034 μM Compound: AZT	Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	[PMID: 18316521]
PBMC	IC₅₀	>100 μM Compound: AZT	Cytotoxicity against human PBM cells after 3 days by MTT assay Cytotoxicity against human PBM cells after 3 days by MTT assay	[PMID: 19153047]
PBMC	CC₅₀	126 μM Compound: AZT	Cytotoxicity against human PBMC by XTT assay Cytotoxicity against human PBMC by XTT assay	[PMID: 19581097]
PBMC	EC₅₀	0.05 μM Compound: AZT	Inhibition of HIV1 viral replication infected in human PBMC cells assessed as viral p24Ag concentration after 7 days postinfection by ELISA Inhibition of HIV1 viral replication infected in human PBMC cells assessed as viral p24Ag concentration after 7 days postinfection by ELISA	[PMID: 19581097]
PBMC	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against human PBMC after 2 to 4 days by MTT assay Cytotoxicity against human PBMC after 2 to 4 days by MTT assay	[PMID: 19596885]
PBMC	CC₅₀	75 μM Compound: AZT	Cytotoxicity against human PBMC by MTT assay Cytotoxicity against human PBMC by MTT assay	[PMID: 19944610]
PBMC	IC₅₀	>100 μM Compound: AZT	Cytotoxicity against human PBMC after 5 days Cytotoxicity against human PBMC after 5 days	[PMID: 19948402]
PBMC	CC₅₀	31.2 μg/mL Compound: AZT	Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay	[PMID: 21334901]
PBMC	IC₅₀	>100 μM Compound: AZT	Cytotoxicity against human PBMC after 5 days by trypan blue assay Cytotoxicity against human PBMC after 5 days by trypan blue assay	[PMID: 21371895]
PBMC	CC₅₀	>100 μM Compound: AZT, zidovudine	Cytotoxicity against human PBMC infected with Human immunodeficiency virus 1 LAV1 by MTS assay Cytotoxicity against human PBMC infected with Human immunodeficiency virus 1 LAV1 by MTS assay	[PMID: 21376429]
PBMC	IC₅₀	>100 μM Compound: AZT	Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method	[PMID: 22014549]
PBMC	CC₅₀	128 μM Compound: AZT	Cytotoxicity against human PBMC after 7 days by XTT assay Cytotoxicity against human PBMC after 7 days by XTT assay	[PMID: 22763201]
PBMC	IC₅₀	>100 μM Compound: AZT, zidovudine	Cytotoxicity against human PBMC Cytotoxicity against human PBMC	[PMID: 23085031]
PBMC	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against human PBMC Cytotoxicity against human PBMC	[PMID: 23623492]
PBMC	IC₅₀	>100 μM Compound: AZT	Cytotoxicity against human PBMC Cytotoxicity against human PBMC	[PMID: 24091080]
PBMC	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against human PBMC Cytotoxicity against human PBMC	[PMID: 25458500]
PBMC	EC₅₀	0.0033 μM Compound: AZT	Antiviral activity against HIV1 LAV-1 infected in human PBMC cells after 6 days by RT assay Antiviral activity against HIV1 LAV-1 infected in human PBMC cells after 6 days by RT assay	[PMID: 25701249]
PBMC	IC₅₀	>100 μM Compound: AZT	Cytotoxicity against human PBMC cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay	[PMID: 25701249]
PBMC	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against human PBMC assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay Cytotoxicity against human PBMC assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay	[PMID: 26451771]
PBMC	CC₅₀	>1 μM Compound: AZT	Cytotoxicity in human PBMC cells Cytotoxicity in human PBMC cells	[PMID: 27933957]
PBMC	CC₅₀	1071 μM Compound: AZT	Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31557609]
PBMC	CC₅₀	126 μM Compound: AZT	Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by XTT assay Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by XTT assay	[PMID: 32244098]
PBMC	CC₅₀	>10 μM Compound: AZT	Cytotoxic concentration against PBMC cells Cytotoxic concentration against PBMC cells	[PMID: 7684450]
PBMC	EC₅₀	0.004 μM Compound: AZT	Antiviral activity against HIV-1 strain LAI in PBM cells on day 6 Antiviral activity against HIV-1 strain LAI in PBM cells on day 6	[PMID: 8057301]
PBMC	IC₅₀	>100 μM Compound: AZT	Cytotoxic concentration against PBM cells was determined on day 6 Cytotoxic concentration against PBM cells was determined on day 6	[PMID: 8057301]
PBMC	EC₅₀	0.004 μM Compound: AZT	Concentration required for antiviral activity in PBMC (human peripheral blood mononuclear cells) infected with HIV-1 strain LAV Concentration required for antiviral activity in PBMC (human peripheral blood mononuclear cells) infected with HIV-1 strain LAV	[PMID: 8410975]
PBMC	IC₅₀	>100 μM Compound: AZT	Cytotoxicity against uninfected PHA-stimulated human PBMC assessed as thymidine incorporation after 24 hrs by trypan blue exclusion method Cytotoxicity against uninfected PHA-stimulated human PBMC assessed as thymidine incorporation after 24 hrs by trypan blue exclusion method	[PMID: 9322359]
PBMC	IC₅₀	>100 μM Compound: AZT	Cytotoxicity against Homo sapiens (human) PBMCs after 5 days celltiter 96 aqueous assay Cytotoxicity against Homo sapiens (human) PBMCs after 5 days celltiter 96 aqueous assay	10.1007/s00044-011-9912-x
PBMC	IC₅₀	0.8291 mM Compound: AZT	Antiviral activity against NRTI-resistant HIV-1 D67N, T69D, K70R, A98G, V118I, M184V, T215F and K219Q mutant isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA Antiviral activity against NRTI-resistant HIV-1 D67N, T69D, K70R, A98G, V118I, M184V, T215F and K219Q mutant isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA	10.1039/C4MD00003J
PC-3	IC₅₀	>100 μM Compound: AZT	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis	[PMID: 38964258]
SK-MEL-28	IC₅₀	>10 μM Compound: AZT	The compound was tested in vitro for anticancer activity against SK-MEL-28 cells The compound was tested in vitro for anticancer activity against SK-MEL-28 cells	[PMID: 10072683]
SK-MES-1	IC₅₀	>100 μM Compound: AZT	Tested in vitro for anticancer activity against SK-MES-1 cells Tested in vitro for anticancer activity against SK-MES-1 cells	[PMID: 10072683]
SMMC-7721	IC₅₀	>100 μM Compound: AZT	Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis	[PMID: 38964258]
SUP-T1	IC₅₀	50 nM Compound: AZT	Tested for the inhibitory activity against HIV-1 in Sup T1 cell lines assessed by syncytium formation and reverse transcriptase assay Tested for the inhibitory activity against HIV-1 in Sup T1 cell lines assessed by syncytium formation and reverse transcriptase assay	10.1016/0960-894X(95)00306-E
SW-620	IC₅₀	39.11 μM Compound: AZT, Zidovudine	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 25440502]
SW-620	IC₅₀	>100 μM Compound: AZT	Antiproliferative activity against human SW620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis Antiproliferative activity against human SW620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis	[PMID: 38964258]
T-cell	IC₅₀	0.01 μM Compound: AZT	Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01) Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01)	[PMID: 1573638]
T-cell line	CC₅₀	66000 nM Compound: Zidovudine (AZT)	In vitro cytotoxicity in CD4+ human T-cells (c8166), using HIV-1 RT enzyme assay In vitro cytotoxicity in CD4+ human T-cells (c8166), using HIV-1 RT enzyme assay	[PMID: 1712395]
TZM	IC₅₀	0.8 nM Compound: AZT	Antiviral activity against HIV1 NL43 infected din human MT4 cells pre-incubated in presence of compound for 48 hrs followed by TZM cells infection with compound treated virus supernatant by X-gal staining based microscopy Antiviral activity against HIV1 NL43 infected din human MT4 cells pre-incubated in presence of compound for 48 hrs followed by TZM cells infection with compound treated virus supernatant by X-gal staining based microscopy	[PMID: 22858300]
TZM	CC₅₀	872 μM Compound: AZT	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31557609]
TZM	CC₅₀	>0.374 μM Compound: AZT	Cytotoxicity in human TZM assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity in human TZM assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32631509]
TZM	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay	[PMID: 33157478]
TZM	CC₅₀	>6300 nM Compound: AZT	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay	[PMID: 33340914]
TZM	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38954919]
U1	EC₅₀	25 μM Compound: AZT	Antiviral activity was determined in chronically infected U1 cell line with HIV-1 Antiviral activity was determined in chronically infected U1 cell line with HIV-1	[PMID: 11170632]
U-87MG ATCC	IC₅₀	11.88 μM Compound: 3; AZT	Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
U-937	CC₅₀	110 μM Compound: AZT	Cytotoxic concentration against HIV-1 infected U937 cell lines Cytotoxic concentration against HIV-1 infected U937 cell lines	[PMID: 7837220]
U-937	IC₅₀	0.04 μM Compound: AZT	Inhibitory concentration against HIV-1 infected U937 cell lines Inhibitory concentration against HIV-1 infected U937 cell lines	[PMID: 7837220]
U-937	EC₅₀	0.03 μM Compound: AZT	Effective concentration required for antiviral activity against Macrophage cell line of U937 cells of Human by XTT assay Effective concentration required for antiviral activity against Macrophage cell line of U937 cells of Human by XTT assay	[PMID: 7932526]
Vero	IC₅₀	29 μM Compound: AZT	Tested in vitro for cytotoxicity against Vero cells Tested in vitro for cytotoxicity against Vero cells	[PMID: 10072683]
Vero	IC₅₀	29 μM Compound: AZT	Inhibitory activity was evaluated in Vero cells. Inhibitory activity was evaluated in Vero cells.	[PMID: 10197975]
Vero	IC₅₀	29 μM Compound: AZT	In vitro cytotoxicity in vero cells. In vitro cytotoxicity in vero cells.	[PMID: 11689085]
Vero	IC₅₀	29 μM Compound: AZT	Cytotoxicity against Vero cells was determined. Cytotoxicity against Vero cells was determined.	[PMID: 11882000]
Vero	IC₅₀	28 μM Compound: AZT	Cytotoxicity against Vero cells Cytotoxicity against Vero cells	[PMID: 12383014]
Vero	IC₅₀	14.3 μM Compound: AZT	Evaluated in vitro for their potential toxic effects against Vero cells Evaluated in vitro for their potential toxic effects against Vero cells	[PMID: 12540238]
Vero	IC₅₀	29 μM Compound: AZT	Compounds were evaluated for their potential toxic effect on uninfected PHA-stimulated Vero cells Compounds were evaluated for their potential toxic effect on uninfected PHA-stimulated Vero cells	[PMID: 15027854]
Vero	IC₅₀	29 μM Compound: AZT	Cytotoxicity was determined in Vero cells, relative to RVT Cytotoxicity was determined in Vero cells, relative to RVT	[PMID: 15081000]
Vero	IC₅₀	28 μM Compound: Zidovudine (AZT)	Inhibitory concentration against uninfected Vero cells Inhibitory concentration against uninfected Vero cells	[PMID: 15916425]
Vero	IC₅₀	28 μM Compound: AZT	Cytotoxicity in vero cells. Cytotoxicity in vero cells.	[PMID: 1597854]
Vero	IC₅₀	29 μM Compound: AZT	Cytotoxicity against Vero cells Cytotoxicity against Vero cells	[PMID: 16509580]
Vero	IC₅₀	50.6 μM Compound: AZT	Cytotoxicity against Vero cells Cytotoxicity against Vero cells	[PMID: 17085053]
Vero	IC₅₀	50 μM Compound: AZT	Cytotoxicity against Vero cells after 3 days Cytotoxicity against Vero cells after 3 days	[PMID: 17158051]
Vero	EC₅₀	>100 μM Compound: AZT	Antiviral activity against Vero cells, infected with HSV-1 Antiviral activity against Vero cells, infected with HSV-1	[PMID: 1720175]
Vero	IC₅₀	26 μM Compound: AZT	The compound was tested for toxicity in Vero cells The compound was tested for toxicity in Vero cells	[PMID: 1720175]
Vero	CC₅₀	126 μM Compound: AZT	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 18486994]
Vero	IC₅₀	50.6 μM Compound: AZT	Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay	[PMID: 19153047]
Vero	CC₅₀	>100 μM Compound: AZT	Cytotoxicity against african green monkey Vero cells after 2 to 4 days by MTT assay Cytotoxicity against african green monkey Vero cells after 2 to 4 days by MTT assay	[PMID: 19596885]
Vero	IC₅₀	50.6 μM Compound: AZT	Cytotoxicity against african green monkey Vero cells after 5 days Cytotoxicity against african green monkey Vero cells after 5 days	[PMID: 19948402]
Vero	IC₅₀	56 μM Compound: AZT	Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometer analysis Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometer analysis	[PMID: 22014549]
Vero	IC₅₀	56 μM Compound: AZT, zidovudine	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 23085031]
Vero	CC₅₀	53 μM Compound: AZT	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 23623492]
Vero	IC₅₀	56 μM Compound: AZT	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 24091080]
Vero	CC₅₀	56 μM Compound: AZT	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 25458500]
Vero	IC₅₀	56 μM Compound: AZT	Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay	[PMID: 25701249]
Vero	CC₅₀	39.5 μM Compound: AZT	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay	[PMID: 26451771]
Vero	EC₅₀	>50 μM Compound: AZT	Antiviral activity against HSV-1 strain F in Vero cells on day 2 Antiviral activity against HSV-1 strain F in Vero cells on day 2	[PMID: 8057301]
Vero	IC₅₀	29 μM Compound: AZT	Cytotoxic concentration against Vero cells was determined on day 3 Cytotoxic concentration against Vero cells was determined on day 3	[PMID: 8057301]
Vero	IC₅₀	>100 μM Compound: AZT	Inhibition of cell growth in vero cells Inhibition of cell growth in vero cells	[PMID: 8410975]
Vero	IC₅₀	28 μM Compound: AZT	Cytotoxicity against uninfected PHA-stimulated vero cells was determined. Cytotoxicity against uninfected PHA-stimulated vero cells was determined.	[PMID: 8421287]
Vero	IC₅₀	>100 μM Compound: AZT	Cytotoxicity was determined in the vero cells infected with HIV-I Cytotoxicity was determined in the vero cells infected with HIV-I	[PMID: 8423591]
Vero	IC₅₀	28 μM Compound: AZT	Cytotoxic effect against vero cells. Cytotoxic effect against vero cells.	[PMID: 8496934]
Vero	IC₅₀	29 μM Compound: AZT	Compound was evaluated for its toxicity by Calorimetric assay in vero cells Compound was evaluated for its toxicity by Calorimetric assay in vero cells	[PMID: 9357530]
Vero	IC₅₀	27.7 μM Compound: AZT	Compound was evaluated for its cytotoxicity against vero cells. Compound was evaluated for its cytotoxicity against vero cells.	[PMID: 9873395]
Vero	IC₅₀	56 μM Compound: AZT	Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 5 days celltiter 96 aqueous assay Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 5 days celltiter 96 aqueous assay	10.1007/s00044-011-9912-x
Vero	IC₅₀	28 μM Compound: AZT	Cytotoxic activity against HIV-1 in rapidly dividing vero cells Cytotoxic activity against HIV-1 in rapidly dividing vero cells	10.1016/0960-894X(95)00107-5
Vero	IC₅₀	27.7 μM Compound: AZT	Cytotoxicity in Vero cells Cytotoxicity in Vero cells	10.1016/0960-894X(95)00133-E
Vero	IC₅₀	27.7 μM Compound: AZT	Compound was evaluated for cytotoxicity against Vero cells Compound was evaluated for cytotoxicity against Vero cells	10.1016/0960-894X(96)00171-0
Vero	IC₅₀	29 μM Compound: AZT	Compound was evaluated for the toxicity in rapidly dividing Vero cells (African Green monkeys kidney cells) Compound was evaluated for the toxicity in rapidly dividing Vero cells (African Green monkeys kidney cells)	10.1016/0960-894X(96)00210-7
WI-38	CC₅₀	>100 μM Compound: Azidothymidine	Cytotoxicity against human WI38 cells by neutral red assay Cytotoxicity against human WI38 cells by neutral red assay	[PMID: 18285481]
WI-38	EC₅₀	>100 μM Compound: Azidothymidine	Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis	[PMID: 18285481]

In Vitro

Zidovudine inhibits SVG, Primary human fetal astrocytes (PFA), peripheral blood mononuclear cells (PBMC), and monocyte-derived macrophages (MDM) with EC₅₀ of 17, 1311, 8, and 5 nM, respectively. Zidovudine inhibits SVG, PFA, PBMC, and MDM with EC₉₀ of 0.205 μM, 44.157 μM, 0.481 μM, and 0.219 μM, respectively^[1]. The Cas9-mediated ablation of CXCR4 demonstrated high specificity and negligible off-target effects without affecting cell division and propagation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Intravitrous injection of the NRTIs Lamivudine (3TC), Zidovudine (AZT), or Abacavir (ABC) suppresses the laser-induced choroidal neovascularization (CNV) in wild-type mice compared to PBS vehicle. The mean level of VEGF-A in the RPE/choroid, which peaks on day 3 after laser injury, is significantly reduced in 3TC-, AZT- and ABC-treated eyes compared with control eyes in wild-type mice, but not inP2rx7^-/- mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 30516-87-1
Appearance Solid
Masse moléculaire 267.24
Formule C₁₀H₁₃N₅O₄
Color White to off-white
SMILES

OC[C@@H]1[C@@H](N=[N+]=[N-])C[C@H](N2C(NC(C(C)=C2)=O)=O)O1
Synonyms

Azidothymidine; AZT; ZDV
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (10)

All Bio/Physico-chemical AssayCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Phytomedicine

Wikstrol B reactivates latent human immunodeficiency virus (HIV-1) via the nuclear factor-κB (NF-κB) pathway. [Abstract]

2025 Jun:141:156667. PMID: 40233507
Arch Toxicol

The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro. [Abstract]

2022 Aug;96(8):2341-2360. PMID: 35579693
Pharmaceutics

Effects of Drug Physicochemical Properties on In-Situ Forming Implant Polymer Degradation and Drug Release Kinetics. [Abstract]

2022 Jun 1;14(6):1188. PMID: 35745761
Int J Antimicrob Agents

Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro. [Abstract]

2019 Dec;54(6):814-819. PMID: 31479744
Virol Sin

Development of a reporter HBoV1 strain for antiviral drug screening and life cycle studies. [Abstract]

2025 Mar 25:S1995-820X(25)00031-8. PMID: 40147635
ACS Infect Dis

Targeting the Rift Valley Fever Virus Polymerase: Resistance Mechanisms and Structural Insights. [Abstract]

2025 Oct 30. PMID: 41166549
Res Sq

2026 Apr 21.
bioRxiv

Commensal bacteria inhibit viral infections via a tryptophan metabolite. [Abstract]

2025 May 12:2024.04.21.589969. PMID: 38659737

Zidovudine purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 May 12:2024.04.21.589969. [Abstract]

Time-of-addition assay results for Zidovudine (1 μM; 2-12 h).
Heliyon

Inhibition of human immunodeficiency virus type 1 by niclosamide through mTORC1 inhibition. [Abstract]

2020 Jun 3;6(6):e04050. PMID: 32529067

Zidovudine purchased from MedChemExpress. Usage Cited in: Heliyon. 2020 Jun 3;6(6):e04050. [Abstract]

Zidovudine (AZT) (10 μM) efficiently inhibited HIV-1 infection showing 97% and 98% inhibition in TZM-bl cells and SupT1 cells, respectively.

Zidovudine purchased from MedChemExpress. Usage Cited in: Heliyon. 2020 Jun 3;6(6):e04050. [Abstract]

SupT1 cells were evaluated for long-term cytotoxicity of Zidovudine (AZT) (10 μM; 30 d) treatment.

Zidovudine purchased from MedChemExpress. Usage Cited in: Heliyon. 2020 Jun 3;6(6):e04050. [Abstract]

Zidovudine (AZT) (10 μM; 30 d) verified the inhibitory effect against HIV-1 replication in SupT1 cells over a prolonged treatment.
bioRxiv

2020 May.

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (374.20 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 16.67 mg/mL (62.38 mM; ultrasonic and warming and heat to 60°C)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7420 mL

18.7098 mL

37.4195 mL

5 mM

0.7484 mL

3.7420 mL

7.4839 mL

10 mM

0.3742 mL

1.8710 mL

3.7420 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 20 mg/mL (74.84 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protocole

Cell Assay^[1]

Assays are performed in all cell types in the presence of titrating concentrations of ARV. 5,000 SVG, 2,500 PFA, 200,000 PBMC, or 50,000 MDM cells/well are seeded into triplicate wells of 96-well plates. Twenty-four hours later, the culture medium is removed and replaced with medium containing the ARV or DMSO (0.5% vol/vol), and equivalent TCID50 infectious units of luciferase reporter virus are added to the cells. After a 16 h incubation at 37°C, the initial viral inoculum is removed and replaced with culture medium containing the same antiretroviral drug (ARV) or DMSO (0.5% vol/vol) concentrations. At 72 h post infection, the medium is aspirated, the cells are lysed and HIV-1 infection measured using the Luciferase Assay System. Luminescence is measured using a FLUOStar Optima microplate reader. Inhibition curves and the 50% (EC₅₀) and 90% (EC₉₀) effective concentrations are determined by nonlinear regression analysis, using GraphPad Prism software^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

Mice^[3]
C57BL/6J (wild-type) and P2rx7^-/- mice are used. The Nlrp3^-/- mice are used. The NRTIs 3TC, AZT, and ABC or the P2X7 antagonist A438079 hydrochloride are dissolved in PBS. For CNV, each group of mice is injected once with 1 μL of NRTIs (3TC, 125 ng/μL; ABC, 183 ng/μL; AZT, 146 ng/μL), 1 μL of A438079 hydrochloride (3, 30, or 300 ng/μL), or the same volume of vehicle (PBS) into the vitreous humor using a 33-gauge needle immediately after laser injury. Another group of mice is injected with 3TC (125 ng) in combination with an anti-mouse VEGF polyclonal antibody (10 ng). Goat whole IgG (10 ng) is used as a biological control for the anti-mouse VEGF antibody.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (281 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Gray LR, et al. The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One. 2013 Apr 16;8(4):e62196. [Content Brief]

[2]. Hou P, et al. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep. 2015 Oct 20;5:15577. [Content Brief]

[3]. Mizutani T, et al. Nucleoside Reverse Transcriptase Inhibitors Suppress Laser-Induced Choroidal Neovascularization in Mice. Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7122-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	3.7420 mL	18.7098 mL	37.4195 mL	93.5489 mL
	5 mM	0.7484 mL	3.7420 mL	7.4839 mL	18.7098 mL
	10 mM	0.3742 mL	1.8710 mL	3.7420 mL	9.3549 mL
	15 mM	0.2495 mL	1.2473 mL	2.4946 mL	6.2366 mL
	20 mM	0.1871 mL	0.9355 mL	1.8710 mL	4.6774 mL
	25 mM	0.1497 mL	0.7484 mL	1.4968 mL	3.7420 mL
	30 mM	0.1247 mL	0.6237 mL	1.2473 mL	3.1183 mL
	40 mM	0.0935 mL	0.4677 mL	0.9355 mL	2.3387 mL
	50 mM	0.0748 mL	0.3742 mL	0.7484 mL	1.8710 mL
	60 mM	0.0624 mL	0.3118 mL	0.6237 mL	1.5591 mL
DMSO	80 mM	0.0468 mL	0.2339 mL	0.4677 mL	1.1694 mL
DMSO	100 mM	0.0374 mL	0.1871 mL	0.3742 mL	0.9355 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Zidovudine

10 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Zidovudine

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Nucleotide Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Tumorigenesis-Related Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Bioactive Compound Library Max

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

Azide Compound Library

Publications Citing Use of MedChemExpress (MCE) Zidovudine

Voir tous les produits spécifiques à Isoform HIV

Activité biologique

Chemical Information

Publications (10)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Zidovudine Related Classifications

HY-17413 Related Classifications